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Dr Christopher Boos  
Abstract 
Introduction 
The cardiovascular adaptations to high altitude (HA) exposure and its relationship to acute 
mountain sickness (AMS) are incompletely understood.  
Aims 
This thesis addresses four main hypotheses 1. HA adversely affects biventricular cardiac 
function leading to an increase in estimated filling pressures which is influenced by the mode of 
hypoxia. 2. HA exposure leads to myocardial injury that is linked to the development of AMS. 3. 
HA exposure is associated with a reduction in arterial compliance and an increase in central 
blood pressure (BP). 4. HA exposure reduces heart rate (HR) variability (HRV) that is linked to 
AMS an increased risk of cardiac arrhythmias.  
 
Methods 
This consisted of eight independent studies conducted at terrestrial and ‘simulated’ HA 
(hypobaric hypoxia [HH] and normobaric hypoxia [NH] Cardiac function and arterial 
compliance were examined using portable transthoracic echocardiography and pulse contour 
analysis respectively. Myocardial injury was measured in venous blood by cardiac troponin T 
(cTnT) quantification. Cardiac inter-beat interval data for HRV analysis was acquired using 
single lead ECGs and novel finger and patch sensor technologies. Cardiac rhythm was 
investigated using a novel implantable cardiac monitor. 
 
Results  
HA exposure was associated with a non-pathological increase in cTnT, and mild diastolic 
changes without adversely affecting systolic function or ventricular filling pressures. Resting 
cardiovascular responses were similar with HH, NH and HA, though notable differences 
emerged with exercise. Resting central BP, HR and BP-augmentation increased at terrestrial HA.  
HRV fell (eg reduced time-domain measures, increased LF/HF ratios and less chaos) at HA and 
was consistently different between men and women. Significant HA (>3500m) was associated 
with the development of tachyarrhythmia (atrial fibrillation and supraventricular tachycardia) 
and asymptomatic nocturnal bradycardias and pauses (>3.0 seconds). There were no 
independent predictors of AMS and its severity. 
 
Conclusion 
HA-related hypoxia induces early sympathetic activation leading to an increase in resting HR 
and central BP and may be proarrhythmic. Parasympathetic activation with acclimatisation can 
trigger nocturnal pauses at higher altitudes. HA exposure does not adversely affect cardiac 
function.   
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PWV  Pulse wave velocity  
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Chapter 1  
Introduction 
Access to high altitude (HA) has never been easier. Continued improvement in travel access 
and infrastructure has led to increasing demand to experience this exciting environment. 
Consequently, there has been a marked rise in the number of people travelling to HA each 
year. In fact, approximately, 140 million people worldwide live permanently at high altitudes  
and at least another 40 million people are estimated to travel to HA each year [1].  The HA 
environment differs markedly from one location to the next (eg the Alps versus the 
Himalayas) and depends on the season (winter versus summer or monsoon versus dry 
season), altitude, climate and terrain. With the recent improvements in transport one  could, 
for example, have breakfast in Bournemouth on Saturday morning and potentially be skiing at 
>2500m in the Alps by the late afternoon.  
 
Beyond the enticing beauty of the scenery, and the unique sporting and recreational 
opportunities of HA, lie a number of dangers that if not respected, can lead to potentially 
serious health consequences. The adverse weather (intense cold, high winds, heavy rain or 
snow), the physical challenges (climbing or long treks and high gradients) and physical risks 
(eg avalanches and landslides) are some of the obvious dangers, yet they can often be 
unpredictable. The mental challenges are even more unpredictable and are highly dependent 
on the HA environment, previous HA experience and an individual’s background mental 
health and resilience [2-5]. 
 
One of the greatest risks that all individuals travelling to HA and above 2000m must face is 
the effects of the falling partial pressure of oxygen (PaO2). Gases including oxygen, unlike 
liquids can be compressed and expand and hence whilst the percentage of oxygen in the air 
remains constant at any altitude within the earth’s atmosphere (at 20.9%), with rising altitude 
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the partial pressure of oxygen (PO2) falls leading to less available oxygen in the inspired air 
(Figure 1).  
 
Figure 1 Simple graphical illustration to demonstrate explain the fall in barometric and 
partial pressure of Oxygen (PO2) at high altitude (source google images from 
http://www.priory.com/anaes/altitude.htm) 
 
For example, whilst the PO2 at sea level is approximately 159 mmHg (21 kPa), on the peak of 
Mount Everest PO2 it falls to only about 53 mmHg (7kPa) [6, 7]. This leads to hypobaric 
(reduced pressure) hypoxia (HH) in humans. At HA whilst there is still the same percentage 
of oxygen (21%; and nitrogen ~79%) in the air as observed at sea level its concentration in air 
dramatically falls leading to less available oxygen molecules to take part in gas exchange. 
Consequently, the air is ‘thinner’ at HA as the weight of gas is less as there are fewer 
molecules present.  This fall in the atmospheric pressure at higher altitude decreases the 
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partial pressure of inspired oxygen and hence the driving pressure (or diffusion gradient) for 
gas exchange in the lungs [6, 7].   
 
Acute Physiological Responses to Hypoxia 
Acute Hypoxia leads to a number of well-established compensatory physiological responses 
which include hyperventilation and increase in resting heart rate [6]. Whilst an increased level 
of carbon dioxide is the main stimulus to ventilation at sea level at altitude hypoxia only 
increases ventilation when the inspired partial pressure of oxygen is less than about 
100mmHg (13.3 kPa) which equates to an altitude of approximately 3000 m. Owing to the 
shape of the oxygen dissociation curve at this inspired oxygen pressure the alveolar oxygen 
pressure (PaO2) is about 60mmHg (8 kPa), and with further increases in hypoxia ventilation 
rises exponentially (figure 2) [8]. 
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Figure 2 Changes in alveolar minute ventilation (VA) in response to the alveolar partial 
pressure of Oxygen (PaO2) 
(http://www.anaesthesia.med.usyd.edu.au/resources/lectures/ventilation_clt/ventilation.h
tml) 
 
This hypoxic hyperventilatory response is one of the earliest homeostatic responses to 
maintain tissue oxygenation. It is mediated by the carotid body, and its response varies widely 
between individuals [9]. This hyperventilation leads to a respiratory alkalosis as the PaCO2 
falls in response to the hyperventilation. This leads to a shift in the oxyhaemoglobin 
dissociation curve to left (the so-called Bohr effect), which acts to enhance the oxygen 
saturation of blood leaving the lungs (figure 3) [9, 10]. However, as the driving pressure for 
oxygen from the air to the blood is lower (due to the lower partial pressure of oxygen) 
coupled with the more rapid transit time of blood across the pulmonary capillary (due to a rise 
in resting heart rate) there is less time for equilibration of oxygen with the blood [11]. This 
leads to a diffusion limitation of oxygen across the alveolar–capillary membrane and, thus, 
more accentuated hypoxemia and a reduction in maximal oxygen consumption and maximal 
exercise capacity on cardiopulmonary exercise testing [12, 13].   
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Figure 3 The effects of high altitude on the oxyhaemoglobin dissociation curve 
 
 
Hypoxaemia within the pulmonary artery circulation leads to a widespread activation of 
pulmonary artery smooth muscle and pulmonary artery vasoconstriction [14]. This is 
primarily driven by hypoxic activation of smooth muscle cells within the smaller 
intrapulmonary arteries in response to the generation of reactive oxygen species within their 
mitochondria [15].  These changes are thought to improve the delivery of blood to better-
oxygenated lung segments in order to optimise ventilation/perfusion matching and systemic 
oxygen delivery [16]. This response is triggered by changes in the pulmonary artery smooth 
muscle mitochondrial reactive oxygen species and redox couples in pulmonary artery smooth 
muscle cells leading to a rise in pulmonary artery systolic pressure (PASP) [16]. Hypobaric 
hypoxia also stimulates diuresis and natriuresis in the kidneys and a fall in circulating plasma 
volume (hence relative rise in haemoglobin due to haemoconcentration) which acts to 
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improve oxygen uptake and delivery [17]. Circulating erythropoietin levels increase which 
leads to a gradual rise in haemoglobin over many weeks to improve oxygen content and 
delivery [18].  Gastrointestinal upset is very common with HA exposure. The expansion of 
gases in the  stomach and intestines leads to increased flatulence and even diarrhoea [19]. 
This factor along with nausea and alterations in circulating gut hormones (eg acylated ghrelin) 
leads to a reduction in appetite [20, 21]. Insomnia is common and sleep quality shares a 
strong association and reciprocal relationship with anxiety at altitude [22, 23].   Both the 
quality and duration of sleep are known to be affected and sleep disordered breathing is not 
uncommon and is caused by the fall in PaCO2 which leads to periods to apnoea [24-26]. 
Cerebral blood flow increases in an attempt to preserve the oxygenation of the brain [15].  
 
High Altitude Related Illness 
High altitude-related symptoms are one of the greatest impediments to completing any 
significant (≥2000 m) HA venture. These typically present in the form of one of several 
recognised syndromes with the most common being that of acute mountain sickness (AMS) 
[15, 27]. AMS has been historically defined as syndrome of nonspecific symptoms which 
include headache and one or more of fatigue, altered appetite, dizziness/light headedness and 
insomnia in the presence of recent altitude gain [28, 29]. Each of these five symptoms are 
rated on a scale of scale of severity from 0 (not present) to 3 (severe). A total score of >3, in 
the presence of a headache, has been traditionally considered diagnostic for AMS [28, 29]. 
The definition of AMS has been very recently revised (and subsequent to the publications 
contained within this PhD Submission) [30]. The reason for this update to the definition 
related to issues around the inclusion of sleep quality into the definition of AMS. It has been 
well reported that whilst sleep disturbance is obviously very common at HA it is discordant 
from other symptoms of AMS [31, 32]. Hence, the latest AMS Consensus Guideline 
Committee has decided to remove question on sleep from the LLS questions. Consequently 
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the new consensus definition of AMS now only incorporates four symptoms (insomnia 
removed) [30].  
 
AMS usually develops >6 hours after a gain in altitude and should not be confused with 
confounding symptoms related to travel (eg fatigue and dehydration) or responses to acute 
hypoxia (above). Whilst AMS is usually a relatively benign and self-limiting syndrome its 
identification and effective management is crucial. It can rapidly worsen and progress to the 
development of HA cerebral oedema (HACE) [15]. HACE usually appears between 24 and 
72 hours after a gain in altitude and is characterised by change in mental status and/or ataxia. 
It usually (though not always) occurs in persons with AMS or high-altitude pulmonary 
oedema (HAPE) [15, 30]. HACE is a medical emergency and can rapidly to progress to coma 
and death if not detected and adequately treated (intravenous steroids, high flow oxygen and 
descent). HAPE is generally thought to be a non-cardiogenic form of pulmonary oedema 
which is caused by a heterogeneous and heightened pulmonary artery vasoconstrictor 
response to alveolar hypoxia [33]. With HAPE there is regional hyper-perfusion of capillaries 
in areas of lower arterial vasoconstriction leading to increased blood flow into these ‘more 
compliant’ (less vasoconstricted) vessels which leads to endothelial disruption and increased 
capillary leakage of a protein-rich fluid into the alveolar interstitial space and pulmonary 
‘oedema’ [34].  It can lead to right heart dilatation and evidence of myocardial injury, such as 
a rise in cardiac troponin [35]. High Altitude Pulmonary Oedema can be fatal if not 
recognised and treated promptly [17, 27]. It affects between 0.1 and 7% of persons travelling 
to altitudes above 2500m [17, 27]. The pathophysiology of AMS is highly complex and 
poorly understood. Putative mechanisms  include alterations in vascular permeability within 
the blood brain barrier, attenuation of effective diuresis and natriuresis in response to 
hypobaric hypoxia [36] with associated alterations in heart rate variability (HRV) and 
autonomic balance [15].  
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The reported prevalence of AMS is highly variable and depends on multiple factors. These 
include the population studied, the amount and intensity of exercise undertaken, the mode of 
HA ascent (passive eg aeroplane or cable car versus active by climbing or trekking), the 
acclimatisation protocol as well as the actual altitude achieved [22, 37, 38]. The development 
of AMS is known to be markedly influenced by individual susceptibility which may have a 
genetic input, though the genetic hypothesis remains controversial [39]. Furthermore, whilst a 
consensus definition for AMS does exist other definitions have been suggested and reported 
[27]. These factors help to explain the marked variation in its reported frequency of HA-
related illness across differing published studies and datasets. In general AMS is known to 
affect at least 1 in 4 persons who ascend to an altitude of >2000m and >50% of those 
travelling to >5000m [40, 41]. Given the huge number of persons trekking to these altitudes 
each year the potential burden of HA-related illness and its potential outcomes are enormous. 
 
High Altitude research is of vital importance given both the huge clinical burden of AMS and 
potentially profound effects of the HA environment on human physiology. Despite intense 
research into this field a reliable sea level marker that can be used to reliably predict AMS 
development at HA has still not been identified. The discovery of a simple and reproducible 
sea level marker of future AMS risk and in severity would be of enormous clinical value and 
remains one of the holy grails of HA research. There is, however, another perhaps equally 
persuasive, and translational reason to examine the effects of acute hypoxia and HA on 
human beings. Tissue hypoxia is one of the central physiological insults of critical illness 
[42]. This can occur for a host of reasons due to abnormalities of oxygen uptake, extraction 
and delivery which can all lead to the common insult of tissue hypoxia.  Hence HA-related 
research has enormous translational potential to improve our understanding of the human 
responses to critical illness [43, 44].  
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Cardiovascular Adaptations to HA 
The cardiovascular responses to HA have been well described [8, 14, 45].   Hypobaric 
hypoxia at HA leads to an increase in resting sympathetic activity and a consequent rise in 
resting heart rate and variable changes in brachial blood pressure [17, 45, 46]. The effects of 
HA-related hypoxia on arterial compliance and central blood pressure are less well 
understood. Despite the rise in resting heart rate the maximal heart rate is reduced [47]. The 
reduction in maximal heart rate has been shown to be strongly related to the degree of 
hypoxia with a roughly linear dose-response between the reduction in arterial oxygen 
saturation and the reduction in maximal heart rate [45]. The mechanism for this effect is 
thought to be caused by counter-regulatory stimulation of the parasympathetic nervous system 
and increased vagal tone [47]. The reduction in circulating plasma volume (due to increased 
micturition and relative dehydration) coupled with the rise in pulmonary vascular resistance 
and PASP leads to blunting of the usual increase in stroke volume rise with exercise noted at 
sea level [48]. This, along with the obvious fall in arterial oxygen content, limits both 
maximal cardiac output and oxygen consumption (VO2 max) [49]. Despite the blunting of 
stroke volume, left ventricular ejection fraction, which is measure of radial left ventricular 
systolic function (and the fraction of blood leaving the heart in a single beat), appears to 
remain preserved in spite of a fall in left ventricular end diastolic volumes [50].  
 
Until recently the effects of HA exposure on long axis systolic function, diastolic function 
(cardiac relaxation) and left ventricular filling had been less well described. The effects of HA 
on complex right ventricular and regional cardiac function is another area that needs greater 
clarity.  The relationship between potential changes in cardiac physiology and function and 
the development of HA-related illness, and the influence of exercise, are other areas where 
there are limited data.  
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There have been several observational reports that have suggested that HA exposure increases 
the risk of acute and major adverse cardiovascular events. Sudden cardiac death has been 
reported to be one of the leading causes of non-traumatic deaths in adults at HA particularly 
during leisure time [51-55]. There are several potential mechanisms that might explain this 
finding which include reporting bias and the compounding effects of physical exhaustion and 
dehydration during hypoxia in ‘at risk’ individuals with ‘silent’ pre-existing cardiovascular 
disease [56].  Another plausible explanation is that the HA environment may be pro-
arrhythmic [57]. High altitude-related hypoxia leads to sympathetic activation which is a 
recognised arrhythmogenic stimulus [46]. Unfortunately, there is paucity of previous research 
conducted during exercise at natural genuine HA, with the majority performed at rest during 
‘simulated’ high altitude using hypoxic chambers or breathing a low oxygen gas mixture.  
 
The ability to better examine the autonomic balance by the quantification of changes in Heart 
rate variability (HRV) has created exciting prospects for further research at HA. Heart rate 
variability refers to the changes in the cardiac inter beat interval and hence heart rate which is 
subject to continuous autonomic control. Sympathetic activation is well known to lead to an 
increase in heart rate and a reduction in the HRV and the converse following opposing 
parasympathetic innervation. The measurement of HRV has emerged as non-invasive, albeit 
indirect, measure of autonomic balance. It main current clinic applications are in the 
monitoring of mental resilience, physical fitness, training and injury prevention due to over 
training [58-61].  
 
The Challenges of High Altitude Research  
There are a number of considerable challenges to the conduct research at HA. Firstly, the 
financial costs tend to be far higher than that for an equivalent study at or near sea level due to 
the considerable expense of transporting research equipment and personnel to HA. The 
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hypoxia, obvious cold and potentially limited access to hard structures, sanitation and power 
add to the logistical challenges and cost. In general there tends to be a reciprocal relationship 
between altitude and facilities. Hence, the highest altitudes tend to be the most remote with 
the least available facilities, yet they are the very areas of greatest research interest. The 
physical risks and dangers of HA research can be considerable leading to high travel and 
insurance costs. Consequently, the sample size for HA studies tend to be far smaller than for 
equivalent normoxic sea level studies.  The size of the challenge depends on multiple factors, 
including the type of research study, the season and the actual HA location/environment.  
 
In an attempt to overcome many of the constraints of natural HA, research is often conducted 
under simulated HA conditions. Simulated high altitude aims to reproduce the degree of 
hypoxia of genuine/natural HA, but at sea level [62]. This is performed either by breathing a 
low oxygen gas concentration (eg FiO2 of 14% rather than 21%) using a tight-fitting face 
mask or by the use of a normobaric or hypobaric hypoxic chambers. A normobaric hypoxic 
(NH) chamber (figure 4) also reduces the concentration of inspired oxygen within the room. 
Conversely, a hypobaric hypoxic (HH) chamber (figure 5 and 6) reduces the oxygen 
percentage constant whilst reducing its partial pressure [63]. They tend to be more expensive 
than normobaric chambers and more challenging for research owing to their typically smaller 
size, high background noise and their restrictions on chamber entry/exit.  
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Figure 4 Illustration of the inside of the normobaric hypoxic chamber used in several of 
my studies at Leeds Beckett University (personal photograph) 
 
Figure 5 Example of three Hypobaric Hypoxic Chambers at the centre of Aviation 
Medicine (Personal photographs taken during one of the studies) 
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Figure 6 Illustration of the interior of one of the hypobaric hypoxic chambers at the 
Centre for Aviation Medicine (personal photographs taken during four-way study 
Chapter 5) 
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One area of ongoing debate has been whether hypoxic chambers are effective surrogates for 
natural terrestrial HA. Whilst they can replicate the degree of hypoxia they cannot replicate 
the hardships of natural HA. These additional challenges of natural HA include the extreme 
cold, high winds, limited access to varied food choice, insomnia, anxiety, intense exercise and 
associated muscle aches and physical risks. Conversely, they also cannot reproduce the many 
positives of genuine HA which include the freedom, the beautiful scenery and the greater 
sense of accomplishment. There is also considerable debate on the question as to whether HH 
chambers offer superior HA simulation to that of NH. Comparative studies have tended to 
focus on one modality versus another (eg NH versus HH). There has been very little research 
into the comparative effects of both HH and NH to natural HA.  Furthermore, chamber 
studies tend to be conducted over minutes to hours rather than the days or weeks as would be 
the case with natural HA exposure.  
 
Another fundamental reason, beyond those cited above, for the dominance of simulated HA 
research has been the issue of research equipment portability.  The difficulties of transporting 
traditional mains powered stand-alone equipment to terrestrial HA can be considerable. The 
operating temperatures at genuine HA can damage equipment that was designed to be used at 
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higher temperatures at sea level. The cold can lead to the rapid depletion of battery life. One 
way to lessen this challenge to use more accessible natural HA locations where there is good 
road links or even cable car access. However, this generally limits the altitude to generally 
less than 3500m as above this facilities and transport links tend to be far less.   
 
Recent improvements in equipment technology, portability and battery performance have 
been considerable. This has led to the creation of new opportunities for HA research. For 
example, in the field of cardiac research (which is the focus of my PhD) we have witnessed 
the advent of portable and even ultraportable devices that have capabilities exceeding even 
that of older devices designed for laboratory use. This has generated new prospects for HA 
research that was previous untenable. These opportunities have been exercised across all of 
the studies relating to this PhD submission and discussed further in subsequent sections.  
 
Aims and Scope of my PhD Research  
This thesis is focussed on the central theme of the cardiovascular responses to acute hypoxia 
and HA in healthy adults. In order to deliver my thesis aims (stated below) and the science 
under the challenging research environments used have required the use of portable and often 
novel cardiovascular equipment and bioassays.  
The four main research hypotheses examined in this thesis are as follows: 
1. High altitude (HA) adversely affects cardiac diastolic function and increases estimated 
filling pressures. These changes are influenced by the mode of hypoxia and the hypoxic 
environment. 
2. Exposure to HA leads to an abnormal rise in circulating biomarkers of myocardial injury 
that are linked to the development of acute mountain sickness.  
3. Acute HA exposure reduces arterial compliance and increases central blood pressure.  
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4. Exposure to HA reduces heart rate variability (HRV) and increases risk of cardiac 
arrhythmias. The reduction in HRV at HA is influenced by ventilation and biological sex 
and is linked to the development of acute mountain sickness. 
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Chapter 2  
Research Methods, Literature Review and Supporting Synthesis 
This ‘PhD by Publication’ thesis submission consists of eight published original research 
studies that were conducted over a period of seven years from 2011 to 2017. The study 
environments varied considerably across these seven studies and are described below. 
 
Personal Contribution to the Research and Publications  
The eight submitted publications for consideration for this PhD all relate to original 
prospective observational studies conducted on healthy adult British Military Servicemen. 
Two publications relate to one study. Each study had its own separate research proposal. All 
of these studies had full ethics approval granted by the Ministry of Defence Research and 
Ethics Committee (MoDREC) prior to commencement. All ethics submissions required a pre 
ethics committee meeting attendance (usually Porton Down, Wiltshire) followed by 
attendance in person at MoDREC at Whitehall, London. I was either first author or co-
authored all of the ethics submissions and played a principal role in the preparation and 
conduct for all of these eight studies relating to this PhD submission. I was personally in 
attendance ‘on the ground’ at all of the research locations relating to this thesis with the 
exception of the Bernese Alps study. I personally sourced all of the key cardiac research 
equipment via a variety of funding streams which will be discussed below.  
 
I played a principal role in data entry and undertook all of the main data analysis relating to 
these publications. I was first author on all of the manuscripts comprising this PhD 
submission.  I was supported in all of the studies by my co-authors who assisted with the 
editing and proof reading of the final versions of all manuscripts.  The individual 
contributions made by my colleagues are cited at the end of each publication.  The detailed 
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methods, findings and limitations of each study are discussed in depth under the individual 
publications.  
 
Research Methods, Publications and the Research Environment 
Publication 1  
The 1
st
 publication in this thesis is entitled ‘The effects of acute hypobaric hypoxia on arterial 
stiffness and endothelial function and its relationship to changes in pulmonary artery pressure 
and left ventricular diastolic function’ [64]. This study was conducted over five days at the 
end of 2011. This study aimed to address two of my research hypotheses: high altitude (HA) 
affects cardiac diastolic function and estimated filling pressures and acute HA exposure 
reduces arterial compliance and increases central blood pressure. This study was conducted 
over five consecutive days at the Centre for Aviation Medicine in Henlow, UK. Ten healthy 
adults were studied at baseline under normobaric normoxia (NN, sea level breathing room air) 
and at 45, 90 and 150 minutes during 180 minute exposure to hypobaric hypoxia (HH; 
equivalent to 4800m). Arterial compliance (stiffness index) was measured using a validated 
device known as the Pulse TracePCA2 (figure 7). The PCA2 estimates large artery stiffness 
(stiffness index) using the principle of pulse waveform analysis of the digital artery waveform 
measured at a fingertip via an infra-red finger sensor (photo-plethysmography). This validated 
device also measures vascular tone and potentially endothelial function using its vascular tone 
measure known as the reflective index (methods described in greater detail later) [65-67]. A 
good pulse volume is crucial for this method to be able to detect and analyse the arterial 
waveform. This led to several challenges at HA under the cold environment where peripheral 
vasoconstriction led to a reduction in signal strength and the need to warm the fingers.  
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Figure 7 Graphical Illustration of the Pulse Trace PCA2 Arterial waveform Device 
(image source: https://www.mistrymedical.com/item/9924/carefusion-pulse-trace--36-
pt2000-stk-)  
 
Assessments of cardiac function, estimated PASP and vascular resistance were performed 
using GE Vivid Q transthoracic cardiac ultrasound device (echocardiography) as shown 
below, at baseline and after 150 minutes of hypobaric hypoxia (figure 8).  
 
  
20 
 
Figure 8 Example of a GE Vivid Q portable transthoracic echocardiogram machine 
Image source: (google images) 
 
Additional measures undertaken in this study included brachial blood pressure and peripheral 
oxygen saturations (SpO2). The echocardiogram and pulse waveform equipment were 
provided to me as a free research equipment loan from GE Healthcare and CareFusion 
respectively, following my successful research bid. I attended all of the hypobaric chamber 
experiments in person. 
 
Diastolic function was assessed using a combination of recognised methods. The first was by 
examination of the left ventricular inflow by a process known as pulse wave Doppler by 
sampling the change in blood velocity as it cross the mitral valve using echocardiography as 
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shown [68] (figure 9). This identifies two discrete waves known as the E wave (marker of 
early mitral inflow and left ventricular relaxation) and an A wave (later mitral flow and left 
ventricular filling caused by left atrial contraction) (Figure 9).  
 
Figure 9 Illustration of the measurement of mitral pulsed wave Doppler to assess 
diastolic function and estimated left ventricular filling (google images) 
 
 
Tissue Doppler imaging was used to measure the velocity of the mitral annulus motion to 
obtain an equivalent but lower early E’ and later A’ wave deflections related to left 
ventricular relaxation and atrial contraction respectively (figure 10). Long axis systolic 
(contractile phase) function of the myocardium can also be quantified by the velocity of the 
identified S’ wave as shown on the image below (figure 10). The data from these 
measurements were used to build up a comprehensive assessment of diastolic function and 
estimated left ventricular filling (more detailed methods in main publication).  
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Figure 10 Graphical Illustration of the typical tissue doppler imaging with sampling 
from the basal septum (source: https://isctr.org/chapter-i-7/)  
 
 
The findings of this study were published as an original paper in High Altitude Medicine and 
Biology (Impact factor [IF]: 1.98). To the best of my knowledge was the first study to 
investigate effects of acute hypoxia on simultaneous assessment of large artery stiffness and 
endothelial function and its inter-relationship to left ventricular diastolic function and PASP. 
 
Hypobaric hypoxia (HH) led to a significant increase in the estimated PASP and pulmonary 
artery vascular resistance and a reduction in both systolic blood pressure and the systemic 
vascular resistance (versus baseline) without clinically significant changes in large artery 
stiffness or left ventricular filling.  There was a strong inverse correlation between changes in 
the arterial reflective index (a marker of medium sized artery tone and endothelial activation) 
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and in the pulmonary artery vascular resistance. This finding would suggest that 
haemodynamic responses in the pulmonary artery and systemic arterial circulation to acute 
hypobaric hypoxia are intricately linked. My results strongly support the concept that acute 
hypoxia leads to differential haemodynamic effects along the arterial tree with a greater 
influence on the muscular smaller peripheral versus central elastic arteries (eg aorta) with 
variable effects on brachial blood pressure [69]. Unfortunately, owing to study design I am 
unable to infer whether this association equates to causation or a mechanistic relationship 
whereby the vasomotor changes in pulmonary artery lead to reciprocal changes in the 
systemic circulation and vice versa.   
 
Publication 2 
The 2
nd
 publication is entitled ‘the effects of exercise at high altitude on high-sensitivity 
cardiac troponin release and associated biventricular cardiac function [70]. This study was 
conducted over a three week period in the Himalayas in March and April 2012. This study 
addressed the first two hypothesis of my thesis: 
1. High altitude (HA) adversely affects cardiac diastolic function and increases estimated 
filling pressures. These changes are influenced by the mode of hypoxia and the hypoxic 
environment. 
2. Exposure to HA leads to an abnormal rise in circulating biomarkers of myocardial injury 
that are linked to the development of acute mountain sickness.  
 
Cardiac function, high-sensitivity cardiac troponin T (hs-cTnT, circulating marker of 
myocardial injury measured) and AMS scores were measured at rest at 1,300m (Kathmandu, 
Nepal). Cardiac hs-cTnT levels were obtained by peripheral venesection followed by 
centrifugation for later batch analysis. Cardiac function and PASP were quantified using 
transthoracic echocardiography (figure 11) and AMS scores were obtained using validated 
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questionnaires. These three measures were repeated, following exercise and again, at rest 12 h 
later during incremental terrestrial HA treks to 3,440m, 4,270 m and at 5,150 m (following 
the summit of Kala Patthar at 5,643 m) on 19 healthy adults.  
 
The echocardiogram machine used was a Sonosite M Turbo (figure 11) which was supplied 
free of charge for the duration of this study from the manufacturer Sonosite Inc. The cost and 
conduct of the Cardiac troponin assays were covered following my receipt of an assay grant 
from the Department of Biochemistry at Poole Hospital NHS Trust. I assisted with data 
collection and undertook all of the echocardiograms over the duration of this study.  
 
Figure 11 Sonosite M Turbo cardiac ultrasound (echocardiogram) machine 
(https://www.google.co.uk/search?q=Sonosite+M+turbo+Ultrasound+Machine&rl)  
 
 
This was the first study to investigate the relationship between changes in cardiac function 
and biventricular filling and markers of myocardial injury during incremental HA. The 
manuscript was published in Clinical Research in Cardiology (IF 4.5) [45].   
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The key findings of this study were that exercise at HA led to a significant, but only minor 
overall increase, in hs-cTnT which was most notable at the highest altitudes in the absence of 
any notable change in cardiac biventricular filling. The independent predictors of the rise in 
hs-cTnT were increasing cardiac output (supporting its association to exercise), PASP and 
decreasing SpO2 (and hence in proportion to the degree of hypoxia). Cardiac TnT was not an 
independent predictor of AMS. Hence exercise at HA led to an increase in cardiac troponin 
levels but not to pathological levels and this rise was not related to any major deleterious 
effects of cardiac function. The mechanism for the increase in cTnT appears to be the 
combined effects of exercise and hypoxia. The translational finding of this research are that 
the rise in cardiac troponin following exercise at HA is transient unlike the sustained and 
higher levels observed over several days with a myocardial infarction (‘heart attack’) [71]. 
Furthermore, there were no clear deleterious effects of exercise on cardiac function at very 
high altitude.  It is unknown whether these findings apply to older subjects with clinical or 
subclinical cardiac disease as we included a cohort of healthy and generally young adults.  
 
Publication 3  
My 3
rd
 publication is entitled ‘A Four-Way Comparison of Cardiac Function with normobaric 
normoxia, normobaric Hypoxia, Hypobaric Hypoxia and Genuine High Altitude’ [72]. This 
study was specifically designed to investigate the influence hypoxia on resting and post 
exercise changes in cardiac function. The specific hypothesis was that HA would adversely 
affect cardiac diastolic function and lead to an increase in estimated filling pressures.  
This was an extremely challenging collaborative research study conducted over four differing 
and consecutive (with a washout period in between) research environments in 2013. 
Transthoracic echocardiography (GE Vivid I Machine – personal purchase), physiological 
measures and AMS scores  were undertaken  at rest and at 15 and 120 minutes following two 
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hours of exercise at sea level normobaric normoxia (NN; Leeds Beckett University), at 
natural HA at 3,375m (Margherita Hut, Italian Alps, figure 12), normobaric hypoxia (NH; 
hypoxic chamber at Leeds Beckett University) and with hypobaric hypoxia (HH; Centre of 
Aviation Medicine, Henlow, UK) to simulate the equivalent hypoxic stimulus to genuine HA.  
 
Figure 12 Image of the view from the Magherita Research Hut where the high altitude 
component of this study was conducted (personal photo).  
 
 
 
The original cohort consisted of 14 participants. However, the sample size varied by study 
environment with 14 volunteers completing the experiment at genuine HA, 11 with NN and 
12 and 6 with NH and HH, respectively.  
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The original paper relating to this manuscript was published in PLOS One (IF 2.77) [72].  
This was the first observational study to compare the effects of exercise on detailed cardiac 
function and physiological responses under three differing hypoxic environments versus sea 
level normoxia.  The key finding in this study was that the resting cardiac responses to 
hypoxia were similar under the three hypoxic conditions. However, significant differences 
emerged following exercise in SpO2, right ventricular systolic pressure and function.  
Compared with NH, HH and GHA led to lower oxygen saturations (hence hypoxia), higher 
heart rates and a greater negative change in the right ventricular Tei (marker of global cardiac 
function) and increase in the right ventricular systolic pressure [73]. These data emphasises 
the importance of the type and mode of hypoxic environment as well as the influence of 
exercise on cardiac function. Data obtained from one environment cannot necessarily be 
assumed to translate to another environment and simulated hypoxia is not a reliable substitute 
for genuine HA exposure. Unfortunately, there was a much smaller sample size for the HH 
protocol (which was the third hypoxic environment to be tested), which was an important 
confounder. 
 
Publication 4  
My 4
th
 publication is entitled ‘the effect of high altitude on central blood pressure and arterial 
stiffness’.  This study was conducted in 2016.  This study is linked to my third hypothesis 
which is that high altitude exposure leads to a reduction in arterial compliance and an increase 
in central blood pressure.  
 
The measurement of brachial blood pressure has been most widely reported using brachial 
readings. However, relying solely on brachial blood pressure has a number of limitations. 
Brachial blood pressure reflects the hydrostatic pressure of arterial blood in the upper arm and 
tends to be higher than the actual central blood pressure [74-76]. The reason for this 
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phenomenon is due to systolic blood pressure amplification from the central to peripheral 
arterial tree. This pressure amplification is caused by the relative increase in arterial stiffness 
and vascular tone as the arterial pressure wave travels from the highly elastic central arteries 
to the stiffer and more muscular peripheral arteries [77]. This causes the upper portion of the 
arterial wave to become narrower with a more prominent systolic peak and the systolic blood 
pressure increases (figure 13). Hence the brachial blood pressure does not provide a reliable 
insight into central blood pressure.  
 
Figure 13 Peripheral amplification of systolic blood pressure image source: 
https://www.researchgate.net/publication/313259486_I_Luso-
Brazilian_Positioning_on_Central_Arterial_Pressure/figures?lo=1  
 
 
Central blood pressure is a recognised cardiovascular risk factor. It reflects the direct 
hydrostatic pressure of blood as it leaves the heart and its effects on the organs in close 
proximity (heart via increased afterload, aorta, brain and kidney). This is thought to explain 
why central blood pressure has been shown to be a better independent predictor of future 
cardiovascular risk and adverse cardiovascular endpoints including cardiovascular death and 
stroke [78, 79].  
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The differences in the central and brachial blood pressure can vary considerably between 
individuals and with increasing age and cardiac risk factors. Consequently, accurate 
quantification of central blood pressure is desirable. Its measurement has traditionally 
required the use of invasive arterial catheterisation. Technical advances have led to the recent 
development and availability of several relatively portable devices that can provide accurate 
(albeit indirect) measures of central blood pressure and large artery compliance/stiffness [80].   
 
Changes in the travelling arterial waveform are caused by alterations in the reflections of the 
initially forward travelling arterial wave following its ejection from the heart during left 
ventricular systole (figure 14). The forward travelling arterial wave is followed by a single 
summated backward-travelling reflected wave (figure 14) which is generated at sites of 
impedance mismatch such as where the arterial tree tapers or bifurcates [77, 81].  
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Figure 14 Demonstration of varying arterial augmentation with increasing arterial 
stiffness with augmentation of the reflected wave lead to an increase in arterial blood 
pressure 
https://www.google.com/search?q=14+Demonstration+of+varying+arterial+augmentati
on+with+increasing+arterial+stiffness&rlz=1C1CAFB_enGB663GB671&source=lnms&
tbm=isch&sa=X&ved=0ahUKEwjPqd2K3NngAhXuVhUIHeTfAkIQ_AUIDigB&biw=1
920&bih=933#imgrc=evSXoVKVcS7P7M:  
 
It is thought that this reflected wave can act to augment and increase the systolic blood 
pressure in the central arteries. The augmentation index is used to quantify the extent of the 
augmented pressure relative to the central pulse pressure as shown (figure 14). It is calculated 
as the percentage ratio of the augmentation pressure (%) relative to the central pulse pressure 
as shown below (figure 15).   
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Figure 15 Calculation of the central augmentation index  
https://commons.wikimedia.org/wiki/File:Augmentation-index.PNG  
 
However, the augmentation index can also be calculated from the peripheral (brachial or 
radial) arterial waveform by the % ratio of the reflected (P2) to the incident (forward 
travelling P1) wave as shown (figure16).  
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Figure 16 Calculation of the peripheral (Brachial or radial) augmentation Index  
http://file.scirp.org/Html/3-1910314_45642.htm  
 
 
In general a higher augmentation index can be caused by an increase in arterial stiffness or 
peripheral vascular tone leading to earlier arterial wave reflection.  With an increase in 
augmented pressure (and augmentation index), the absolute aortic systolic pressure increases 
(figure 14). 
Pulse wave velocity (PWV) is considered by to be the gold standard functional measure of 
large artery stiffness [82, 83]. It refers to the velocity at which an arterial 
pressure wave moves along a blood vessel. Its measurement requires the  quantification of the 
desired path length to be examined and a means of calculating the time it takes for the arterial 
pressure wave to move along the chosen path length (∆L) as shown (figure 17). This is 
typically conducted by using two pressure catheters placed at each end of the path length. 
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Figure 17 Demonstration of the concept of Pulse wave velocity (PWV) and its calculation 
from the path length (∆L) and time (∆t) for the arterial waveform to travel from the 
aorta to the proximal femoral artery 
https://www.google.com/search?q=Demonstration+of+the+Concept+of+Pulse+wave+vel
ocity&rlz=1C1CAFB_enGB663GB671&source=lnms&tbm=isch&sa=X&ved=0ahUKE
wjnjMTh3NngAhWLSRUIHbqZAuMQ_AUIDigB&biw=1920&bih=933#imgrc=4idsyu
pw5c6AUM   
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Pulse wave velocity (PWV) and augmentation index have evolved as two of the most 
commonly cited methods to indirectly determine arterial stiffness. The widely used ‘arterial 
stiffness index’ is another frequently quoted measure of arterial stiffness [84, 85]. However, it 
is a non-specific term and this index can measured in a number of ways.   
 
In my 4
th
 publication brachial the arterial augmentation index, peripheral and central blood 
pressure were measured at sea level (UK) using the Uscom BP
+™ (Pulsecor.com, Sydney 
NSW 2000 Australia) (figure 18). This device non-invasively measures blood pressure at the 
brachial artery using a sphygmomanometer. Examination of the low-frequency supra-systolic 
arterial waveforms waveform at the occluded brachial artery enables the calculation of 
peripheral augmentation index [86]. The arterial waveform in conjunction with the brachial 
blood pressure is used to provide a validated measure of central systolic blood pressure [77, 
80, 87]. The advantage of the BP
+
 over many other recent central blood pressure reading 
devices is in its ultra-portability and simplicity of use which is highly operator independent. It 
can provide a highly accurate and repeatable measurement of central blood pressure within 40 
seconds, using a simple oscillometric blood pressure device.  
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Figure 18 Illustration of the BP
+
 device used to measure central blood pressure and 
arterial compliance using the augmentation index:  
https://www.uscom.com.au/products/  
 
 Lin et al compared 94 central systolic pressures, estimated using this device to 
simultaneously measure central aortic pressures obtained at the time of coronary angiography 
in 37 individuals [87]. He found a very strong correlation in the measurements (r >0.95; 
p < 0.0001) with a mean difference (± standard deviation) in central systolic pressure of 
2.7±3.90 mmHg with a coefficient of variation of 3%. In a further validation study,  of 47 
healthy adults,  the BP
+
 central blood pressure measurements strongly correlated and was in 
agreement with that of a SphygmoCor device, which is considered the gold standard non-
invasive device for arterial stiffness assessment [88].  
 
In my 4
th
 publication, brachial and central blood pressures and the peripheral arterial 
augmentation index were measured at rest and seated at sea level, 3619m, 4600m and 5140 m 
in the Mount Dhaulagiri circuit in the Himalayas on 90 healthy adults. I went to the 
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Himalayas in support of this project but received collaborative help with data capture. The 
results of this study supported my hypothesis as it was found that the arterial augmentation 
index (marker of arterial compliance) and central blood pressure both significantly increased 
at HA. This rise largely reflected subject-related factors (eg age, sex and smoking history) 
rather than SpO2, actual altitude or AMS scores. The manuscript was published in the Journal 
of Human Hypertension (IF 2.433) [89]. Given the time frame of less than three weeks 
coupled by the information gained from my earlier acute hypobaric hypoxia experiment 
(publication 1) it can be hypothesised that the increase in central systolic blood pressure and 
peripheral augmentation index reflect earlier and increased arterial waveform reflection by the 
peripheral muscular arteries, rather than any material changes in the vascular wall or 
endothelium. Interestingly the greatest increase in central systolic blood pressure and the 
augmentation index were at 3619 and 4600m, which thereafter marginally fell suggesting the 
impact of HA acclimatisation on blood pressure homeostasis. These results emphasise the 
importance of a gradual ascent profile, which may be of particular importance for those with a 
history of sustained hypertension.  
 
Publication 5 
My 5
th
 publication study is entitled ‘the Effect of Sex on Heart Rate Variability at High 
Altitude’ was also conducted in 2016 [90]. Most of the population within this study had also 
taken part in the Dhaulagiri Blood pressure/augmentation index study above. The 
measurement of the cardiac inter beat interval for heart rate variability (HRV) analysis was 
recorded using a novel, validated, and dedicated ultraportable battery operated HRV device 
known as the CheckMyHeart Plus (Daily Care BioMedical Inc) (figure 19) [91]. I supported 
the research on the ground during baseline measures and was physically present during the 
study conduct in the Himalayas.  
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Figure 19 Illustration of the CheckMyHeart heart rate variability device in which the 
cardiac inter beat interval is obtained via two electrodes which are attached to the front 
of the anterior chest wall (personal photograph) 
 
 
This study is linked to my fourth hypothesis that ‘terrestrial HA exposure reduces HRV and 
increases risk of cardiac arrhythmias. The changes in HRV at HA are influenced by 
ventilation and biological sex and are linked to the development of acute mountain sickness.’ 
Sixty two volunteers were studied during rest, whilst seated, at sea level (SL), 3619m, 4600m, 
and 5140m.   
 
This was the first study to examine the comparative changes in HRV among men versus 
women at natural HA. The main results from this study were that HA significantly affected 
several measures of HRV (discussed later). We also observed a significant main effect for sex 
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on heart rate and time domain measures of HRV at HA, with men having consistently higher 
scores and greater variability which is a novel finding. Men also had greater low frequency 
and total power (on frequency domain analyses) than women. These sex-related differences 
were maintained with increasing HA with no evidence of a statistical interaction between sex 
and altitude for any of the HRV indices measured.  HRV did not predict either AMS or its 
severity. This result would suggest that there are clear differences in HRV between men and 
women and these differences persist. The study was published in Medicine & Science in 
Sports and Exercise (IF 4.291) [90]. 
 
Publication 6 
The 6
th
 study is entitled a ‘comparison of spontaneous versus paced breathing on heart rate 
variability at high altitude’ [92].  This prospective observational study was conducted in 2017 
on 30 healthy male volunteers over nine days at altitudes ranging from 800-4107m in the 
Bernese Alps in Switzerland in 2017.  Cardiac inter beat intervals were recorded using a 
simple digital finger sensor attached to a mobile phone (methods discussed in greater detail 
later). A patented time domain measure of HRV was provided by the ithlete App within the 
phone following a 55 second recording (figure 20) [93, 94].  
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Figure 20 Image of the ithlete sensor linked to an iPhone to record the cardiac inter beat 
intervals and the ithlete heart rate variability score 
https://www.google.com/search?q=ithlete&rlz=1C1CAFB_enGB663GB671&source=ln
ms&tbm=isch&sa=X&ved=0ahUKEwiS9tr53tngAhVcVRUIHeKOBt8Q_AUIECgD&bi
w=1920&bih=933#imgrc=kdrwHlJ5mr6oAM:  
 
 
This study was linked to my fourth hypothesis that ‘exposure to HA reduces HRV and 
increases risk of cardiac arrhythmias. The changes in HRV at HA are influenced by 
ventilation and are linked to the development of AMS.’ One of the specific research questions 
that I was keen to explore was whether paced breathing would attenuate altitude-related 
changes in HRV at HA and its potential relationship to AMS. The purchase of the devices 
was made possible via a research discount from the supplier HRV Fit Ltd. Individual 
researchers, under my direction, undertook the ‘on the round research in the Alps’ which 
involved the recording of the HRV data.  
The main message of this paper is that whilst HRV scores obtained with paced breathing 
strongly correlated with that with spontaneous breathing at moderate HA, the values during 
paced breathing were consistently higher and the measurement variability was lower with 
paced breathing.  This relationship remained consistent across multiple altitudes but appeared 
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to be affected by the presence of AMS.  Given the notable effect of ventilation and breathing 
rate on HRV, this should have translated into greater discordance in HRV scores between the 
two breathing modes at higher altitudes. However this was not observed. Although a 
significant main effect for altitude and breathing modality was observed (higher HRV score 
with paced breathing), there was no altitude-x-breathing interaction on HRV scores at HA. 
This supports the hypothesis that paced breathing does negate the HA related changes in the 
ithlete HRV score. However, given that the HRV scores were consistently higher with paced 
breathing, the two breathing methods cannot be used interchangeably and there is a risk that 
paced breathing could mitigate genuine changes in HRV with AMS. There is a need for a 
larger study at higher altitude and burden of AMS cases. This manuscript is due for 
publication in The Journal of Clinical and Diagnostic Research (IF 0.65). 
 
Publication 7  
My 7
th
 study was a parallel study from a subset of the participants from the above Bernese 
Alps study in 2017. It was entitled ‘High Altitude Affects Nocturnal Non-linear Heart Rate 
Variability: PATCH-HA Study [95]. This study was very novel as it was the first study to 
investigate HRV at natural HA using a patch cardiac Monitor and one of very few studies to 
examine nocturnal HRV. It was also the first study to examine non-linear measures of 
nocturnal HRV. This study aimed to further examine my hypothesis that HA affects HRV, by 
investigating the changes in nocturnal HRV and its relationship to AMS and sleep quality.  A 
prototype patch monitor, which is still under development, was used for this study (figure 21). 
This monitor was unique in that it was far smaller than any other available portable ECG 
monitor on the market at the time and it could record ‘the wearer’s body position (ie supine 
one back or side or upright). Moreover it could record a high resolution single lead ECG and 
the recordings were able to be sent via Bluetooth signal to a linked mobile phone for later 
cloud storage and offline analysis of HRV using dedicated HRV software.  This capability 
along with its comfort allowed it to be worn during normal sleep (without the distraction and 
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interference of traditional ambulatory monitors). In this study a one hour continuous period of 
cardiac inter-beat recording was obtained during nocturnal sleep (at 0200 hours). Sixteen 
volunteers were studied at baseline (800 m, first night) and over eight consecutive nights, at a 
sleeping altitude of up to 3600 m.  
 
Figure 21 Example of the Lumira Cardiac Patch Monitor which is applied to skin over 
the left anterior chest wall (personal photograph) 
 
 
I won a research grant (Lumira Dx) to cover the technical support and the supply of the patch 
monitors and the linked iPhones.  The data collection was undertaken by the same researchers 
used for my other HRV study which investigated the influence of sex on HRV at natural HA 
(publication 6).  
 
The key findings of this study are that non-linear HRV is more sensitive to the effects of HA 
than time and frequency domain indices. High altitude exposure leads to a compensatory 
decrease in nocturnal HRV and complexity, which is influenced by the perceived intensity of 
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exercise in the previous 12 hours. Again changes in HRV failed to predict AMS development.  
This study highlighted the influence of exercise on subsequent HRV measurement at HA and 
has challenged the results of several studies that have cited the utility of HRV measures to 
predict AMS. This study was published in Frontiers in Physiology (IF 4.13) [95].  
 
Publication 8 
My 8
th
 and final study related to this thesis submission is entitled ‘Assessment of Cardiac 
Arrhythmias at Extreme High Altitude Using an Implantable Cardiac Monitor: REVEAL HA 
Study (REVEAL High Altitude)’.  This specific hypothesis of this study was that increasing 
HA exposure is pro arrhythmic and the burden of cardiac arrhythmias is higher at greater 
altitudes.  
 
One of the greatest limitations of traditional ambulatory ECG monitors is the need for ECG 
cables which link the surface electrodes to the recording device. Even with excellent skin 
preparation these devices are highly prone to movement artefacts (eg during sleep, exercise or 
by rucksack straps) (figure 22). Furthermore, they are expensive and highly vulnerable to 
water ingress and cold damage at HA, which is not their designed environment of use.   
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Figure 22 Example of a conventional ambulatory ECG monitor (Lifecard by 
Spacelabs
TM
)
 
 
 
Two major and very recent developments in ambulatory recording are already transforming 
the monitoring of patients for the presence of important cardiac arrhythmias. The first device 
is known as an implantable cardiac monitor (ICM). These devices are implanted pre 
pectorally over the left anterior chest wall (under the skin and fascia) which means they are 
far less affected by movement artefact and electrical interference than traditional ambulatory 
ECGS. Owing to their smaller size, internal fitting (under the human skin and fascia) and 
avoidance of ECG cables they are also less intrusive than a traditional ambulatory ECG 
monitors. However, they are considerably more expensive and require a small operation for 
their insertion. They are ideal devices in circumstances where a prolonged period of cardiac 
monitoring >one week) is required as they can record single lead ECG data for up to an 
incredible three years.  
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The hypothesis of my 8
th
 study was that exposure to HA would lead to a reduction in HRV 
and an increased risk of cardiac arrhythmias. This study was unique in that it was the first to 
investigate the risk of arrhythmia development at HA using a continuously recording ICM. 
Sixteen healthy adults underwent a detailed clinical assessment to determine their health 
(clinical history, normal echocardiogram and ECG) at sea level (Poole Hospital NHS 
Foundation Trust) prior to inclusion. All volunteers underwent the operative insertion of an 
implantable cardiac monitor (Reveal LinQ, Medtronic) at sea level prior to HA exposure (at 
Poole Hospital). I was first operator in 14 out of 16 ICM implants (figure 23). The Reveal 
LINQ has superior ECG signal quality, data storage and arrhythmia detection and battery life 
to the original Reveal device. Furthermore, its stored ECG data can be uploaded wirelessly to 
secure cloud storage for remote analysis. I won a research grant from Medtronic that covered 
the cost of the implantable cardiac monitors, the supply of two dedicated devices to allow the 
upload of the data stored on the cardiac monitors at HA as well as full technical support.  
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Figure 23 Graphical illustration of the Reveal LINQ implantable cardiac tor 
a. Its method of insertion a (Source Googleimages.co.uk/Medtronic)  
 
 
 
b. its size in comparison to the previous Reveal device (personal photo) 
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This study was conducted in 2016 again at Dhaulagiri but on a completely different cohort 
and at different altitudes to the central blood pressure and HRV Dhaulagiri studies cited 
above. I went to the Himalayas to support this project. This device allowed for the continuous 
recording of the subjects’ cardiac rhythm which commenced >7 weeks prior to prior to HA 
exposure and over a time period of up to two months during an attempted ascent of Mount 
Dhaulagiri (8,167 m). A maximal altitude of 7550m was achieved by three subjects. The 
cardiac monitors remained implanted in the volunteers for a least two months post HA 
exposure. The results of this study confirmed my hypothesis that HA exposure does increase 
the tendency to cardiac arrhythmia development.  Two sustained (>30 seconds) pathological 
tachyarrhythmias (atrial fibrillation in one subject and supraventricular tachycardia in 
another) were detected only at HA above 3800m. Multiple cardiac pauses (of >2.5 seconds) 
were observed in >50% of the subjects at HA only. The frequency and duration of the cardiac 
pauses increased at higher altitudes. This study has potentially important translational 
implications for persons with a history of brady- or tachy-arrhythmias who wish to go to HA 
above >4000m. This manuscript was originally submitted as full paper but changed to a 
shorter Scientific Letter on the Journal’s request and was published in ‘Circulation’ (IF 19.31) 
[96].  
 
The deeper relevance of these publications to the background literature and the state of 
knowledge are explored further below.  
 
Background Literature Review, Research Context and Further Synthesis 
This literature review reflects the synthesis and brief overview of some of the most relevant 
published research that was available at the time of writing the manuscripts related to my 
publications within this thesis. Entrez-PubMed and Google Scholar was used for all the 
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literature searches. The vast majority of cited references in this PhD submission relate to peer-
reviewed publications that are cited on PubMed.  
 
Hypothesis 1 High altitude (HA) adversely affects cardiac diastolic function and increases 
estimated filling pressures. These changes are influenced by the mode of hypoxia and the 
hypoxic environment (publications 1, 2 and 3).  
 
There is a strong rationale to explore the effects of hypoxia on diastolic function in healthy 
human beings at HA. Across a broad range of clinical diseases that are associated with 
hypoxia, such as sleep apnoea, pulmonary oedema and chronic obstructive airways disease 
there is evidence of impairment in left ventricular relaxation and diastolic function. These 
cardiac changes have been principally observed using transthoracic cardiac ultrasound 
(known as echocardiography). The mechanism for these changes are multifactorial and are 
thought to include altered left ventricular filling secondary to the association increase in 
pulmonary vascular resistance and rise in PASP, pericardial constraint with the increased 
right ventricular pressure as well as abnormal interventricular septal motion [97]. These 
observations have led to the obvious question as to whether healthy persons exposed to the 
physiological hypoxia at HA develop significant diastolic dysfunction which is linked to 
HAPE susceptibility.  
 
Operation Everest II (OEII) Study was one of the first studies to examine the cardiac effects 
of HA exposure. At the time it was probably the most extensive and wide ranging ‘high 
altitude’ study to date [98]. This landmark study sought to examine a wide array of human 
biological responses during progressive simulated HA exposure in a hypobaric hypoxia (HH) 
chamber. Eight young adult and healthy (aged 21-31 years) male volunteers were exposed to 
progressive HH during a ‘simulated’ 40-day ascent of Mount Everest. Impressively the 
investigators managed to place both systemic arterial and pulmonary arterial catheters 
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(allowing blood sampling) at rest prior and during maximal exercise at sea level at the start of 
OE II and at PB 347 mmHg (∼20,000 ft, ∼6100 m); PB 282 mmHg (∼25,000 ft, ∼7600 m) and 
the summit equivalent: PB 253 mmHg (∼29,000 ft, ∼8848 m).   
 
Six out of the eight participants managed to successfully reach the ‘summit’. The key cardiac 
findings were that maximal cardiac output fell in response to increasing  HA, yet despite this 
ventricular systolic function at all altitudes was similar to that at sea level, or even slightly 
enhanced [99]. Interestingly, they also found that left ventricular filling pressures actually fell 
with worsening hypoxia. Right ventricular function (inferred form the physiological data and 
not directly examined) remained preserved at HA despite the substantial increase in increase 
in pulmonary vascular resistance and PASP (33 ±1 mmHg at sea level to 54 ± 2 mmHg at PB 
282 Torr). Despite the increase in PASP right ventricular pressure remained normal and there 
was no clinical evidence of right heart failure or increase in right atrial and pulmonary 
capillary wedge (indirect measure of left atrial filling pressure) pressures. Furthermore, whilst 
acute 100% O2 breathing did lower cardiac output and the PASP it did not lower the 
pulmonary vascular resistance [100].  
 
One of the obvious limitations of the Everest II study was that it utilised simulated rather than 
natural terrestrial HA. Another important limitation was that the investigators could only 
indirectly assess cardiac function using the data obtained from filling pressures and 
calculations of cardiac output and stroke volume. They did not have access to 
echocardiography (cardiac ultrasound) which is now the gold standard measure of ‘real time’ 
cardiac function. The Everest II investigators were also unable to measure regional cardiac 
function or fully quantify diastolic function. As the left ventricular filling pressures were 
normal in OEII it can be reasonably assumed that there was not severe diastolic function. 
However, in the absence of transthoracic echocardiography the presence of less severe grades 
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of diastolic function, in which atrial and ventricular filling pressures are typically usually 
normal, could not have been excluded.  
 
Using echocardiography, global and regional cardiac systolic function and complex measures 
of diastolic function can now be quantified non-invasively in a matter of minutes. In the last 
20 years we have witnessed the advent of increasingly portable yet robust echocardiogram 
machines that have even better capabilities than their large, laboratory-based predecessors.  
These advances have been exploited in three of my publications within this thesis. All three of 
the portable echocardiogram machines used in the studies linked to this thesis (Sonosite M 
Turbo 2. GE Vivid I and Q) are no bigger than a large laptop.  
 
In one of the seminal HA studies Alleman et al investigated 41 healthy adults (30 men and 11 
women; mean age 41 ± 12 years) at low altitude (550 m) and following a rapid accent to HA 
at 4,559 m [101]. Cardiac function was examined using transthoracic echocardiography. HA 
exposure led to an at least two-fold increase in the PASP which was associated with change in 
left ventricular diastolic function that was directly correlated with the severity of pulmonary 
hypertension. They observed a decrease in the mitral E/A ratio consistent with grade I 
diastolic dysfunction. The authors hypothesised that these changes actually reflected a 
significant increase in mitral A velocity and augmented atrial contraction. The authors coined 
these changes as reflecting ‘compensated diastolic (dys)function’ to explain their findings 
[101]. 
   
In a subsequent study by Kjaergaard et al two years later 17 healthy adults underwent 
transthoracic echocardiography, including tissue Doppler imaging of the septal mitral annulus 
and basal segments before and after an 18-h overnight stay in a HA simulation tent with a 
FiO2 of 12% (equivalent to 4,000 m above sea level) [102]. They measured myocardial 
velocities using tissue Doppler imaging and also measured the left ventricular Tei Index. The 
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Tei index is a measure of global left ventricular performance (known as Myocardial 
Performance Index) that has been validated [73]. It is calculated using pulsed wave Doppler 
echocardiography measured at the left ventricular outflow tract using the left ventricular 
ejection time ejection time (LVET) and isovolumic contraction (IVCT) and isovolumic 
relaxation times (IVRT) (Tei et al. 1997). The Tei index is calculated as IVCT 
+IVRT)/LVET. Again it was shown that hypoxia led to a significant increase in the E/A ratio 
owing to an increase in mitral A velocity but they also noted that there was a decrease (-26%) 
in the peak early myocardial velocity (E’) despite retained systolic function. Paradoxically the 
Tei index significantly increased. An increase in Tei function has been generally reported to 
represent a fall in global cardiac function however this rise was not at the level reported in 
patients with heart failure, which was the validation patient cohort for this measure, but 
nevertheless was an intriguing finding and difficult to reconcile given the other findings 
suggesting enhanced cardiac function.  
 
The concept of potentially deleterious effects of HA exposure on cardiac function failed to 
diminish following the studies above and if anything gathered greater momentum as the 
complexity of cardiac functional measures increased. Bernheim et al did not observe any 
significant changes in diastolic function or estimated left ventricular filling pressures among 
39 subjects (including 29 known to be HAPE susceptible) either at rest or during submaximal 
exercise at low (490 m) or high altitude (4,559 m). Moreover, changes in right ventricular 
pressure gradients did not correlate to any changes in left ventricular measures of diastolic 
function or left ventricular filling.  Zhou et al examined 96 healthy young male adults (aged 
18-35 years; mean 21.8 ± 3.6 years) old following rapid accent from 1500m to an altitude of 
3700m, where they spent 50 days involved in heavy labour (up to 10 hours per day) [103].  
Echo parameters were measured on the 50
th
 day after completing their heavy labour duty at 
HA and on the 2
nd
 and 15
th
 day after a 48-hour by bus return to lower (1500m) altitude. They 
compared their findings to a control group of similar aged adult men who were from the same 
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unit but who had not been exposed to HA. They found both the mean PASP and left 
ventricular Tei index increased. However, contrary to previous work they found that short-
term exposure to HA led to a reduction in left ventricular ejection fraction and fractional 
shortening and that these changes positively correlated with altitude. These negative 
ionotropic effects of HA on cardiac function, were partly inferred as baseline low altitude 
measures were not undertaken [103]. The authors also observed  that compared with day 50 
on the 15th day post HA exposure (hence at 1500m), the ejection fraction, systolic shortening 
and pulmonary levels returned to the same level as those of 98 similar aged male control 
subjects who were not exposed to HA. The reduction in Tei index following return to near sea 
level (1500m) was far slower. It is worth noting that the exercise burden in this study was 
considerable and may be an important confounding factor that was not addressed in the 
manuscript.  
 
In a more recent study conducted at a similar time to my thesis submission work 
echocardiography was performed to a defined protocol on 14 healthy adults over three 
altitudes: in Montreal (30 m) Canada and at Namche Bazaar (3450 m), and Chukkung (4730 
m) in the Himalayas [104]. The investigators used cardiac ultrasound to identify the presence 
of lung comets (acoustic reflections noted on ultrasound related to the presence of increased  
lung water) [105, 106]. This novel technique entails the identification of lung artefacts related 
to the presence of extravascular lung water, which is increased in the presence of clinical and 
subclinical pulmonary oedema. As expected, PASP significantly increased at HA. They 
measured the right ventricular Tei performance index and a cardiac functional modality which 
at the time was still in its infancy and known as systolic strain, which is measure of actual 
myocardial deformation. The investigators noted that the right ventricular Tei index increased 
significantly (0.32 ± 0.08 at 30 m vs. 0.41 ± 0.10 at 4730 m; P = 0.046) and that there was a 
trend toward deteriorating right ventricular free wall longitudinal strain between 30 and 
4730m (-25.9 [5.3%] vs. -21.9 [6.4%]; p=0.092). Again, it is worth emphasising that whilst 
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there an increase these values were not in the typical heart failure range. Contrary to Alleman 
and Kjaergaard they did not detect any significant changes in diastolic function. Interestingly, 
whilst there were no cases of clinical HAPE they identified lung comets, in all but one case at 
4730 m, suggesting the presence of pulmonary interstitial fluid, [104]. In another acute 
hypoxic chamber study Hanoaka sought to investigate the relative changes in the myocardial 
performance Tei Index in a participants with known susceptibility to HAPE (n=11) versus 
those who were more resistant (n=9) [107]. They found that normobaric hypoxia led to 
enhanced left ventricular myocardial performance yet impaired right ventricular performance 
in the HAPE susceptible individuals. These differences were not observed in the resistant 
cases.   
 
Whilst hypoxia is the common physiological stimulus in all of the studies cited above the 
mode of hypoxia and duration of exposure markedly differ between the studies. Some of the 
studies have used normobaric or hypobaric hypoxia whereas others have used a genuine 
natural terrestrial HA challenge.  Yet, it is not known if and to what extent the mode of 
hypoxia influences the cardiac response.  Prior to my collaborative work there had been, to 
my knowledge, only two studies that have attempted to examine the comparative cardiac 
responses to differing hypoxic environments [108, 109]. Beidleman et al noted that 
cycling time trial performance was more impaired with HH than NH at the same ambient PO2 
(equivalent to 4,300 m, despite similar cardiorespiratory responses (heart rate, mean arterial 
pressure and cardiac output) [109]. Miyagawa noted similar changes in heart rate and stroke 
volume (hence cardiac output) with exercise with normobaric and hypobaric hypoxia.   In 
neither of these studies were echocardiographic assessments of biventricular performance 
and/or right ventricular systolic pressure measured. A four way comparison of the cardiac 
adaptations to normobaric hypoxia (NH), hypobaric hypoxia (HH) and genuine HA and its 
comparison to during similar exercise with normobaric normoxia (normal sea level breathing) 
had not been performed. This is examined for the first time in one of my thesis studies.    
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In summary, previous research has clearly shown that acute hypoxia and HA leads to an 
increase in PASP. The effects of HA on diastolic function are mild and depend on the 
population studied and may be influenced by the hypoxic environment and its degree. 
Measures of global and right ventricular function have yielded very mixed results as have the 
data examining the inter relationships between right and left ventricular function.   Acute 
hypoxia does not appear to lead to an increase in left ventricular filling pressure. There is very 
limited data on right ventricular filling particularly with terrestrial HA. The majority of the 
published studies have mainly examined either a single altitude or level of hypoxia and the 
influence of exercise needs much greater clarification. Little work has been done on the on 
the relationship between potential changes in cardiac function to the development of HA 
related illness and AMS. A comparison of normoxia to the three main modalities of hypoxic 
challenge had never been previously conducted.  
 
All of these unresolved issues are addressed, at least partially, in the series of independent yet 
linked research studies within this thesis (studies 1, 2 and 3). My data has confirmed that 
whilst acute hypoxia and HA exposure leads to minor alterations in diastolic indices it does 
not lead to an increase in ventricular filling pressures or severe diastolic dysfunction. Whilst 
the Tei index does increase with HA this does not reflect adverse effects of cardiac filling or 
global cardiac dysfunction and likely relates to the shortening of the ejection time with 
increased heart rate. Acute HH and NH elicit similar hypoxic effects on resting cardiac 
responses to that of genuine HA exposure. However, differences emerge with exercise with a 
greater increase in RVSP, right ventricular Tei Index and oxygen desaturation. This must be 
borne in mind when interpreting the results of acute hypoxia and natural cardiac studies.  
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Hypothesis 2 High Altitude exposure leads to an abnormal rise in circulating biomarkers of 
myocardial injury that are linked to the development of acute mountain sickness.  
There are two cardiac biomarkers that have dominated the clinical and research literature over 
the least 10 years. The most established and widely used cardiac biomarker is the 
measurement of cardiac troponins. Cardiac troponins are regulatory proteins that are integral 
to muscular contraction. Cardiac troponin I and T are more exclusively found in skeletal 
muscle and hence their release into the systemic circulation is a sensitive and relatively 
specific marker of myocardial injury [110].  Cardiac troponins are the gold standard 
circulating biomarker for the diagnosis of myocardial injury, necrosis (cell death) infarction 
[111].  
 
Brain natriuretic peptide (BNP) is probably the second most widely used and studied cardiac 
specific biomarker.  It is a peptide that is secreted by cardiomyocytes within the left and to a 
lesser extent (less muscle) right ventricle in response to increased ventricular volumes and 
pressure overload [112]. It is secreted in two isoforms from a prohormone known as 
proBNP:  NT-proBNP and the biologically active acid polypeptide BNP-32. Both forms can 
be measured clinically, though NT-proBNP tends to be more typically measured in routine 
clinic practice given its stability in whole blood of up to 72 hours [112]. Where circulating 
BNP is examined it needs to be either measured in whole blood within four hours or 
centrifuged from whole blood within one hour (ideally)  and its serum component stored at <-
20°C for later batched analysis. Along with the use of transthoracic echocardiography the 
measurement of BNP and NT-proBNP are now the gold standard marker for the diagnosis of 
heart failure [113].  
 
Given the utility of Cardiac tropoinins and BNP to identify cardiomyocyte injury and stretch 
respectively they could have valuable translational uses for the examination of the 
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controversial issue of whether hypoxia and HA exposure leads to myocardial dysfunction and 
injury. This is particularly pertinent as it is well known that changes in these biomarkers, 
particularly troponins can precede any notable impairment in cardiac function, and hence 
before any significant notable changes observed by echocardiography [114].  
 
In the first study to examine the effects of HA on BNP in healthy humans Tosher investigated 
10 healthy non-HAPE-susceptible lowlanders during acute exposure to 5200 m in Bolivia. He 
found that whilst the estimated PASP, measured using echocardiography, significantly 
increased as expected at HA, he failed to observe a rise in NT-pro BNP [115].  
 
In another recent study from our research group [37] - not included in this PhD submission) 
the above findings were challenged. We (Boos C on authorship) found that HA led to a 
significant rise in both NT-proBNP and BNP which were closely correlated and that BNP 
levels were significantly higher in those who developed severe AMS versus those who did not 
[37].  Furthermore, BNP levels correlated with total body water supporting an association 
between the rise in BNP and failure to clear water with AMS. This finding is interesting as 
one of the fundamental functions of BNP is to physiologically promote diuresis to counteract 
the volume overload of heart failure. Increased diuresis is fundamental to HA acclimatisation 
and altered diuresis is thought to be one of the principal mechanisms for the development of 
AMS which is implicated by our study results [40]. Indeed, animal studies have shown that 
BNP is released from isolated perfused ventricles in response to local hypoxia [116]. Hence 
the examination of BNP levels in persons with AMS could be important. Fedderson et al 
examined 14 (10 men and four women) healthy adult mountaineers who ascended to an 
altitude of 5050m from 100m over nine days [117]. He found that BNP (measured using a 
point of care assay on whole blood) values did not significantly increase from baseline to HA, 
despite evidence of increased diuresis. Furthermore, a relationship between BNP and AMS 
development was not observed; in fact, BNP levels were similar in the six subjects who 
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developed AMS versus the eight who did not.  Interestingly, the authors did note a significant 
elevation in BNP in a single subject who developed features consistent with HAPE. They 
concluded that BNP was not the cause of HA-related diuresis [117].  
 
In another study by our group (again not in this thesis, Boos C on authorship) Mellor et al 
examined 48 healthy adults post-trekking and at rest at three altitudes: 3833 m, 4450 m, and 
5129 m. NT-proBNP, hs-cTnT and hsCRP (C reactive protein; marker of inflammation) 
measured using immunoassays, and PASP, measured using echocardiography [118]. We 
found that NT-proBNP, hs-cTnT, hsCRP all increased at HA and that the increase in NT-
proBNP  and hs-cTnT  were linked to higher PASP  (≥40 mm Hg) and the natriuretic peptides 
to AMS development and the cTnT more closely to exercise.  Independent predictors were 
not examined.  
 
I recently described the case of a highly experienced healthy mountaineer who presented with 
HAPE at 3800m and a significant simultaneous increase in BNP (111 ng/L; normal <5), hs-
cTnT (43.7 ng/l) and PASP (Boos, Holdsworth et al. 2013). Despite these biomarker 
increases, particularly in relation to BNP, the estimated left ventricular filling pressures 
remained normal [35]. In another study Gao et al observed significantly higher levels of NT-
proBNP (pg/ml) at HA (>3,000m) in 21 individuals diagnosed with HAPE versus those 
without HAPE [119]. They also noted that treatment for HAPE led to a drop in the BNP 
levels to values observed in the control group strengthening the potential utility of BNP as a 
marker of HAPE and its severity.  
 
The published data on the effects of HA on cardiac troponin levels have also been 
inconsistent. In one of the seminal studies Davila-Roman studied 14 participants who were 
competing in a 163-km HA ultra-mountain marathon (elevation 2,350 to 4,300 m) 
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[120]. Transthoracic echocardiography and cTnT levels were measured before the race, 
immediately post and then again 18-24 hours later. The lower limit of detection for the cTnI 
used was is 1.5 mg/ml and the upper reference limit was 3.1ng/ml. Despite evidence of right 
ventricular impairment (reduced fractional area change with right ventricular dilatation) on 
measures of cardiac function on echocardiography immediately post exercise in 9 out of the 
14 subjects studied  cTnI levels were undetectable in all but one subject and this rise was very 
small (5 ng/ml) [120]. Interestingly, the subject with small rise in cTnI had marked right 
ventricular dysfunction and the highest PASP at 65 mm Hg, which represented 35 mmHg 
increase from baseline. At 18-24 hours post-race the subject with the elevated cTnI had 
detectable but normal (1.8 ng/ml) cTnI levels and all echocardiograms had returned to 
normal.  
 
Shave et al (n=8) did not observe any significant differences in either systolic or diastolic 
function following a 50 mile cycle ride under NH and a marginal rise in cTnT was only 
observed in one athlete [121]. Conversely, Ortega et al observed a significant increase in  
cTnI immediately after a mountain bike challenge (distance 95 km, 
cumulative altitude difference 2340 m) conducted on eleven amateur male cyclists [122] and 
Banfi et al noted a small but significant rise in both cTnT and BNP among 15 mountain 
marathoners following a race [123].  
 
These publications have identified inconsistencies in the available data on the effects of acute 
hypoxia and HA exposure on these cardio specific circulating biomarkers. As with the data on 
cardiac function, the findings have been heavily influenced by the individual, the HA 
environment and the burden of exercise. These studies have predominantly examined the 
impact of a single high intensity exercise in non-acclimatised subjects. Furthermore, again it 
is difficult to fully appreciate the significance of the positive HA studies when a sea level or 
lower altitude exercise control study on the same population was never conducted. Several of 
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these studies predate the availability of modern high sensitivity cardiac troponin assays. These 
assays are able to detect the same biomarker but at much lower concentrations than were 
previously possible with a high degree of accuracy. High-sensitivity assays are thus able to 
detect changes in troponin concentrations even within the normal limits in healthy 
populations. By being able to accurately detect lower concentrations of cardiac Troponin in 
the blood they are able to identify earlier and smaller changes in troponin which has huge 
research and clinical applications. For example, the high-sensitivity Roche Elecsys troponin T 
(hsTnT) assay, used in my local hospital (Poole Hospital NHS) has an upper limit of normal 
(99
th
centile) of 14 ng/L, which removes the need to wait several hours after the onset of chest 
pain symptoms to reliably confirm or exclude a diagnosis of myocardial infarction.  
 
In this thesis I have presented a study that investigated the effects of increasing altitude on the 
levels of ultra-high sensitivity cTnT levels (publication 2). The factors influencing the 
potential rise in cTnT and their relationship to changes in cardiac function (using portable 
echocardiography) and HA related symptoms are examined for the first time.  This research 
has shown that the rise in cTnT tends to be mild and not in the pathological range. The 
increase relates to the rise in cardiac output (hence linked to exercise), PASP and degree of 
hypoxia and not to any changes in cardiac function or filling. Hence, whilst hypoxia and 
exercise at HA does influence circulating cardiac troponin levels this influence in a non 
HAPE population is minor, transient (not sustained) and does not reflect the presence of 
significant myocardial injury.  
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Hypothesis 3 Acute High altitude reduces arterial compliance and increases central blood 
pressure.  
The vascular response to acute hypoxia is highly complex and involves both local nitric oxide 
mediated vasodilatation [124] and sympathetically mediated arterial vasoconstriction [125], 
that act to balance vascular tone. In healthy adults the net effect is a rise in resting heart rate 
with variable changes on brachial blood pressure depending on the severity and duration of 
hypoxia [52, 69, 124-126]. Sustained exposure (>24 hours) to terrestrial HA tends to increase 
systolic and diastolic blood pressure which is mostly evident at night [46, 127-129].  
 
There are a number of rational reasons to explain the potential vasopressor effects of acute 
hypoxia and HA. As mentioned above acute hypoxia leads to increased sympathetic 
activation. Another potentially important mechanism relates to the effects of hypoxia on 
arterial endothelial function. The endothelium is also a principle regulator of arterial stiffness 
and influences both peripheral and central arterial pressure (Wilkinson et al., 2002; Boos et 
al., 2007). Acute hypoxia has been shown to cause endothelial activation and even 
dysfunction within the systemic and pulmonary artery circulation in vulnerable healthy adults 
[130, 131]. It has been shown that reduced nitric oxide availability and an impairment of 
vascular endothelial function in the systemic circulation may be a key mechanism for the rise 
in PASP among HAPE susceptible individuals [132-134].  
 
The measurement of brachial blood pressure is one of the obviously and most practical ways 
of assessing the potential vasopressor effects of HA. A further and potentially more useful 
clinical marker of cardiovascular risk would be the measurement of central blood pressure 
(within the ascending aorta) as it more closely reflects the pressure afterload on the central 
vital organs (heart, brain and kidneys) [76]. One of the critical obstacles to the measurement 
of central blood pressure at HA relates to the difficulties of measuring central blood pressure 
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itself. As mentioned earlier this has traditionally required the use of an arterial sensor catheter 
delivered into the ascending aorta via peripheral arterial access. This would be very 
challenging to do at terrestrial HA and particularly above 4000m. Fortunately, there are now 
several available devices that can provide a non-invasive measure of central blood pressure. 
This is typically acquired using combined information from the arterial waveform (at the 
brachial or radial artery) and the knowledge of the brachial blood pressure typically using a 
generalised transfer function [77].  These indirect peripheral measures of central blood 
pressure have been consistently shown, with a number of available devices, to strongly 
correlate with that obtained using gold standard catheter measures [77]. However, the level of 
agreement (and bias) does appear to be highly dependent on the type of device and its method 
of central blood pressure estimation [135, 136].   
 
Widespread sympathetic activation and arterial endothelial dysfunction are common to the 
aetiology of both HAPE and AMS and are implicating factors in the development of systemic 
hypertension [137].   It would be plausible to hypothesise that HA exposure would lead to an 
increase central blood pressure and a fall in arterial compliance and that these changes might 
be linked to the development of HA related illness. This concept has not been proven or 
demonstrated. The availability of ultraportable devices that are capable of measuring both 
central blood pressure and arterial compliance has paved new research avenues at HA. The 
ability to almost simultaneously examine arterial compliance and central blood pressure as 
well as cardiac performance using echocardiography has provided novel research 
opportunities at HA that would previously have been impossible.  
 
A number of investigators have examined the effects of acute hypoxia on arterial compliance. 
The use of simulated hypoxia and very short duration of hypoxic exposure (<1 hour) 
dominated the earlier research in this field [69, 124, 126]. These studies have shown that 
acute NH leads as an increase in resting heart rate and a significant reduction in the arterial 
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augmentation index and systemic vascular resistance with variable effects on arterial blood 
pressure.   
 
There have been very few terrestrial HA studies in which the effects of genuine HA on 
arterial stiffness or central blood pressure have been studied and the available data has been 
conflicting.  In the first terrestrial HA study Rhodes et al examined the effects of HA on 
brachial blood pressure, arterial stiffness (using a measurement known as the stiffness index) 
and vascular tone (by measurement of the reflective index)  using a non-invasive finger 
photoplethysmography [138]. Seventeen adults (three with a history of hypertension) were 
studied at sea level, 3,450m and 4,770m over an 11 day ascent at HA. They observed that 
HA exposure was associated with an increase in brachial blood pressure without affecting the 
arterial stiffness Index. However, they did note temporal changes in a surrogate measure of 
endothelial function (and vascular tone known as the reflective index). They observed a non-
significant fall in the reflective index (hence lower vascular tone) during first day at 3,450m 
from 74.4±7.9% to 70.5±13.8% (p > 0.05) and significantly so by 4,770m (69.9±12.0%; p < 
0.02) which then reverted to baseline with acclimatisation. The changes in the stiffness index 
and reflective index did not relate to changes in blood pressure or the presence of AMS. They 
did not examine central blood pressure or associated changes in cardiac function. There were 
also clear limitations in their method of large arterial stiffness assessment which related to 
difficulties in obtaining good pulse waveform traces at the finger at increasing HA. 
 
In another recent HA study Parati et al (2013) investigated 42 adults (21 males, age 36.8 ± 
8.9 years) who were randomised to double blinded treatment with either acetazolamide 250 
mg b.i.d. or placebo [128]. They examined brachial blood pressure, pulse wave velocity 
(PWV) and arterial augmentation index using a high-fidelity PulsePen device. The subjects 
were studied at baseline sea level and following two days of treatment and after 6h and on 
3rd day after exposure to high altitude at (Capanna Regina Margherita, Monte Rosa, 4559 
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m). HA (versus sea level) led to a significant increase in brachial diastolic (p<0.005) and 
mean blood pressure in the placebo group, which was prevented by the use of oral 
acetazolamide. There was a non-significant rise in both brachial and central blood pressure 
which was also prevented by acetazolamide.  There was no significant change in carotid 
femoral PWV. Conversely, HA led to a significant increase in the augmentation index 
(normalized for a theoretical heart rate of 75/minute) in the placebo but not acetazolamide 
group. Given that acetazolamide is a recognised first line drug for the prevention and 
treatment of AMS (mechanism includes reducing alkalosis to improve ventilation [15]) this 
data further supports this and endorses a potentially additional role for acetazolamide to 
reduce the haemodynamic effects of hypobaric hypoxia.  
 
My fourth publication in this thesis submission represents the first study to explore the 
effects of incremental terrestrial HA on both central blood pressure and the arterial 
augmentation index. The potential factors influencing changes in these parameters at HA, 
including the degree of hypoxia and their relationship to HA related symptoms were 
explored. My data showed that HA led to an increase in central blood pressure arterial 
augmentation index which were strongly correlated (as expected), confirming the data 
reliability. There was no link between changes in either measure to the development of AMS. 
This data suggests that the increase in the arterial augmentation index following hypoxia is 
not explained by a true increase in arterial stiffness which takes many months and generally 
years to develop.  The increased in augmentation index with HA more likely relates to 
haemodynamic changes in the arterial wall which lead to earlier arterial wave reflections 
(which act to increase the augmented pressure and augmentation index). These findings have 
implications for persons with known and particularly poorly controlled hypertension, who 
plan to travel to HA. These persons need to be aware of the potential for significant further 
increases in their blood pressure at HA. A further HA study with the inclusion of 
hypertensive subjects would be insightful as we don’t currently know whether the increase in 
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the blood pressure would be even greater and pose a greater risk to these individuals.  
Hypothesis 4 High Altitude exposure leads to a reduction in heart rate variability and an 
increased risk of cardiac arrhythmias. The changes in HRV at HA are influenced by 
ventilation and biological sex and are linked to the development of acute mountain sickness 
 
There are a number of possible reasons to explain why acute hypoxia and the HA 
environment might affect heart rhythm and potentially increase the risk of cardiac arrhythmia 
development. It has been widely reported that sudden cardiac death is the leading causes of 
non-traumatic deaths in adults at HA, particularly during leisure time activity [51, 54, 55]. 
Given that most sudden cardiac deaths are caused by sustained haemodynamically significant 
cardiac arrhythmias it would be reasonable to hypothesise that hypoxia and HA could be pro-
arrhythmic [56, 139]. Furthermore, several of the factors that are known to be provocative in 
the development of cardiac arrhythmias are synonymous with significant HA exposure and 
include sympathetic activation, heavy exercise, dehydration, mental stress and sleep 
deprivation [4, 5].   
 
 
This hypothetical HA-arrhythmia link has prompted medical researchers to obtain more 
robust data from detailed ECG monitoring at HA.  Delivering this research has been very 
challenging at terrestrial HA. Consequently, there has been a surprising paucity of real world 
data during terrestrial HA exposure. The majority of published studies have been performed 
during passive ascent, simulated hypoxia (HH and NH) and using repeated 12 lead ECGs 
[140-143]. There is far less data following continuous ambulatory ECG monitoring [144-
146]. 
 
 
In a seminal ECG at extreme terrestrial HA study, Hori et al examined nine adults  during an 
ascent of up to 7800m (mean 5710 m) [142]. They acquired 7.5 second ECG print outs, every 
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60 minutes, over a period of 16-24 hours at HA. They noted that the nocturnal corrected QT 
interval (QTc) was also significantly prolonged in spite of shortened RR interval. This  was 
challenged in a very large recent simulated HA study whereby the resting 12 lead ECGs of 13 
healthy adults  were compared at sea level with that at 3000-3600 m [147]. The authors 
analysed a series of 10 ECG complexes at seven time periods over the 30 minutes. They 
found that there was no discernible difference in P wave, PR, QRS, and QT interval. 
However, there was an overall decrease in the T wave amplitude. Coustlet et al investigated 
456 adults during normoxia and following 20 minutes exercise under simulated HA using NH 
(equivalent to 4800m)  [141]. They found that whilst the amplitude of all ECG wave 
deflections had reduced, there were no significant abnormalities and no single ECG change 
was predictive of AMS development.  They did not measure the QT interval.  
 
Kujanik et al studied 20 healthy elderly men (50-64 years) during passive ascent to HA in a 
cable cabin at 898 m, 1764m, and 2632m [146]. They observed a significant increase in both 
supraventricular and ventricular premature beats but no evidence of sustained arrhythmias. In 
a recent study (Boos C et al), not included in thesis submission) of 10 healthy adults during 
active exercise with ascent and decent at 2610-5140m ventricular premature beats 
(extrasystoles/ectopy) were observed in all subjects [144]. Supraventricular premature beats 
were observed in less than half of the cohort.  Whilst a trend to higher SVE and VE burden on 
ascent versus descent was observed this did not reach statistical significance. This research 
raised the suspicion that HA could be pro-arrhythmic. ECG artefacts were relatively high 
(6.0±14.5%) and most prominent during the most intense exercise which is the period of 
greatest interest.  
 
There has been only one previous study has an ICM been used to capture ECGs at HA to 
identify its potential pro-arrhythmic risk. Woods et al studied nine participants at sea level (>2 
weeks) and for approximately three weeks at HA (1400 to 5200m) using a first generation 
65 
 
ICM (Medtronic
TM
, Model 9525) [148].  They observed that development of likely fast atrial 
flutter (150/minute) lasting 8.5 minutes in one subject (11.1%) immediately after a period of 
severe exertion at 4500 m. Unfortunately, being a first generation device it did not have auto-
detection settings and hence all ECG uploads needed to be triggered at the time of symptoms, 
undermining its capabilities. Consequently, there was a considerable risk of missing important 
asymptomatic episodes, particularly during sleep. The Reveal LINQ ICM device has 
transformed the landscape for cardiac monitoring and its capabilities were examined in my 
eighth publication [96]. This device is seven times smaller than the device used by Woods et 
al and can be implanted by an injectable technique with the added capability of being able to 
remotely monitor its recordings via a conventional wired telephone signal. 
 
In my 8
th
 publication within this thesis I examined the hypothesis that HA exposure increases 
risk of cardiac arrhythmias by implanting Reveal Linq devices in 16 healthy adults travelling 
to extreme HA [96]. My findings supported my study hypothesis as more than half of the 
studied subjects developed significant cardiac arrhythmias at HA. This was manifested as the 
development of significant brady-arrhythmias and pauses (>2.5 seconds) in the majority, but 
with the additional observation of two sustained (duration >30 seconds) pathological 
tachyarrythmias (atrial fibrillation of >5 hours in one subject and a supraventricular 
tachycardia of 31 seconds in another) at HA. Interestingly, all of the arrhythmias were 
detected at >3500m and there were no arrhythmias during >4 months of recording, including 
activity at activity at sea level and lower altitudes. This was the first definite study to confirm 
this. All of the bradyarrhythmias were nocturnal and asymptomatic and the severity and 
number of pauses increased with altitude gain and likely represent the effects of increased 
nocturnal vagal tone during possible sleep disordered breathing. These findings have 
important clinical implication for cardiac patients with a history of brady and 
tachyarrhythmias that need to be advised that there is a theoretically increased risk 
perpetuation above 3500m.     
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The second major technical advance in portable cardiac monitoring has been the very recent 
development of the ECG patch Monitor. They have the ability to non-invasively combine the 
features of the present-day Holter and event/loop recorders with real-time data transmission 
and analysis capabilities [149]. They are attached to the skin via an adhesive carrier with 
embedded wet gel electrodes. The electrodes within the patch are closely spaced to facilitate 
the placement of the adhesive patch on the body. This is a rapidly expanding field and the 
capabilities of these devices are already extending well beyond continuous ECG monitoring 
to the potential measurement of respiratory rate, skin temperature, physical activity, step 
counts. There is even the potential to measure capillary SpO2 recording and record location 
and track distance and altitude using GPS. Their translational impact on HA research is 
enormous. A patch with detailed cardiac rhythm monitoring has not been tested at HA.  
 
My 7
th
 publication, in this thesis, represents the use of a novel ‘prototype’ cardiac patch 
monitor to measure changes in heart rate and its variability at HA [95]. This allowed, for the 
first time, the ability to non-invasively record the cardiac inter beat interval comfortably 
whilst sleep at HA. This Lumira cardiac patch monitor has the added advantage of being able 
to record the position of subjects at the time of recording (upright, on side lying or on back). 
This enhanced capability is of fundamental importance in the measurement of HRV, given the 
influence of position of its results.   
 
The third crucial advance in portable cardiac monitoring technology, related to my HA 
research, has been the advent of other wearable technologies for the measurement of the 
cardiac inter beat intervals and hence heart rate. This has most notably been with the use of 
heart rate sensing chest straps linked to smart watches or smart phones and more recently via 
heart rate sensors embedded within the wrist straps of smart watches or within simple finger 
67 
 
sensors. At present these devices do not have the capabilities for complex heart rhythm 
detection and function mainly as heart rate monitors to facilitate athletic training. Another 
form of ‘wearable technology’ is the use of a simple finger sensor linked to smart phone to 
detect heart rate which was utilised in my 7
th
 publication at natural HA [150].  
 
One common application of all of these devices is their ability to detect the cardiac inter beat 
interval which is essential for the quantification heart rate variability (HRV). Research has 
shown that acute hypoxia and HA exposure can lead to significant alterations in HRV [52, 
150-160]. The generable interpretation of these changes and supported by hormonal data (eg 
measurement of urine and circulating catecholamines) is that acute hypoxia induces an initial 
decrease in parasympathetic and increase in sympathetic tone, which is partially reversed with 
acclimatisation. This interpretation is probably over simplistic but nevertheless, does 
emphasise the importance of autonomic control in effective HA acclimatisation. Indeed, 
alterations in autonomic balance have been cited as one of the pathophysiological factors in 
the development in HA-related illness and HACE [15, 27].  
 
The results of research into the relationship between changes in HRV and HA-related 
illnesses are inconclusive [15, 161-165]. There are number of factors that might help to 
explain this. Firstly there was a wide range of differing HRV measures used in these studies. 
Secondly, there was major heterogeneity in the populations (ages and men versus women) 
studied as well as the HA profile (ascent, height, passive versus active ascent). Finally, even 
the duration of cardiac recordings varied considerably between studies (minutes to hours).  
 
The array of HRV parameters that are currently available is staggering. Whilst many of the 
simple time and frequency domain measures are highly correlated a number of highly 
complex and novel measures of HRV measures have evolved. These include detrend 
68 
 
fluctuation analysis, correlations dimension and entropy [166, 167]. The complexity of HRV 
measures and their interpretation can be very challenging, even for those actively involved in 
their use (myself included). 
 
In the last 10 years we have witnessed the development of multiple highly portable methods 
to examine HRV. The capabilities of these devices are highly variable and whilst the majority 
can provide HRV outputs within seconds of full data capture there is usually the option of 
later offline further data analysis using a variety of HRV analysis software.  Sensors can 
range from a simple finger probe (figure 12), wrist or chest strap sensor linked to a 
smartphone (eg ithlete™) or smartwatch to more advanced yet dedicated ECG derived 
portable HRV devices (eg CheckMyHeart Device
TM
) [93, 94]. These modern portable devices 
have transformed the research opportunities as traditional HRV devices were both largely non 
portable and prohibitively expensive.  
 
One of the key potential confounders in HRV analysis relates to the influence of breathing on 
HRV. It is generally recognised that controlled breathing during the measurement of HRV 
reduces the variability in the results variance. However, it is still uncertain whether this is 
better done using the encouragement of slow and relaxed breathing or using timed breathing 
prompts. This issue becomes even more contentious at HA where hypoxia driven 
hyperventilation is part of the physiological adaptation [8]. It could be strongly argued that 
the imposition of a slower breathing pattern could potentially negate the important interaction 
between physiological breathing on autonomic output. My study of the influence of 
spontaneous versus timed breathing at HA was the first to compare HRV under these 
conditions.  
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Another area of uncertainty relates to the influence of biological sex on HRV and whether 
any observed differences or similarities noted at sea level are maintained at HA. Differences 
in several measures of HRV and indirect measures of autonomic tone have been reported 
between men and women [168-171].  Women tend to have lower blood pressure yet relatively 
higher heart rates than men. There is some evidence to suggest that women are more 
vulnerable to AMS development and are more likely to suffer with a greater severity [172-
174]. This raises the question of whether differences in autonomic regulation and relative 
HRV between men versus women help to explain this finding; a question that was addressed 
for the first time in publication 5 of this thesis. Whilst there are important biological 
differences between men and women relative changes in their HRV may add further insight 
into their differences in HA acclimatisation and susceptibility to HA related illness. A 
prospective study examining potential sex related changes in HRV at HA has not been 
previously conducted. In this thesis I have described what is to my knowledge the first study 
to examine the influence of biological sex on changes in HRV and its links to AMS. In this 
study I found that, whilst HRV measures differed between men and women, these differences 
were maintained at HA.  This suggests that the effects of HA on HRV remain consistent in 
both men and women.  
 
Another potential clinical application of HRV is its utility to identify individuals at high risk 
of developing adverse cardiac events including significant cardiac arrhythmia and even 
sudden cardiac death. Reduced HRV has been strongly linked to an increased the risk of SCD 
among a number of different clinical patient groups [52, 175-177].  Its utility for risk 
prediction in healthy persons has been less well established. However, there is data emerging. 
For example in the Copenhagen Holter Study of 678 health adults (aged 55-75), it was shown 
that nocturnal HRV was a strong and independent predictor of the development of stroke 
[178]. The authors go on state that whilst the mechanisms for this finding was uncertain they 
hypothesised from their data that reduced parasympathetic activity may have increased the 
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risk of stroke by increasing the risk of cardiac arrhythmias. Animal data has also supported 
the link between reduced HRV and arrhythmic risk in healthy hearts. For example it has been 
shown in a single animal study of 43 healthy dogs that reduced vagal activity using HRV was 
predictive of higher fatal cardiac arrhythmic risk during their first myocardial ischemic 
episode. It is still not known whether alterations in HRV at HA are predictive of arrhythmic 
risk. I was unable to answer this question. I did not find a link between HRV measures and 
AMS. The patch monitor did not have sufficient rhythm detection capabilities to fully explore 
this relationship and the Reveal LINQ whilst superb as a method of detecting cardiac 
arrhythmias its platform did not allow for the detailed inter beat transparency to allow HRV 
quantification. The integration of the two capabilities would be a worthy future study.   
 
Concluding synthesis 
This thesis addresses four hypotheses and presents eight original research studies that have 
examined the cardiovascular responses to acute hypoxia and natural high altitude exposure in 
healthy adults.  
 
My first and second studies have led me to partly reject my hypothesis that acute hypoxia and 
HA exposure adversely affects cardiac diastolic function and increases estimated filling 
pressures. My data has convincingly shown that minor alterations in diastolic function do 
occur in response to hypoxia that are sustained, however advanced diastolic function and 
increase in estimated left ventricular filling pressured do not occur.  The changes in diastolic 
function are influenced by the hypoxic environment (hypobaric versus normobaric hypoxia 
versus natural HA). Based on the findings of my second study my has led me to reject my 
second hypothesis HA leads to an abnormal rise in circulating biomarkers of myocardial 
injury that are linked to the development of acute mountain sickness. Whilst HA exposure did 
lead to a significant increase in cardiac troponin T the effect size and increase was marginal 
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and was not associated with the development of AMS or to changes in cardiac function. The 
troponin rises tended to be affected by exercise and its associated increase in cardiac output 
and the rise in pulmonary artery systolic pressure with increasing hypoxia.   
 
My first and sixth studies support my third hypothesis that acute HA exposure reduces arterial 
compliance and increases central blood pressure. However, these effects plateau with HA 
acclimatisation and relate to haemodynamic effects of hypoxia on the arterial wall and arterial 
wave reflections rather than any sustained increased in large artery stiffness.   
My 5-8
th
 Studies relate to my hypothesis that exposure to HA exposure reduces heart rate 
variability (HRV) and increases risk of cardiac arrhythmias. The changes in HRV at HA are 
influenced by ventilation and biological sex and are linked to the development of acute 
mountain sickness.  My data has supports the first part of my hypothesis as HA exposure 
reduces time domain measures of HRV which then increases with acclimatisation.  My data 
(5
th
 study) suggests that that there are consistent differences in HRV between men and women 
which become more significant at HA.  However, changes in HRV (5
th
 and 6
th
 studies) were 
not predictive of AMS or its severity.  
 
Finally my eight and final publication supported my hypothesis that HA increases the risk of 
developing cardiac arrhythmias. My data demonstrated that this is true for both 
bradyarrhythmias and pauses which increased in number and severity with increasing HA and 
probably reflected increased vagal tone. HA increase the risk of narrow complex 
tachyarrhythmias which was manifested as a prolonged episode of nocturnal atrial fibrillation 
(which was likely vagally-mediated) and one episode of exercise induced supraventricular 
tachycardia which was likely sympathetically triggered.  
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The results in this thesis leads me to conclude that acute HA-related hypoxia induces early 
sympathetic activation followed by delayed parasympathetic activation with acclimatisation. 
These factors might explain the increase in heart rate, central blood pressure and 
proarrhythmic risk and the increasing burden of pauses at higher altitudes.   
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Abstract 
Background and Aims:  This study investigated, for the first time, the effects of simulated 
high altitude, following acute hypobaric hypoxia (HH), on simultaneous assessment of large 
artery stiffness and endothelial function and its inter-relationship to left ventricular (LV) 
diastolic function, pulmonary artery systolic pressure (PASP) and estimated PA vascular 
resistance (PVR). 
Methods: Ten healthy subjects were studied at baseline pre and following acute HH to 
4800m for a total of 180 minutes. Assessments of LV diastolic function, mitral inflow, 
estimated LV filling pressure (E/e’), PVR and PASP were undertaken using transthoracic 
echocardiography. Simultaneous assessments of arterial stiffness index (SI), systemic 
vascular resistance (SVR), vascular tone and endothelial function (reflective index [RI]) were 
performed using pulse contour analysis of the digital arterial waveform.   
Results:  Acute hypoxia led to a fall in SpO2 (98.1±0.7 vs.71.8±7.1%; p=0.0002), SVR 
(1589.1±191.2 vs. 1187.8±248.7; p=0.004) and RI (50.8±10.3 vs. 33.0±6.5%; p=0.0008) with 
an increase in PASP (24.3±2.2 to 35.0±5.3mmHg; p=0.0001) and estimated PVR 
(116.40±19.0 vs. 144.6±21.5; p<0.001). There was no rise in either SI (p=0.13), mitral early 
annular early e’ filling velocity or E/e’. There was a significant inverse correlation between 
SpO2 and PASP (r=-0.77; p<0.0001), PVR (r=-0.57; p=0.008) and between the fall in SpO2 
and change (∆) in RI (baseline vs. 150 minutes, r=-0.52; p<0.001). There was a modest 
inverse correlation between ∆RI (lower ∆RI=worsening endothelial function) and ∆PASP (r=-
0.55; p=0.10) and a strong inverse correlation between ∆RI and ∆PVR (r=-0.89; p=0.0007).  
Conclusions: Acute hypobaric hypoxia does not significantly alter large artery stiffness or 
cause overt LV diastolic function. However the degree of hypoxia influences both the 
systemic endothelial and pulmonary vascular responses. This noted association is intriguing 
and requires further investigation. 
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Introduction 
Pulmonary arterial (PA) vasoconstriction is one of the key physiological responses to high 
altitude (HA) exposure and may be a contributory factor to the associated limitation in 
exercise capacity [49, 179]. The systemic vascular response to hypoxia depends on the 
balance between local endothelial derived vasodilatation [124] and sympathetically mediated 
vasoconstriction [125]. Despite hypoxia driven PA vasoconstriction and increase in PA 
systolic pressure (PASP) there is, in contrast, net systemic vasodilatation and a variable 
clinical blood pressure response to hypoxia [69, 131].   
Endothelial activation and even dysfunction has been observed in both the systemic and PA 
circulation following hypoxia in healthy controls [130, 131] and among individuals prone to 
HA pulmonary oedema (HAPE) [133, 134]. The endothelium is also a principle regulator of 
arterial stiffness [85, 180]. There have been very few studies that have investigated the effects 
of hypoxia on arterial stiffness and its relationship to endothelial function under hypoxic 
conditions and the findings have been inconsistent [66, 69, 138].  This has clinical 
implications as changes in arterial stiffness influence diastolic function and left ventricular 
(LV) filling [52, 82, 181, 182]. Variable changes in LV diastolic function (including no 
change in some studies) have been reported [102, 183-185] and in a single study the degree of 
LV diastolic dysfunction was linked to the rise in PASP [101]. However, the influence of 
arterial stiffness on LV filling and diastolic function has not reported following acute hypoxia 
in humans.  
In this study, we sought to investigate, for the first time, the effects of simulated HA, 
following acute hypobaric hypoxia, on simultaneous assessment of arterial stiffness and 
endothelial function and its inter-relationship to LV diastolic function and PASP. We 
hypothesized that the increase in PASP would lead to reciprocal changes in endothelial 
function, arterial stiffness and LV diastolic function. 
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Methods  
This was a prospective interventional study that included ten healthy British military 
servicemen aged 18-35 years. Confirmation of health status was undertaken via a detailed 
history and clinical examination by qualified general practitioner and further secondary 
assessment by an aviation-specialized occupational physician. All subjects were also required 
to be in sinus rhythm and have a normal baseline echocardiogram study. All subjects avoided 
any caffeine or stimulants as well as smoking for 12 hours prior to the first baseline 
measurements. The study was approved by the Ministry of Defence Research and Medical 
Ethics Committee.  
 
Simulated altitude  
Simulated HA was undertaken using a hypobaric chamber. Barometric pressure in the 
hypobaric chamber was reduced at a rate of 1219 m (4,000ft) per minute until a final 
simulated altitude equivalent to 4800m (15748ft). All volunteers continued to breathe ambient 
air throughout the exposure for a total duration of 3 hours at 4800m. The temperature in the 
chamber was maintained at 22-24ºC. The target altitude was held with constant cross-
ventilation of the chamber such that the concentration of oxygen in the chamber remained at 
20.9% throughout the study.  After a total time of 180 minutes at 4800m, the hypobaric 
chamber was recompressed to ground level at 1219 m per minute.  All investigators within 
the chamber breathed enriched oxygen via a face mask for the duration of the study. HA 
related symptoms were assessed using the Lake Louise Scoring System (LLS) [29]. 
Physiological measurements 
Simultaneous resting recordings of oxygen saturations (SpO2) and heart rate were performed 
using a Nellcor NP-20 pulse oximeter (Covidian, MA, USA). Blood pressure was measured  
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using an automated blood pressure cuff with the subject sat upright for >10 minutes at rest  
(Omron MX2; Omron®, Ca, USA)
 
 
Assessments of arterial stiffness and vascular tone  
Assessments of large artery stiffness, using the stiffness index (SI), and vascular tone, by 
reflectivity index (RI) were undertaken using pulse contour analysis of the digital volume 
pulse (DVP) measured from the index finger of the non-dominant (Pulse Trace PCA2; 
CareFusion™, Basingstoke, Hants, UK [67, 85]. The DVP consists of two traveling pulse 
waves: the first represents an early systolic peak and relates to pressure waves transmitted 
along a direct path from the ventricle to the finger, where it generates a consequent measured 
change in blood volume and the second peak or point of inflection occurs a short time later 
and reflects pressure waves that have been reflected from along the aorta and larger arteries 
from major impedance sites in the lower body (figure 1). The reflectivity index (RI) is a 
measure of vascular tone in the small medium sized muscular arteries, in which the higher the 
RI, the higher the greater the vascular tone (figure 1) [67]. Quantification of the changes in 
arterial RI (∆RI) is a validated method of assessing endothelial function, whereby a lower ∆RI 
equates to worsening endothelial function as a less reactive vascular system [180, 186]. The 
arterial SI is relates to the subjects height divided by the time difference between inflection 
points (the peak-to-peak time) (figure 1). As arterial stiffness increases (higher SI) reflected 
waves will appear closer to the forward wave due to the increased pulse wave velocity [180, 
186]. All pulse wave assessments were undertaken with the subjects fully relaxed and seated 
having rested for at least ten minutes in a temperature controlled environment (22-24°C). 
Pulse waveform analyses were performed 30 minutes prior to and at 45, 90 and 150 minutes 
after exposure to simulated HA.  
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Echocardiographic assessment 
All echocardiographic assessments were undertaken using a portable Vivid Q echocardiogram 
machine (GE Healthcare™, Amersham, Bucks, UK) with a 1.5-3.6 MHz S4 transducer. An 
initial baseline echocardiogram was performed at 30 minutes prior to and at 150 minutes of 
simulated HA exposure at the same time as the first and final arterial wave form analysis. 
PASP was calculated as the sum of the right atrial pressure (assessed by inferior vena caval 
size and collapse with inspiration) and the right ventricular systolic pressure (assessed using 
continuous wave Doppler of the tricuspid valve). Cardiac output was assessed by 
quantification of the LV outflow tract (LVOT) dimension, the LVOT velocity time integral 
and simultaneous heart rate. The aortic systolic flow velocity integral (SVI), using pulse wave 
doppler profile of aortic blood flow from the apical five chamber view and the cross sectional 
area (CSA) of the LVOT was used to calculate the cardiac output (SV=SVI x LVOT CSA). 
The systemic vascular resistance (SVR) was calculated as the mean arterial pressure x 80 
divided by the cardiac output (Johnson et al. 2001). The PA vascular resistance was estimated 
using the following equation PVR = 80 x ([10 x TRV/VTI RVOT] + 0.16) (dynes / sec / cm
-5
) 
where TRV was the maximal tricuspid regurgitation velocity and VTI RVOT was the velocity 
time integral of the right ventricular (RV) outflow tract velocity measured using pulsed wave 
doppler at the level of the pulmonary valve in the parasternal short axis view [187, 188].  The 
pulsed wave sample volume of the conventional doppler was placed at the tips of the mitral 
valve leaflets. The obtained variables included peak early transmitral flow velocity (E, cm/s), 
deceleration time (ms) of early diastolic transmitral filling and peak flow velocity (A, cm/s) of 
late diastolic transmitral filling, the isovolumetric relaxation time (in ms) and the E/A ratio 
[68]. Tissue doppler imaging (TDI) was used to calculate the early diastolic filling (e’) 
velocity of the basal lateral and basal septal mitral valve annulus which were measured 
separately (Paulus et al., 2007). TDI was also used to quantify the respective left ventricular 
isovolumic contraction (IVCT) and isovolumic relaxation times (IVRT). Estimation of LV 
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filling pressure was undertaken from the ratio of mitral valve E (early filling) velocity divided 
by average e’ [68]).  
 
Statistical analysis and power calculations 
Data were analysed using GraphPad InStat version 3.05 and with all graphical figures 
presented using GraphPad Prism version 4.00 for Windows (GraphPad Software, San Diego, 
CA, USA; www.graphpad.com). The Kolmogorov-Smirnov test was undertaken to assess 
normality of all continuous data. Paired continuous data comparisons were undertaken using 
the paired t test for normally distributed data and the Wilcoxen matched pairs test for non-
parametric data respectively.  Time-dependent comparisons of >3 groups was performed with 
Repeated measures ANOVA for normally distributed data, with the Tukey post-test for all 
significant results.  Repeated measures of non-parametric continuous data were performed 
using the Friedman test with post-test for all significant results. Correlation was assessed 
using Pearson and Spearman correlation coefficients for normal and non-parametric data 
respectively. A two tailed P value <0.05 was considered statistically significant for all 
comparisons.  
Sample size calculations were performed using GraphPad StatMate version 2.00 for Windows 
(GraphPad Software).  In a previous study of 8 subjects Thomson et al demonstrated a 10% 
fall in augmentation index following acute hypoxia (Thomson et al., 2006).  In another 
previous study, also of 8 subjects, Blitzer et al demonstrated a significant increase in PA 
vascular resistance and fall in systemic vascular resistance (SVR) following acute hypoxia 
[124]. Hence, based on this previous data coupled with our own previously published healthy 
population data [85] it was calculated that a sample size of 10 subjects would have a >80% 
power to detect a >8% change in arterial stiffness index as well as any significant changes in 
pulmonary artery vascular resistance and SVR with a two-tailed significance level of 0.05. 
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Results  
The average age of included subjects were 29.7±3.0 years with 70% being male. They 
weighed 77.9±17.5kg, were 177.9±17.5 cm tall with an average body mass index and 
abdominal waist circumference of 25.7±3.4kg/m
2 
and 84.2±7.6cm respectively. Acute 
hypobaric hypoxia lead to an increase in heart rate from 61.0±6.0 to 80.1±11.8 beats/minute 
(p=0.0001) and reduction in oxygen saturations from a baseline level of 98.1±0.7 to 
71.8±7.1% (p=0.0002). Compared with baseline levels there was a significant increase in LLS 
scores (0 vs. 3.4; range 0-10; p=0.02). 
There was no significant rise in arterial SI (p=0.13; table 1). However, acute hypoxia led to a 
significant reduction in both arterial RI (p=0.0008) and the SVR (0.0004) with an associated 
fall in both systolic blood pressure (p=0.006) and mean arterial blood pressure (p=0.032) 
(table 1 and figure2). There was no association between arterial SI and estimated LV filling 
pressure (E/e’; p=0.83). However, SI correlated with mean arterial blood pressure (r=0.39; 
p=0.01). There was a positive correlation between RI and SVR (r=0.46; p=0.043), systolic 
blood pressure (r=0.46; p=0.003), mean arterial blood pressure (r=0.33; p=0.035) and pulse 
pressure (r=0.50; p=0.001) but not diastolic blood pressure (NS).   
Acute hypoxia increased (baseline vs. 150 minutes) PASP (24.3±2.2 vs. 35.0 ±5.3 mmHg; 
p=0.0001) and estimated PVR (116.4±10.0 vs. 144.6±21.4; p<0.0001). Estimated LV filling 
pressure (E/e’) remained unchanged (p=0.78) (table 1). There was no change in mitral early 
inflow (E) velocity (p=0.21) or average early e’ velocity (p=0.13) with hypoxia (table 2). 
There was no correlation between arterial SI, RI or PASP and LV filling pressure (E/e’).  
There was a significant inverse correlation between SpO2 and PASP (r=-0.77; p<0.0001), 
PVR (r=-0.57; p=0.008) (figure 3) and between the degree of fall in SpO2 and change (∆) in 
RI (r=-0.52; p<0.001). There was a modest inverse correlation between ∆RI and ∆PAP (r=-
0.55; p=0.10) and a strong inverse correlation between ∆RI and ∆PVR (r=-0.89; p=0.0007) 
(figure 4).  
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Discussion 
This is the first study to assess the effects of acute hypoxia on simultaneous assessment of 
large artery stiffness and endothelial function and its inter-relationship to LV diastolic 
function and PASP. Our results have shown that acute hypobaric hypoxia led to systemic 
vasodilatation of the smaller and intermediate sized muscular arteries, demonstrated by a fall 
in SVR, blood pressure and RI, without a change in large artery stiffness (SI). The only 
observed significant changes in diastolic indices were an increase in mitral valve inflow A 
velocity and an associated reduction in the E/A ratio without any changes in tissue doppler 
derived indices of left ventricular filling or in the estimated LV filling pressure (E/e’).  
 
The moderate inverse correlation between ∆RI (marker of endothelial derived vasodilatation 
and function) and ∆PASP and the strong correlation between PA vascular resistance are novel 
findings in a healthy human acute HH study.  Blitzer et al had previously shown that acute 
hypoxia (n=8; to oxygen saturations = 84%) led to reciprocal changes in endothelial function 
(using arterial haemodynamic changes) and PASP, however the authors did not directly 
examine their correlation [124]. Berger et al demonstrated an inverse correlation between 
endothelial function (flow mediated vasodilatation) and PASP among HAPE susceptible 
individuals (n=9) but not among healthy controls (n=9), following acute hypoxic exposure (to 
SpO2 75%) [133].  In their study arterial stiffness, SVR and LV diastolic function were not 
assessed. Whilst the noted fall in SpO2 was accompanied by an increase in PASP their direct 
correlation was not reported (Berger et al. 2005). In the current study we observed a 
significant inverse correlation between arterial SpO2 and both PASP and PVR further 
validating the central role of hypoxia and its severity in influencing PA vascular responses. 
More recently, Jayet el al demonstrated a strong reciprocal relationship between flow-
mediated dilation and PASP in the offspring of mothers with preeclampsia and living at high 
altitude [189].  
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In our study changes in PASP and PVR led to a reciprocal impact on systemic vascular tone 
and endothelial function without overtly affecting arterial stiffness or diastolic function.  Our 
data showed that the subjects who exhibited the lowest fall in RI, and thus a more blunted 
vasodilatory response to hypoxia, suggestive of worsening endothelial function, developed 
the greatest increase in PASP and estimated PVR resistance. Furthermore, this process was 
influenced by the severity of hypoxia and reducing SpO2 and may relate to reduced 
availability of endothelial-derived nitric oxide with worsening hypoxia. It has been previously 
shown that endothelium-derived nitric oxide contributes to systemic vasodilation and serves 
as a regulatory mechanism to attenuate pulmonary vasoconstriction during acute hypoxia in 
healthy humans. [124]. The results of the current study may have further clinical applications 
given the increasingly recognised relationship between worsening vascular endothelial 
function and susceptibility to HAPE [133, 134]. However, it must be emphasized that our 
study did not include known HAPE susceptible subjects.  
 
There have been an increasing number of studies that have shown that even short-term 
exposure to hypoxia is associated with new abnormalities in diastolic function that were not 
present prior to the hypoxic stimulus [102, 183-185]. However, these changes were generally 
very mild and noted mainly on pulsed wave mitral inflow only with a reduction in E velocity 
and an increase in A velocity and were not associated with an increase in estimated LV 
pressure or overt diastolic dysfunction. This led to the  led to the concept of compensated 
diastolic (dys)function in which minor alterations in mitral inflow as compensated for by 
enhanced atrial contraction [101, 190]. This finding has been supported by the results of our 
present study.  The mechanism for these minor changes are unknown and might relate to 
direct effects of hypoxia, upstream effects of pulmonary arterial vasoconstriction and possibly 
to changes in arterial stiffness. Increasing large artery stiffness increase afterload pressure on 
the LV and to hypertrophy which subsequently affects cardiac relaxation [181, 182].  
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The few studies that have assessed the relationship between hypoxia and large artery stiffness 
have reported inconsistent results. Thompson et al (n=8) noted a significant fall in arterial 
stiffness, using augmentation index (-10.1±1.1%) and SVR without changes in blood pressure 
during 60 minutes of isocapnoeic normobaric hypoxia [126]. In their study the duration of 
hypoxia was much shorter (one hour), and the average peripheral SpO2 during hypoxia was 
much higher than in our study (82.6% vs. 71.8%). In another more recent study, Vedam et al 
(n=12) noted that acute normobaric hypoxia (20 minutes; to an SpO2 of 80%) initially 
increased augmentation index and large artery stiffness with an associated rise in mean 
arterial pressure [69]. However, during hypoxic recovery there was actually a fall in 
augmentation index to a lower than baseline value. There were no observed changes in the 
heart rate adjusted time to pulse wave reflection suggesting that the hypoxia most likely led to 
changes in the muscular small arteries rather than centrally in the aorta [69]. This is supported 
by our current data.   In a very recently published field study (n=17) to 4770m, Rhodes et al, 
failed to demonstrate a consistent change in arterial SI with high altitude exposure, but did 
observe an initial significant fall in RI, as in our study. However, as with all of the above 
studies assessment of diastolic function and PAP were not performed [138].  
 
Our data appears to suggest that hypoxia leads to differential haemodynamic effects along the 
arterial tree. This would partly explain the variable changes in reported blood pressure 
(increase, no change or even decrease) following acute hypoxia documented in previous 
studies [14, 49, 52, 124, 126, 131]. However, the indices of blood pressure in acute hypoxia 
studies have been variably reported (eg only, MAP, or only systolic blood pressure and 
generally not pulse pressure). Blitzer et al demonstrated a small decrease in MAP following 
acute hypoxic challenge in healthy controls [124]. A similar finding was observed by Johnson 
et al who noted a fall in MAP and an associated reduction in SVR [131].  In our study 
hypoxia led to a significant reduction in systolic blood pressure, mean arterial, pulse pressure 
and RI, reflecting the degree of systemic vasodilatation, yet increased pulmonary 
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vasoconstriction, with an increase in cardiac output. These physiological changes would allow 
for greater blood supply to systemic organs in order to meet the metabolic demands of 
hypoxic tissues [124]. It must be appreciated the mode (eg isopcapnoeic vs poililokapnoeic) 
and duration (minutes versus hours)  of hypoxia and the  sympathetic and ventilatory reponses 
will all influence the haemodynamic responses and in part explains the variation in the 
reported data [14].  
 
This study has several limitations which should be acknowledged. The sample size of the 
current study was relatively small. Nevertheless, our intervention sample size was larger than 
many of the previously reported acute hypoxia studies [52, 124, 126] and our study was 
adequately powered for its principle aims. Moreover, the duration (3 hours) and severity of 
hypoxia was much greater than the two previously previous simulated HA arterial stiffness 
studies [69, 126] with the added advantage that we used hypobaric hypoxia, compared with 
normobaric hypoxia. The PVR and MAP readings are estimated values derived from 
validation studies using echocardiography and cardiac catheterization [187]. The inclusion of 
a control group of patients, studied in the chamber over similar time duration, but without 
actual hypoxic exposure, would have been preferable. However, SI and left LV filling did not 
significantly change with hypoxia further validating our findings. A larger more detailed 
study of diastolic function with acute hypoxia is needed. 
 
Conclusions 
Acute hypobaric hypoxia does not significantly alter large artery stiffness or LV diastolic 
function. However, the degree of hypoxia influences both the systemic endothelial and 
pulmonary vascular responses. This noted association is intriguing and data from further 
studies investigating simultaneous pulmonary and systemic vascular responses would be 
helpful.  
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Table 1 Effects of hypobaric hypoxia on arterial stiffness, symptom scores, and other 
cardiovascular indices 
Variable Baseline  45 
minutes  
90 minutes  150 minutes  P 
Value  
Heart rate (minute
-1
) 61.0 ±6.0 71.8±7.0 78.8±12.4 †† 80.1±11.8 ††† 0.0001 
Systolic blood Pressure, 
mmHg 
129.2±10.5 119.0±14.1 115.6±15.6 †† 115.4±14.4 ††† 0.006 
Diastolic blood pressure, 
mmHg  
74.8 ±7.8 73.6±5.4 72.1±7.1 7.2±9.9 0.58 
Mean systemic arterial 
blood pressure, mmHg  
92.9±6.9 88.7±7.4 86.6±8.2 †† 86.5±10.4 ††† 0.032 
Pulse pressure, mmHg 55.4±11.5 45.4±12.0 43.5±14.7 43.4±11.3 ††† 0.04 
Arterial stiffness  
index (m/s)  
6.2±0.6 6.6±0.9 6.7±0.9 6.2±0.7 0.13 
Arterial reflective  
index , % 
50.8±10.3 42.9±8.1 39.7±12.0 †† 33.0±6.5 ††† 0.0008 
Oxygen saturations, %  98.1±0.7 70.5 ±6.1 † 72.5±7.7 †† 71.8±7.3 ††† 0.0002 
†Significant difference (p <0.05) between baseline and 45 minutes; ††Significant difference  baseline 
and 90 minutes; ††† Significant difference  baseline and 150 minutes 
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Table 2 Arterial stiffness, vascular tone and diastolic function responses to hypobaric 
hypoxia  
Variable Baseline  150 minutes  P Value  
Cardiac output, l/minute
 
4.8 ± 0.8 6.0 ± 1.3 0.0007 
Stroke volume (ml) 74.7 ± 14.6 74.5 ± 16.7 0.73 
Pulmonary vascular resistance  
dynes / sec / cm
-5
 
116.40 ± 19.0 144.6 ± 21.5 <0.0001 
Systemic vascular resistance  
dynes / sec / cm
-5
 
1589.1 ± 191.2 1187.8 ± 248.7 0.0004 
Peak Pulmonary artery systolic 
pressure (mmHg)  
24.3±2.2 35.0 ± 5.3 0.0001 
Left ventricular Isovolaemic 
relaxation time (ms) 
40.8 ± 6.0 38.3 ± 6.9 0.31 
Left ventricular isovolumic 
contraction times (ms) 
61.7 ± 58.3 ± 6.2 0.38 
Mitral E velocity,  m/s 0.95 ± 0.1 0.89 ± 0.09 0.21 
Mitral A velocity, m/s  0.56 ± 0.1 0.67 ± 0.1 0.02 
Mitral E/A ratio 1.76 ± 0.4 1.37 ± 0.26 0.01 
Mitral E deceleration time, ms  148.6 ± 20.4 152.3 ± 9.3 0.57 
Average mitral e’ m/s 0.17 ± 0.02 0.16 ± 0.01 0.12 
Estimated left ventricular filling 
pressure (E/e’)  
5.6 ± 0.7 5.5 ± 0.6 0.78 
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  Figure 1 Illustration of the methods used to calculate the arterial reflective index (RI) 
and stiffness index (SI)  
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Figure 2 Changes in arterial reflective index (RI) following exposure to acute hypobaric 
hypoxia 
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Figure 3 Relationship (correlation) between oxygen saturations and pulmonary vascular 
resistance index following acute hypobaric hypoxia  
 
Figure 4 Relationship (correlation) between reducing fall in RI and pulmonary vascular 
resistance index 
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Abstract 
Background: It has been consistently shown that heavy exercise leads to cardiac troponin (cTn) 
release and variable changes in post exercise cardiac function. This relationship has not been 
explored at increasing or significant high altitude (HA). This study assessed the effects of 
exercise at progressively increasing HA on high-sensitivity (hs)-cTnT levels and their 
relationship to biventricular cardiac function and severity of acute mountain sickness (AMS).  
Methods: Transthoracic echocardiograms, hs-cTnT levels and AMS  scores  were measured at 
rest at 1300m then repeated post exercise and 12 hours later  after progressive trekking to 3440 
m, 4270m and at 5150m (after trekking to 5643m) on 19 healthy subjects (age35.4±years; 52.6% 
males).  
Results: There was a detectable increase (>5ng/l) in post-exercise hs-cTnT with exercise at HA 
which was became significant at 5150m (5.84% at 3440m, 5.2% at 4270m and 56.3% at 5150m; 
p=0.0005).  Compared with baseline, HA to 5150m led to a significant rise in post-exercise Lake 
Louise AMS scores (p<0.001) pulmonary artery systolic pressure ([PASP] 23.7±3.8 vs 37.9±11.7 
mmHg: p<0.001), cardiac output (5.2±1.2 vs 7.5±1.3 l/minute; p<0.001) and a fall in SpO2 
(96.1±vs 77.4±12.0%; p<0.001). There was no change in stroke volume (p=0.10) or estimated 
filling pressures (E/E’) of the left (p=0.50) and right ventricles (p=0.4). On multivariate analysis 
increasing cardiac output (p=0.02) and PASP (p=0.04) and decreasing SpO2 (p=0.01) were the 
only independent predictors of increasing cTnT levels (overall R
2
=0.23; p<0.0001).  
 
Conclusions: Moderate intensity exercise at significant HA influences the post-exercise increase 
in hs-cTnT without overt deleterious effects on cardiac function.  
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Introduction  
Cardiac troponin (cTn) I and T are highly specific markers of myocardial cell injury and damage 
with increasing levels linked to worsening prognosis among patients with myocardial infarction 
[110, 191]. Multiple studies have shown that heavy exercise is associated with detectable 
elevations in cTn levels [114, 192, 193]. This has raised concern as to whether heavy exercise 
may be deleterious and could lead to subclinical myocardial damage [194]. However, the 
increase in cTn associated with exercise, is much lower and less sustained compared with the 
levels observed with ischaemic myocardial injury and has been largely studied in healthy subjects 
[110, 114]. There is marked inter-individual variation in this exercise-related cTn release and the 
factors influencing their release are still not fully understood [110, 114, 192]. They include the 
mode of exercise (eg running > bike) [192], its  intensity and duration [195], the timing of sample 
collection [196, 197] as well as subject-related factors such as age [198, 199] and sex [110], body 
mass and basic underlying fitness [114, 199, 200].  
 
A number of investigators have coupled cTn testing with non-invasive assessment of cardiac 
function/injury, following exercise, but a consistent link between the two has not been shown 
[52, 101, 114, 199, 201, 202].  However, these studies have focused on a single exercise stimulus 
(eg one race) and were predominantly conducted at sea level.  Exercise at high altitude (HA) 
places a number of additional physiological challenges over the equivalent exercise stimulus at 
sea level [14]. The consequent hypoxia and increase in pulmonary artery systolic pressure 
(PASP) reduces maximal exercise capacity, oxygen consumption and associated cardiac output 
[14, 49]. This has raised the question as to whether exercise at HA leads to a greater or 
pathological increase in cTn and associated myocardial dysfunction.  
 
The few previous studies to have investigated the effects of exercise on cTn release at HA 
assessed relatively low altitudes (2500-4300m), predominantly males (>95%), a single exercise 
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stimulus (eg one race) and utilised 4
th
 or older-generation cTn assays, which lack the sensitivity 
of hs-cTnT [120-123, 203]. Only two of these studies assessed the associated changes in cardiac 
function with neither using advances in tissue Doppler imaging (TDI) to more accurately define 
diastolic and regional systolic function [120, 121]. They did not assess the influence of HA-
related symptoms, such as acute mountain sickness scores (AMS) or the independent predictors 
of cTn release. Our group have recently shown that brain natriuretic peptide levels (BNP) are 
related to the severity of AMS however, the relationship of cTn to AMS severity is unknown 
[40]. Consequently, this study aimed to investigate, for the first time, the effects of exercise at 
progressively increasing and significant HA on hs-cTnT release and its relationship to AMS 
scores and changes in left and right ventricular systolic and diastolic function. 
 
Methods 
Study population 
This was a prospective observational study of 19 healthy British military servicemen aged 18-50 
years, who had agreed to participate in Exercise Khumbu Ramble. This was trek from Lukla 
(2840m) to Kala Patthar (KP, 5643 m) in Nepal following assessment of baseline variables at 
Kathmandu (1400m/1300 m). Participants were allowed to take any medication that they needed 
to complete their trek. Confirmation of baseline health status was undertaken via a history, 
clinical examination, bloods, electrocardiogram and transthoracic echocardiogram.  All subjects 
were also required to be in sinus rhythm and have a normal baseline echocardiogram study. The 
study was approved by the Ministry of Defence Research and Medical Ethics Committee and was 
conducted according to the standards of the declaration of Helsinki.  
 
High Altitude Ascent profile 
After 48 hours acclimatization at 1300m, the subjects flew to Lukla (2840 m) by light aircraft and 
trekked on to Phakding (2610m) on the same day (day 1) (figure 1). Thereafter a moderate ascent 
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profile was undertaken which included Namche Bazar (3440 m) on day 2 an acclimatization 
ascent to Khumjung (3780 m) on day 4, Deboche on day 5 (3710 m), Pheriche (4270 m) on day 
6, Lobuche (4910 m) on day 8, Gorak Shep (5150 m) on day 9 and Kala Patthar (5643 m) on day 
10 (returning to Gorak Shep).  
 
Blood sampling 
Baseline venous blood samples and physiological measurements were taken at 1300m. Thereafter 
post exercise blood samples and physiological measurements were taken within five minutes of 
exercise completion after trekking to Namche Bazar (3440 m; altitude gain 830m and trek 
distance 10.25 km; average trek time 7 hours), Pheriche (4270 m; altitude gain 570m; trek 
distance 9.0 km; average trek time 6 hours) and Gorap Shep (5150m after return trek to 5643m 
[Kala Patthar]; 493m of altitude gain; 3.8km; average trek time 3 hours).  The samples were 
repeated at the same altitude after approximately 12 hours rest. Samples for hs-cTnT were 
analysed on a serum sample that had been immediately centrifuged, separated and frozen at -20 
°C. On return to the UK all samples were assayed together using an electro-chemiluminescence 
immunoassay (ECLIA) on a Cobas e601 immunoassay analyser (Roche Diagnostics, Burgess 
Hill, UK on non-affected lots - Lot Number 163704) [24]. This assay has a range from 3-10000 
ng/L with a lower limit of the blank of 3ng/L and a lower limit of detection (LLD) of 5ng/L. 
Values below the LLD were reported as 5 ng/L for statistical analysis. The upper reference limit 
(99th percentile) is 14ng/L.  The coefficient of variation at a mean hs-cTnT level of 13.5ng/l is 
5.2%.   
 
Physiological measurements 
Resting recordings of oxygen saturations (SpO2) were performed using a Nellcor N-20P pulse 
oximeter (Nellcor Puritan Bennett, Coventry, UK). Baseline heart rate and blood pressure were 
measured  using an automated blood pressure cuff with the subject sat upright for >10 minutes at 
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rest  M6 (Omron Healthcare, Milton Keynes, UK). Fat free lean mass was calculated using 
Bodystat® 1500 body composition analyser (Douglas, Isle of Man, British Isles). 
 
AMS scores  
HA related symptoms were assessed using the Lake Louise Scoring System twice daily (LLS) 
{Hackett, 1992). The LLS scores were recorded on arrival to a new altitude and the following 
morning. The LLS score allocates a score of 0–3 (symptom not present to severe) for symptoms 
of AMS (headache, gastrointestinal symptoms, fatigue/weakness, dizzy/light-headedness, 
difficulty sleeping). A total score of >3 in the presence of a headache is consistent with AMS and 
>6 with severe AMS [28, 40]. 
 
Echocardiographic assessment 
All echocardiograms were performed using a Sonosite M-Turbo ultrasound machine (Sonosite 
Inc, Bothell, WA, USA) with a 1.5-3.6 MHz transducer. Pulsed-wave and two dimensional 
colour images were acquired in the parasternal short axis and apical four-chamber view during a 
short end-expiration pause. PASP was estimated from the maximum velocity of the trans-
tricuspid gradient using continuous wave Doppler imaging added to a fixed value of 5 mmHg 
(equating to the average right atrial pressure) as previously validated [49, 204]. The pulsed-wave 
sample volume of the conventional Doppler was placed at the tips of the mitral and tricuspid 
valve leaflets in order to measure the peak early transvalvular flow velocity (E), and the peak 
flow velocity (A) of late diastolic filling and the E/A ratios [68]. Pulsed-wave TDI volume 
samples were recorded at the septal and lateral mitral annulus and over the right ventricular free 
wall [204]. Samples were taken in duplicate and average values were used for all TDI and 
pulsed-wave measurements. Estimation of Left and right filling pressure was undertaken from the 
ratio (E/E’) of the mitral and tricuspid valve E velocity divided by TDI-derived early annular 
filling E’ velocity at the averaged (septal and lateral lateral) mitral annulus and the annulus of the 
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right ventricular free wall respectively [68, 205, 206]. Stroke volume and cardiac output were 
calculated using the aortic systolic flow velocity integral, using pulsed-wave profile of aortic 
blood flow from the apical five chamber view and the cross sectional area of the Left ventricular 
outflow tract [64].  
 
Statistical Methods and power calculations 
Data were analysed using GraphPad InStat version 3.05 and with all graphical figures presented 
using GraphPad Prism version 4.00 for Windows (GraphPad Software, San Diego, CA, USA; 
www.graphpad.com). The Kolmogorov-Smirnov test was undertaken to assess normality of all 
continuous data. Paired continuous data comparisons were undertaken using the paired t test for 
normally distributed data and the Wilcoxen matched pairs test for non parametric data 
respectively.  Time-dependent comparisons of >3 groups was performed using a One-way 
ANOVA (due to variable sample size, due to subject drop out) for normally distributed data, with 
the Tukey post-test for all significant results.  Non-parametric continuous data analyses were 
performed using the Kruskal-Wallis Test with the Dunn post-test for all significant results. 
Correlation was assessed using Pearson and Spearman correlation coefficients for normal and 
non-parametric data respectively. Multivariate analysis was performed to determine the influence 
of several key collected data factors (including age, sex, blood pressure, resting heart rate and 
Lake Louisee Scores) on the continuous dependent variable of cTnT levels. A cTnT level below 
the LLD of <5.0 ng/l was quantified as 5.0 ng/L for the purposes of analysis. A two tailed P value 
<0.05 was considered statistically significant for all comparisons 
 
Sample size calculations were performed using GraphPad StatMate version 2.00 for Windows 
(GraphPad Software). Banfi et al also noted a significant increase in cTn-I among 4/15 persons 
running a mountain marathon (peak altitude <2500m from race course) (Banfi, Lippi et al. 2010) 
and Davila-Roman et al [120] noted a detectable increase in cTnI in 13 out of 14 participants 
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undertaking strenuous exercise at high altitude (max 4300m). Hence, based on this previously 
published work showing cTn increases in >50% of subjects and our own dataset on healthy 
subjects at rest, it was calculated that a sample size of >15 subjects, at multiple altitudes would 
have >95% power to detect a significant increase in hs-cTnT post exercise at HA compared with 
baseline using a two-sided alpha of 0.05. Furthermore >15 subject completions across seven 
sampling time points (1300m rest, rest and exercise at 3440m, 4270m and 5150m) would allow 
for >105 dependent hs-cTnT variables for multivariate analysis. 
 
Results  
The average age (±SD) of included subjects were 35.4 (±) 8.3 years with a near equal balance of 
males (n=10, 52.6%) and females (n=9, 48.4%) (table 1). Complete data was available on 19 
subjects at rest at 1300m, 17 subjects at 3440m, 19 subjects at 4270m and 16 subjects at 5100m 
following exercise to 5643m. This was related to symptoms of severe AMS.  
 
Changes in hs-cTnT 
There was a detectable increase in hs-cTnT in 1/17 (5.8%)  immediately post exercise at 3440m 
with all levels returning to normal 12 hours later with one further isolated rise, which was not 
noted on the post exercise sample. At 4270m the corresponding figures were 1/19 (5.2%) post 
exercise with no new increases noted after 14 hours rest. At 5150m, following exercise to 5643m, 
detectable post exercise increase in hs-cTnT were noted in 9/16 subjects (56.3%) with all 
returning to the LLD of <5ng/L with no new observed rises on the resting sample. Only one 
subject had a hs-cTnT level above the 99
th 
centile post exercise (28.03 ng/l) which was detected 
on the highest post exercise sample (at 5150m after exercise to 5643m) but had returned to the 
LLD of 5.0 ng/l on the post exercise resting sample. There was a significant overall increase in 
hs-cTnT with increasing altitude (table 2, figure 2) with the difference only being detectable at 
post exercise at 5150m on post-hoc analysis (Chi-squared test for trend p=0.0005). On paired 
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testing of exercise compared with rest at subsequent altitudes there was no significant paired 
increase in hs-cTnT at 3440 m (p=0.53) or 4270m (p=0.33), however there was a significant 
increase at 5150m following exercise to 5643m compared with rest (p=0.008).  There was no 
difference in hs-cTnT rise amongst those with and without severe AMS (figure 3) at any altitude 
(p=0.20).  
 
Changes in cardiac function 
Increasing HA led to a progressive increase in PASP which was significant after the first altitude 
challenge (p<0.0001) (table 3). Cardiac output rose from a baseline value of 5.2±l/minute to a 
peak elevation of 7.5±l/minute post exercise at 5150m (table 3) without a significant increase in 
stroke volume. There was a small but significant increase in post exercise Mitral valve A velocity 
and an overall decrease in the E/A ratio and a decrease in mitral E deceleration time (Table 3). 
Apart from a significant increase in mitral septal S’ velocity there were no changes in other 
indices of systolic function and no change in either the estimated left ventricular (E/E’; p=0.5) or 
right ventricular (E/E’; p=0.43) filling pressures (table3).     
 
Factors influencing hs- cTnT elevation 
There was a significant inverse correlation between hs-cTnT levels and SpO2 levels (r=-0.27; -
0.09 to -0.43: p=0.003). Hs-cTnT levels correlated with heart rate (r=0.30; 0.11-0.46: p=0.001), 
cardiac output (r=0.29; 0.10-0.45; P=0.002), and PASP (R=0.33; 0.16-0.49: p=0.0003).  
However, there were no relationship between hs-cTnT and age (p=0.53), sex (p=0.30), systolic 
blood pressure (p=0.56), diastolic blood pressure (r=0.12) height (p=0.68), LLS (p=0.40), 
smoking status (p=0.69) total daily total body weight (p=0.87), lean body mass (p=0.97), body 
mass index (p=0.83), stroke volume (p=0.87), mitral lateral E’ velocity (p=0.78), mitral septal E’ 
velocity p=0.79) mitral E velocity (p=0.81), mitral A velocity (p=0.13), Mitral E deceleration 
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time (p=0.35), mitral E/A ratio (p=0.39), Mitral E/E’ (p=0.28), RV E’ (p=0.87), RV S’ (p=0.12), 
RV E/E’ (p=0.73), mitral lateral S’ (p=0.73), septal S’ (p=0.72) or other echo indices.  
 
We included the 4 significant univariate predictors of increasing hs-cTnT as well as age and sex 
into a multivariate regression analysis with hs-cTnT as the dependent variable. Increasing cardiac 
output (p=0.02) and PASP (p=0.04) and decreasing SpO2 (p=0.01) were the only independent 
predictors of increasing hs-cTnT levels (overall R
2
=0.23; p=<0.0001).  
 
Discussion 
This is the first paper to examine the effects of exercise at progressively increasing HA exposure 
on hs-cTnT levels and associated cardiac function. It is also the first to assess the influence the 
effects of AMS and the degree of hypoxia on the elevation in hs-cTnT. Whilst exercise led to 
minor elevations in hs-cTnT levels, this rise only became significant after exercise to 5643m. 
Despite this there was no evidence of deleterious changes in either systolic or diastolic function.  
The only independent predictors of hs-cTnT levels were increasing cardiac output and PASP and 
reducing SpO2 levels.  
 
There have been five previous studies on healthy subjects that have investigated the effects of 
exercise on cTn levels [120-123, 203]. These studies have all used a single exercise stimulus (eg 
one race or distance), represented predominantly males (>95%) and tested essentially single HA 
challenge at mild/ moderate HA (<4300m). Hence, it was not possible to distinguish increases in 
cTn related to sex or that of heavy exercise from the incremental effects of HA and worsening 
hypoxia. They observed detectable increases in post-race cTn levels in 7-100% of subjects, 
however pathological elevations, consistent with a diagnosis on myocardial infarction were not 
found [120-123, 203]. All of these studies utilised older generation cTn assays and in only two of 
these studies were assessment of cardiac function performed [120, 121] In the first of these 
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studies Davila-Roman et al, studied 14 runners (mean age 43 years), who completed a 163km 
ultra-marathon HA mountain race at elevations ranging from 2350 to 4300m [120]. Exercise led 
to significant decrease in the left ventricular end-systolic and end-diastolic areas and volumes 
with no change in the ejection fraction. However, five subjects developed marked right 
ventricular dilation and global right ventricular hypokinesia, which was corroborated by 
significant increases in the right ventricular end-systolic areas and end-diastolic areas, and a 
significant decrease in the right ventricular fractional area change which was associated with 
greatest increases in PASP [120]. The second study was a simulated altitude study in which 
comparative changes in post exercise (50km stationary bike ride) cardiac function and cTnT 
levels were measured following normobaric then hypobaric hypoxia to the same altitude [121]. 
As in our study, exercise at HA, led to an increase in cardiac output without an increase in stroke 
volume. No significant differences were observed in either systolic or diastolic function across 
but quantification or pulmonary artery pressure was not performed.  
 
Our study is the first HA exercise study to use a high sensitivity TnT assay. Newer generation hs-
cTn assays have several advantages over previous generation cTn assays used in the previously 
published HA exercise studies [110]. They are able to detect cTn in a larger number of healthy 
persons and can more precisely define what is 'normal' (within the 99th percentile) and hence 
allow for earlier detection of pathological myocardial injury/damage [110, 114, 207].  The pattern 
of hs-cTnT release observed in our study differs substantially from that observed with acute 
myocardial infarction where the cTn levels are much higher and usually peak by 12-14 hours 
later [110, 114, 190, 191, 208]. Yet in our study, despite the additional physiological stress of 
HA, hs-cTnT levels had largely returned to normal by 12 hours post exercise and followed a 
similar pattern to the majority of published post exercise cTn data [114, 191-194].  The 
mechanisms for the exercise-induced cTn rise are still not completely clear. Potential 
mechanisms include increased membrane permeability and cytosolic release, genuine myocardial 
necrosis in certain cases or stimulation of integrins by myocardial stretch [114].  
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In a recently published study, using a similar cohort, our group have recently shown that both 
BNP and NT-proBNP, markers of ventricular stretch, increased after exercise and also at rest and 
that BNP levels were significantly higher in those with severe AMS at 5150m [37]. In our current 
study, hs-cTnT levels bore no relationship to the LLS mountain sickness scores and there was no 
difference in the degree of hs-cTnT rise amongst those with and without severe AMS (Figure 2). 
It is interesting that the rise in hs-cTnT only became significant after exercise at the highest 
altitude (5150 m after trekking to 5643m).  Given that the resting levels were normal would 
suggest that the rise may relate to the confounding effects of the HA on the exercise stimulus.  
This is partly supported by the results of the multivariate analysis that has shown that increasing 
cardiac output (suggestive of increased exercise response), reducing SpO2 levels and increasing 
PASP (associated with worsening hypoxia and pulmonary vasoconstriction with increasing HA) 
were independent predictors of the hs-cTnT rise. Whilst the overall model was highly significant 
the model fit was weak (R
2
=23.3%). Hence, the increase in hs-cTnT has been far from fully 
explained. The observed increases in hs-cTnT, whilst significant post-exercise at the highest 
altitude, were very mild and lower than that reported in several sea level exercise studies [114]. 
The reason for this may relate to the fact that whilst the treks were physically challenging, 
subjects underwent gradual acclimatisation process, and did not race, completing the treks in 
their own time [14]. Three subjects did not complete the trek to the highest altitude and there 
were no cases of HA pulmonary oedema (HAPE), both of which may have influenced the results.  
 
Increasing PASP in response to worsening hypoxia (ie reducing SpO2 levels) is one of the 
hallmarks of increasing HA exposure with marked inter-individuals variability in responses [14, 
208]. It would be reasonable to expect that increasing altitude and worsening hypoxia would have 
either direct or indirect effects on cardiac function akin to that noted with pulmonary 
hypertension in acute pulmonary embolism [190].  However, data from the current study and 
previously published work by our group and others have shown that acute hypoxia and HA are 
extremely well tolerated [45, 64, 101]. Despite significant increases in PASP, we did not observe 
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evidence of significant LV or RV systolic or diastolic function. There is early data to suggest that 
the RV E/E’ may be a useful surrogate of RV end diastolic pressure but this is still controversial 
[205, 206]. Nevertheless, there were no observed increased in the estimated RV end diastolic 
pressure with increasing HA in this study. There have actually been very few HA studies that 
have investigated LV diastolic function using tissue Doppler imaging [45, 64, 101] and, to the 
authors knowledge,  this study is the first to assess these changes with progressive HA making it 
unique. 
 
This study has several limitations that should be acknowledged. Each exercise stage was variable 
in terms of altitude gain, difficulty and exercise duration, but reflected a real-life established trek 
to Everest Base Camp. We did not collect individual data on exercise time, medication use, heart 
rate (during exercise) or levels of perceived exertion, owing to the existing challenges of this type 
of extreme study. Consequently, it is difficult to disentangle these confounding factors upon the 
effects of increasing HA. However, the results of the multivariate analysis suggest that the 
worsening hypoxia and increasing PASP are important contributors. Finally, we are aware that 
this investigated recreational hard trekking rather than a race or maximal exercise (eg ultra 
marathon) used in the previous HA cTn studies, which makes comparisons difficult. The exercise 
stimulus used in our current study is, however, ‘more real-life’ and representative of the hundreds 
of thousands of persons undergoing recreational walking to HA each year.   
 
Conclusion 
We conclude that moderate intensity exercise at significant HA influences the post-exercise 
increase in hs-cTnT without overt deleterious effects on cardiac function.  
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Table 1 Baseline demographics  
Variable Baseline  
Age, years 
Range  
35.4 ± 8.3 
29-51 
Males (%) 10 (52.6%) 
Height, m 174.79 ± 7.6 
Ethnicity, %  
-       Caucasian  
-       Afro Caribbean 
  
18 (94.7%) 
1 (5.3%) 
Weight, kg  77.0 ± 14.4 
Lean mass, kg  62.4 ± 11.4 
BMI, kg/m
2
 25.0 ± 2.9 
Smoking history, % 
- current  
- non smoker 
 
2 (10.5%) 
17 (89.5%) 
Systolic blood pressure, mmHg  130.8 ± 15.4 
Diastolic blood pressure, mmHg 78.4 ± 10.3 
Haemoglobin, g/dL 14.0 ± 1.5 
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Table 2 Effects of altitude on Physiological variables and Acute Lake Louise acute mountain 
sickness scores (LLS)  
Variable  1300m 3440m 4270m 5150m P value 
  Rest  Post 
Exercise 
Rest Post 
exercise 
Rest Post 
exercise 
Rest  
Heart rate, 
minute-1  
66.8±9.0 103.0±15.7 80.3±12.1 90.1±14.8 75.1±12.9 96.7±7 78.0±8.1 <0.0001abce 
Systolic blood 
pressure, mmHg 
130.8±15.4 128.6±18.8 123.5±16.4 133.9±10.0 130.5±18.2 127.2±14.5 141.2±17.5 0.08 
Diastolic blood 
pressure, mmHg 
78.4±10.3 80.0±10.9 77.9±9.9 82.6±6.5 79.9±9.4 81.1±10.2 84.8±10.0 0.45 
SpO2 , % 96.1±1.9 87.9±4.0 91.5±4.4 85.8±4.5 86.5±4.8 77.4±12.0 75.3±7.8 <0.0001acfg  
Hs-cTnT levels, 
ng/L  
5.0±0.0 5.2±0.9 5.1±0.9 5.0±0.3 5.0±0.0 7.9±5.7 5.0.2±0.0 <0.0001e 
Lake Louise 
Score  
0.1±0.30 2.2±2.6 4.1±4.0 2.2±3.3 2.0±3.2 3.0±3.3 3.3±3.4 <0.0001abcdef 
Post hoc test compared with baseline; a 3440m post exercise; b 3440m rest; c 4270 post exercise, d 4270 rest; e 5150 post exercise and f 5150 at 
rest; g 3440Ex versus 4270 rest
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Table 3 Changes in echocardiogram indices with increasing altitude  
Variable  
 
1300m 
 
3440m 4270m 5150m 
 
P value 
  At rest Post 
exercise 
Rest Post 
exercise 
Rest Post 
exercise 
Rest  
Cardiac output 
l/minute 
5.2±1.2 6.8±1.5 5.9±1.5 6.8±1.1 5.4±1.1 7.5±1.3 6.0±1.2 <0.0001ace 
Stroke volume, 
ml  
75.6±10.4 67.6±17.3 73.6±17.3 77.6±10.7 73.8±14.5 77.3±14.2 77.1±12.3 0.10 
PASP, mmHg 23.7±3.8 36.2±8.1 31.2±7.9 38.4±9.5 34.6±7.9 37.9±11.7 35.0±8.6 <0.0001acef 
Mitral E 
velocity, cm/s   
93.6±11.8 91.2±26.0 85.0±18.4 97.2±24.4 87.5±16.4 100.3±24.8 92.7±23.1 0.26 
Mitral A 
velocity, cm/s  
61.5±13.0 76.6±17.2 64.3±12.6 76.2±20.2 64.1±15.4 75.8±14.8 69.8±9.3 0.005ac 
Mitral E/A 1.6±0.4 1.2±0.4 1.4±0.3 1.3±0.3 1.4±0.4 1.4±0.3 1.3±0.3 0.04a  
Mitral E 
deceleration 
time. ms 
180.1±3.3 152.6±2.4 185.0±4.3 176.3±2.3 188.9±3.5 165.6±4.1 188.8±4.0 0.02 
Lateral E’ 
velocity, cm/s  
18.7±3.3 16.4±3.5 17.3±4.3 16.4±3.8 16.7±3.3 17.8±3.8 15.8±3.5 0.30 
Septal E’ 
velocity, cm/s    
14.0±2.5 13.0±3.6 12.7±2.8 13.0±2.0 13.0±2.1 14.3±2.5 13.8±2.0 0.44 
LV E/E’ 5.9±1.1 6.1±1.4 5.9±1.0 6.7±1.6 5.9±0.9 6.3±1.0 6.3±1.0 0.50 
Lateral S’ 
velocity, cm/s  
12.3±2.5 13.5±2.9 12.1±2.6 11.9±2.6 12.1±2.1 12.7±2.3 11.5±2.0 0.30 
Septal S’ 
velocity, cm/s   
9.7±1.6 10.8±1.8 9.5±1.4 9.7±1.2 8.9±0.8 10.1±1.7 9.6±1.3 0.004g  
RV S’ velocity, 
cm/s  
14.6±2.8 15.4±1.9 13.6±2.5 14.7±2.4 13.5±2.3 14.4±2.9 13.7±3.0 0.30 
RV E velocity, 
cm/s  
64.1±19.7 69.8±13.1 61.8±16.0 60.0±12.6 57.7±14.1 64.4±12.7 59.6±8.9 0.12 
RV E’ velocity 
cm/s  
14.9±2.7 14.0±4.3 14.2±3.3 12.9±3.7 13.6±3.9 15.0±4.3 13.6±3.9 0.64 
RV E/E’   4.5±1.5 5.5±1.7 4.6±1.7 4.9±1.4 4.6±1.8 4.6±1.1 4.6±1.1 0.43 
LV, left ventricular; RV, right ventricular; Post hoc test compared with baseline; a 3440m post exercise; b 3440m rest; c4270 post exercise, d 
4270 rest; e 5150 post exercise and f 5150 at rest; g 3440Ex versus 4270 rest;  
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Table 4 Results of multivariate Analysis of independent factors influencing cTnT levels with 
increasing high altitude  
Variables Coefficient 95% Confidence Interval for 
coefficient 
P Value 
Age -0.001 -0.003 to 0.001 0.40 
SpO2 -0.002 -0.004 to -0.0005 0.01 
Heart rate  -0.0008 -0.002 to 0.0005 0.22 
Male sex -0.040 -0.09 to 0.0003 0.06 
Cardiac output  0.19 0.003  to 0.03 0.02 
PASP  0.002 0.0001 to 0.0.004 0.04 
SpO2, oxygen saturations; PASP, pulmonary artery systolic pressure
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Figure 1 Ascent profile with study altitudes and time points highlighted (*) 
 
Figure 2 Changes in hs-cTnT levels (ng/l) with increasing altitude post exercise (ex) 
and at rest (res) 
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Figure 3 Hs-cTnT levels (ng/l) with increasing altitude and relationship to presence or 
absence of acute mountain sickness (AMS) 
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Abstract 
Background 
 There has been considerable debate as to whether different modalities of simulated hypoxia 
induce similar cardiac responses.  
 
Materials and Methods 
This was a prospective observational study of 14 healthy subjects aged 22-35 years. 
Echocardiography was performed at rest and at 15 and 120 minutes following two hours 
exercise under normobaric normoxia (NN) and under similar PiO2 following genuine high 
altitude (GHA) at 3375m, normobaric hypoxia (NH) and hypobaric hypoxia (HH) to simulate 
the equivalent hypoxic stimulus to GHA.  
 
Results 
 All 14 subjects completed the experiment at GHA, 11 at NN, 12 under NH, and 6 under HH. The 
four groups were similar in age, sex and baseline demographics. At baseline rest right ventricular 
(RV) systolic pressure (RVSP, p=0.0002), pulmonary vascular resistance (p=0.0002) and acute 
mountain sickness (AMS) scores were higher and the SpO2 lower (p<0.0001) among all three 
hypoxic groups (GHA, NH and HH) compared with NN. At both 15 minutes and 120 minutes 
post exercise, AMS scores, Cardiac  output, septal S’, lateral S’, tricuspid S’ and A’ velocities 
and RVSP were higher and SpO2 lower with all forms of hypoxia compared with NN. On post-
test analysis, among the three hypoxia groups,  SpO2 was lower at baseline and 15 minutes post 
exercise with GHA (89.3±3.4% and 89.3±2.2%) and HH (89.0±3.1 and (89.8±5.0) compared 
with NH (92.9±1.7 and 93.6±2.5%). The RV Myocardial Performance (Tei) Index and RVSP 
were significantly higher with HH than NH at 15 and 120 minutes post exercise respectively and 
tricuspid A’ was higher with GHA compared with NH at 15 minutes post exercise.    
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Conclusions  
GHA, NH and HH produce similar cardiac adaptations over short duration rest despite lower 
SpO2 levels with GHA and HH compared with NH. Notable differences emerge following 
exercise in SpO2, RVSP and RV cardiac function. 
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Introduction  
Hypoxic exposure has a number of important clinical applications. These include pre-
acclimatization training for athletes, the investigation of high altitude (HA) illnesses such as 
acute mountain sickness (AMS) and clinical diseases complicated by tissue hypoxia[17, 209]. In 
order to improve the understanding of the clinical effects of genuine HA, hypoxia has been 
experimentally reproduced typically using normobaric hypoxia (NH) or hypobaric hypoxia (HH). 
NH lowers the partial pressure of inspired oxygen (PiO2) by reducing the fraction of inspired 
oxygen (FIO2) through addition of exogenous nitrogen (N2) without altering the barometric 
pressure whereas HH lowers the PiO2 by reduction of barometric pressure [17].  
 
There has been considerable and ongoing debate in the medical literature as to whether these 
differing methods of hypoxic challenge are meaningfully different or clinically important and 
most importantly whether they are effective surrogate for real life HA [209-215].  A large 
number of the comparative studies have been in animal models and the human studies have been 
predominantly two-way comparisons of NH with HH exposure and have not included either a 
genuine ‘real-world’ terrestrial HA (GHA) or a normobaric normoxia control (NN) group, akin to 
normal sea level, limiting the clinical impact of their findings [209]. It has become increasingly 
appreciated that the physiological responses to GHA at a given altitude are influenced by 
variations in the ambient barometric pressure due to the differences in latitude, time of year and 
prevailing weather conditions which may be an important factor in comparative studies.  Hence, 
it is crucial that the ambient pressure for a given field altitude is documented in to allow more 
reliable comparison both between GHA experiments and with HH chamber studies [127, 216]. 
Most of the previously published studies to compare differing hypoxia modalities have been 
undermined by their relatively short periods of hypoxic exposure (<30 minutes), the use of a 
separate but matched populations for the differing hypoxic challenge groups and the use of  only 
brief wash out periods between each exposure increasing the risk of acclimatization bias [17]. 
Furthermore, the important stimulus of exercise which is a crucial factor in the majority of HA 
ventures in real life has been frequently overlooked.  
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Acute hypoxia leads to a number of recognized cardiopulmonary responses, which notably 
includes pulmonary vasoconstriction and an associated increase in pulmonary vascular resistance 
[15, 35, 64, 70, 217]. Whether HA and the associated hypoxia leads to deleterious effects on 
cardiac function remains still remains a controversial issue [209, 215]. Published studies have 
consistently shown that acute hypoxia leads to an increase in resting cardiac output and 
preservation of long axis systolic and radial systolic function [35, 64, 209, 218]. However, more 
concerning, there is a blunted stroke volume response and variable effects on left ventricular 
diastolic filling and right ventricular systolic function have been observed [35, 217, 218]. Right 
ventricular (RV) diastolic function has been barely explored [64, 209]. Evidence to suggest the 
potential deleterious effects of HA on cardiac performance includes the observed increase in 
brain natriuretic peptide (BNP) levels at HA compared with sea level and their link to AMS and 
its severity [37, 64, 118]. It has also been shown that sustained hypoxia can lead to a decline in 
cardiac energetics, which is linked to adverse changes in left ventricular diastolic function despite 
preservation of systolic function [219].  
 
There have been only two studies to date that have tried to compare potential changes in cardiac 
function during exercise following differing modes of hypoxic challenge and in both 
echocardiographic assessments of biventricular performance and/or right ventricular systolic 
pressure were not assessed [108, 109]. A four-way comparison of NN, genuine HA (GHA), NH 
and HH on cardiac function has never been performed. Furthermore, none of the cross 
comparison studies to date utilized recent advances in echocardiography allowing much detailed 
assessment of biventricular systolic and diastolic function. Consequently, in this study we sought 
to investigate, for the first time, the effects of acute and sustained hypoxia on cardiac function at 
rest and following exercise under NN, NH and HH and GHA.   
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Materials and Methods 
Study population 
This was a prospective observational study of 14 healthy British military servicemen aged 22-
35 years. In addition to completing a detailed health questionnaire all subjects were required to 
have a normal baseline ECG and echocardiogram to confirm suitability for inclusion. Baseline 
health status was undertaken via a history, clinical examination, bloods, electrocardiogram and 
transthoracic echocardiogram.  
 
Study protocol  
All participants completed a standard maximal incremental cycle test to volitional exhaustion 
at sea level (absolute altitude ~113m) under normobaric normoxia (NN) to determine maximal 
oxygen uptake and maximal workload (Wmax [watts]) [220]. This was followed by a maximal 
incremental test to volitional exhaustion >24 hours later under NH (an FiO2 equivalent to 
3375m/11078ft (PiO2 ~95 mmHg) in order to establish and ensure equivalent workloads for the 
hypoxic experimental trials [220].  
 
Participants were then required to complete physiological assessments prior to and during 
exercise and rest under four different conditions. They were then assessed at GHA at 
(3375m/11078ft, 'real' altitude, barometric pressure 506.4 ± 1.7 mmHg), followed in order with 
assessments at NN, NH (TISS, Alton, UK and Sporting Edge, Sherfield on Loddon, UK) and 
HH (Centre for Aviation Medicine, RAF Henlow, Henlow, UK) ensuring a minimum washout 
period of >7 days between each experimental condition. This sequence ensured the PiO2 
experienced breathing ambient air during GHA (PiO2 = 96.3 ± 0.4 mmHg) could be replicated 
for each individual during subsequent NH and HH exposures.   
 
For NH the Fi02 (13.9 ± 0.2%) was manipulated to equate to each individuals Pi02 established at 
terrestrial GHA using the following equation, which considers fluctuations in sea level 
barometric pressure [3,8]:  
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Fi02 = PiO2 (mmHg) / local PB (mmHg) - PH20 (47mmHg) 
 
For the measurements in the HH chamber participants underwent a decompression period (0.33 
mmHg s
-1
 equivalent to 5 m.s
-1
 (ascent rate) ~10 minutes) to the target altitude, recreating each 
participants PiO2, and on completion of the exposure a recompression period (0.33 mmHg s
-1
) to 
the ambient pressure. The chamber was continuously flushed with medical quality gas to 
maintain the inspired fractions of O2 and CO2 at 20.9% and 0.03%, respectively, with nitrogen 
balance. During the HH exposure participants were continuously monitored by a chief medical 
officer, who was present in the chamber breathing through an O2 diluter demand mask. They 
were in constant contact with the chamber operators and additional medical staff.  
 
The GHA challenge involved rapid ascent by cable car to 3375m after the subjects were driven 
in a minibus from sea level to 1400m. The NN and NH experiments were undertaken within a 
NH chamber at Leeds Beckett University and the HH chamber at the Royal Air Force Centre of 
Aviation Medicine, Henlow.  
 
Each experiment was performed following a 12-hour overnight fast. All subjects underwent 30 
minutes of altitude acclimatization followed by a complete 120 minutes of cycling exercise (a 
progressive intensity warm-up for 15 minutes, followed by 105 minutes at 55% Wmax based 
on the NH maximal exercise test). All exercising testing occurred on a bicycle affixed to a 
bicycle trainer (Compu Trainer Pro Lab, Racer Mate, USA). The cycle ergometer was 
calibrated following the manufacturer’s instructions. The load generator ensured the relative 
workloads between conditions for each participant were accurately maintained, taking into 
consideration an individual’s natural torque fluctuations with each pedal stroke. The 
manufacturer’s reports an accuracy of 2.5% and repeatability of 1%.  Each experimental trial 
involved the ingestion of a carbohydrate solution (glucose-fructose) so that the dietary intake 
of each participant was standardised across all four studies. Physiological measurement of 
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AMS scores, haemodynamics and cardiac function were assessed at rest, at 15 minutes into the 
rested acclimatization process in each study condition and then again rested 15 minutes and 
120 minutes post two hours of cycling exercise in the hypoxic environment. A consistent 
temperature range of 18-23°C was maintained for all four study conditions. 
 
Ethics  
The study was approved by the Ministry of Defence Research and Medical Ethics Committee and 
was conducted according to the standards of the declaration of Helsinki and all subjects 
underwent written informed consent.   
 
Physiological measurements 
Resting recordings of oxygen saturations (SpO2) were performed using a Nellcor N-20P pulse 
oximeter (Nellcor Puritan Bennett, Coventry, UK) following a 15 second continuous recording 
using the index finger of the right hand with the most consistent reading being used. Blood 
pressure were measured  using an automated blood pressure cuff with the subject sat upright for 
>10 minutes at rest  M6 (Omron Healthcare, Milton Keynes, UK) and heart rate was measured 
form a single lead ECG at the time of the echocardiogram. The ambient temperature was 
recorded for each experimental condition (NN.NH, HH and GHA) using a PCE-THB 40 
Barometer (PCE Instruments UK Ltd).  
 
Acute mountain sickness (AMS) scores  
HA related symptoms were assessed using the Lake Louise Scoring System (LLS) [28]. The LLS 
score allocates a score of 0–3 (symptom not present to severe) for symptoms of AMS (headache, 
gastrointestinal symptoms, fatigue/weakness, dizzy/light-headedness, difficulty sleeping). A total 
score of >3 in the presence of a headache is consistent with AMS and >6 with severe AMS [28, 
37].  
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Echocardiographic assessment 
All echocardiographic assessments were undertaken using a portable Vivid I echocardiogram 
machine (GE Healthcare™, Amersham, Bucks, UK) with a 1.5-3.6 MHz S4 transducer. Pulsed-
wave and two dimensional colour images were acquired in the parasternal short axis and apical 
four-chamber view during a short end-expiration pause with the subject lying in the left lateral 
position. RVSP was estimated from the maximum velocity of the trans-tricuspid gradient using 
continuous wave Doppler imaging [49, 219]. The pulsed-wave sample volume of the 
conventional Doppler was placed at the tips of the mitral and tricuspid valve leaflets in order to 
measure the peak early transvalvular flow velocity (E), and the peak flow velocity (A) of late 
diastolic filling and the E/A ratios [68]. Pulsed-wave TDI volume samples were recorded at the 
septal and lateral mitral annulus and over the RV free wall to assess early and late diastolic filling 
due to left ventricular relaxation (E’) and atrial contraction (A’) and long axis systolic function 
(S’) [35, 64, 68, 70]. The pulmonary artery vascular resistance (PVR) was calculated using the 
following equation PVR = 80 x TRV/VTI RVOT where TRV was the maximal tricuspid 
regurgitation velocity and velocity time integral of the RV outflow tract velocity measured using 
pulsed wave doppler at the level of the pulmonary valve in the parasternal short axis view as 
previously described [64]. 
 
Pulsed-wave TDI was used to quantify the respective left and right ventricular isovolumic 
contraction (ICT) and isovolumic relaxation times (IRT) and the isovolumic contractile velocities 
(ICV) [3]. Right and left ventricular myocardial performance (Tei) indices (IRT+ICT/ejection 
time) were performed using TDI [64, 73]. Tricuspid annular plane systolic excursion (TAPSE) 
was recorded using M-Mode as previously described [221]. The isovolumic contractile velocity 
was measured at the tricuspid and mitral annulus using PWTDI [49, 68]. Stroke volume and 
cardiac output were calculated using the aortic systolic flow velocity integral, using pulsed-wave 
profile of aortic blood flow from the apical five chamber view and the cross sectional area of the 
Left ventricular outflow tract [35, 70]. 
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Statistical Methods and power calculations 
Data were analysed using SPSS
®
 statistics version 22. The Kolmogorov-Smirnov test and 
inspection of the data was undertaken to assess normality of all continuous data. All data are 
presented as mean ± standard deviations. Between group comparisons of categorical data for 
three or more groups were compared using the Fisher’s Exact Test. Continuous data across the 
four experimental altitude groups (NN, HA, NH and HH) were assessed using Ordinary ANOVA 
with Bonferroni post-test for parametric data and with Kruskal-Wallis and Dunn Post-test for 
non-parametric data when the P value was <0.05. Time dependent changes (rest, 15 and 120 
minutes post exercise) of continuous data within each group were assessed using Repeated 
measures ANOVA with Bonferroni post-test for parametric data and using Friedman Test with 
Dunn Post-test for non- parametric data. Correlation was assessed using Spearman Rank 
correlation with the 95% confidence interval of R.  Further exploratory analyses of the three 
hypoxia groups only were undertaken using a Two-Way split level 3x3 Repeated Measures 
ANOVA. The within-subjects main effect of time (before and 15 and 120 min after exercise) and 
the between-subject main effects mode of hypoxia (GHA, NH and HH) with Bonferroni post-
tests and their interactions (and effect size, Eta [n
2
]) were assessed. A two tailed P value <0.05 
was considered statistically significant for all comparisons. 
 
Sample size calculations were based on previous studies. In 11 out of the 13 prior comparative 
experimental hypoxia studies the sample size has been between 7-12 subjects [209].  In another 
very recent comparative study of six subjects Beidleman et al observed that cycling time trial 
performance was impaired to a greater degree in HH versus NH at the same ambient PO2 
equivalent to 4,300 m despite similar cardiorespiratory responses [109]. Hence, based on this 
previously published work it was calculated that a sample size of >12 subjects would be 
sufficient to detect a significant difference in cardiac performance and allow for a minimum 
group sample size of 6 subjects in the event of any drop outs given the intense and prolonged 
nature of these four group comparisons. 
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Results  
Fourteen subjects completed the genuine HA phase, 11 the sea level study, 12 with NH and 6 
under HH. All subjects completed the exercise task in each group. Non-completion was mainly 
due to inter-current illness and in the case of HH failure to clear their ears or voluntary 
withdrawal. There were no significant differences in any of the baseline demographics across the 
four groups with similar ages, sex, height, and body weight and body mass indices (Table 1).  
 
Physiological and haemodynamic indices 
The mean peak oxygen consumption (VO2) at baseline with NN was 46.3±5.7mls/kg/minute. 
There was no difference in the mean peak VO2 among the subjects who were subsequently 
included in the GHA, NH and HH groups respectively (46.7±5.7, 46.2±5.2 and 47.2±4.7 
mls/kg/minute; P=0.98). As expected peak VO2 was significantly lower under NH versus NN 
(38.9± vs 46.3±5.7 mls/kg/minute; P=0.007).  
 
The ambient temperature was marginally but significantly higher with HH versus NH and HH 
(table 1). There was a significant reduction in SpO2 across all three hypoxia environments (GHA, 
NH and HH) compared with NN (P<0.001), which was sustained at all three time points (rest, 15 
minutes and 120 minutes post exercise) (Table 2). On Post-test analysis SpO2 was lower at 
baseline and at 15 minutes post exercise with GHA (89.3±3.4% and 89.3±2.2%) and HH 
(89.0±3.1 and (89.8±5.0) compared with NH (92.9±1.7 and 93.6±2.5%) (Table 2).  AMS scores 
were higher at all time points in the three hypoxic conditions versus NN with no between group 
differences among the hypoxia groups.  Absolute resting heart rates were higher across all three 
hypoxic group time points compared with NN (Table 2).  At 120 minutes post exercise, resting 
heart rates were significantly greater with GHA than NH. 
 
Echo parameters of left ventricular function  
There were no differences in any of the echo parameters of left ventricular systolic or diastolic 
function at rest across the four groups. However, at 15 minutes post exercise Cardiac output 
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(p=0.01), septal S’ (p=0.02) and lateral S’ (p=0.03) and septal A’ (p=0.003) velocities were 
higher with all forms of hypoxia compared with NN with no differences between the hypoxic 
groups (Table 3). At 120 minutes post exercise cardiac output (p=0.006), septal S’ (p=0.04), 
mitral A (p=0.009) and lateral S’ (p=0.02) velocities were higher with acute hypoxia versus NN, 
with no intergroup differences among the three hypoxia groups (table 3). Exercise led to an 
increase in the post exercise left ventricular myocardial performance (Tei) index across all four 
groups, which was significant at 15 minutes post exercise in the NN, NH and HH groups and 
only in the HH at 120 minutes post exercise compared with baseline rest (Table 3). Compared 
with baseline, stroke volume fell at 15 minutes post exercise under all four experimental 
conditions before increasing again in all except the HH group where the fall in stroke volume was 
sustained. 
 
Echo parameters of right ventricular function  
Resting RVSP (p=0.0002), PVR (p=0.0002) and tricuspid A velocities (p=0.01) were higher with 
all forms of hypoxia compared with NN with no between group differences among the three 
hypoxia groups (Table 4). Compared with NN at 15 minutes post exercise RVSP (p=0.04), 
Tricuspid S’ (p=0.009) and A’ (p=0.0001) velocities and the right ventricular Tei Index (0.001) 
were greater with hypoxia. The tricuspid A’ velocity was significantly higher with GHA and the 
Tei index and RVSP with HH on post-test analysis. At 120 minutes post exercise the RVSP 
(p=0.0006), Tricuspid A (p=0.006), tricuspid S’ (p=0.03) and A’ (p=0.0007) velocities and the 
RV Tei index (p=0.004) were higher with hypoxia than NN (Figure2). The rise in tricuspid A’ 
velocity, RV Tei index and RVSP were greatest among the GHA and HH groups respectively on 
post-test analysis (Table 4). There was a trend for higher PVR with HH than with either NH or 
GHA at all three sampling time points (p<0.05 for trend). There was a significant correlation 
between pulmonary vascular resistance and the RV Tei index (r=0.54; 95% CI 0.09-0.81). 
 
Two-Way Repeated Measures ANOVA comparing the three hypoxia groups  
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The main effects of hypoxia and time and the potential interactions (mode of hypoxia x time) and 
post tests are shown in table 5 for the three hypoxia groups with NN as a reference. There was a 
significant main-effect for mode of hypoxia on SpO2, Tricuspid A, A’ and ICV as well as the RV 
Tei index (table 5). There was a significant main effect for time on heart rate, mitral E and A, 
septal E’ and A’, lateral S’, E’, A’ and ICV, left ventricular Tei index and stroke volume, 
tricuspid E, A’ and ICV and RV Tei Index. Within group comparisons of the three hypoxic 
groups revealed no significant interactions between exercise and time for the majority of echo 
parameters. However there was a significant mode of hypoxia x time interaction effect for the 
lateral S’ (F [2, 56]=3.99; p=0.006: n2= 0.22), tricuspid S’ (F [2, 58]=3.12; p=0.02: n2=0.16) and 
the right ventricular Tei index (F [2,58]=4.1; p=0.006; n
2
=0.23) ( figures 1-3, Table 5). The 
marginal means were consistently higher at 15 minutes post exercise with GHA and HH than NH 
(figure1-3).   
 
Discussion 
This is the first study to assess the comparative changes in physiological and cardiac responses to 
exercise under four differing altitude conditions of NN, GHA, NH and HH. The key findings 
were that whilst all three hypoxic environments (GHA, NH and HH) led to similar cardiac 
adaptations at rest notable differences emerged following exercise.  Compared with NH, the 
RVSP and RV Tei indices were higher with HH and the tricuspid A’ was higher with GHA.   The 
degree of hypoxemia was greater with GHA and HH than with NH at both rest and at 15 minutes 
post exercise. There were no significant interactions between experimental altitude and time with 
the exception of the RV performance (Tei index) and the RV (tricuspid) and lateral S’ velocities.  
 
There has been considerable debate in the literature as to whether differing modalities of hypoxia 
challenge are synonymous [52, 209-214, 222]. This is an important issue that remains unresolved 
and has enormous implications for HA research where inferences are often made from sea level 
chamber or hypoxia studies about potential responses at genuine HA. There have been only two 
studies, to date, that have assessed the effects of differing hypoxic environments on cardiac 
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function. Miyagawa et al investigated seven young men who cycled for 40 minutes at 50% peak 
aerobic power in NN, NH and HH equivalent to 3200m in an artificial climate chamber [108]. 
Hence, this was a smaller sample size but similar altitude to our current study. Cardiac output and 
stroke volume were the only specific cardiac functional assessments performed (beyond heart 
rate) and this was undertaken using pulse dye densitometry using Indocyanine Green [108]. 
However, both the reliability and reproducibility of this method has been challenged and its 
comparison to more invasive methods of cardiac output determination has yielded conflicting 
results [223, 224]. In their study, Miyagawa et al did not find any significant effects of 
experimental condition (trial) on cardiac output or stroke volume but did note there was a 
significant interactive effect of [trial × time] both cardiac output and stroke volume, during 
exercise, (suggesting that their responses to exercise were significantly different between the 
experimental conditions [108].  This related to the finding of a marked increase in cardiac output 
and stroke volume in both hypoxic groups versus the NN rather than any observed differences 
between the two hypoxic groups. Hence, as well as looking at a four-way comparison of the NN, 
GHA, NH and HH we undertook an additional exploratory analyses of the effects of hypoxia 
duration (time) and mode and their potential interactions across the three hypoxia groups.  In 
another previous study two separate groups of six subjects were compared following 
approximately two hours of resting exposure to NH and HH at the equivalent of 4400m [109]. 
The only cardiac functional assessment performed was cardiac output, which was measured non-
invasively using finger pulse waveform analysis [109]. No between group differences in cardiac 
output were observed however cycling time trial performance was worse with HH than NH.  
 
In our study we assessed both right and left ventricular systolic and diastolic performance as well 
as markers of pulmonary artery haemodynamics (RVSP and the PVR) and global biventricular 
function using the Tei Index which adds significant novelty.  Moreover, we ensured that the same 
exercise work and duration was maintained between the groups to reduce the confounding factor 
of differing exercise burden on any observed results.  
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One of the most pertinent findings of our study is the observation that it is not only the hypoxic 
environment but also exercise in this environment, which influences the cardiac and pulmonary 
vascular responses. Hence, ‘resting’ comparisons do not adequately reflect the reality of exposure 
to HA where there is usually an exercise component. This fact is supported in this study by the 
interaction between experimental conditions and exercise time for the Tei index and lateral left 
ventricular and right ventricular (tricuspid) S’ velocities (figure1-3). Whilst no significant 
between hypoxic group differences were observed over the short duration at rest, several 
differences emerged following exercise. For example, the RV Tei index and S’ velocities and the 
lateral left ventricular S’ velocities were consistently higher at 15 minutes post exercise with 
GHA and HH than NH.  The higher values of RVSP, right ventricular Tei index and PVR and 
lower SpO2 post exercise with HH compared with NH are particularly notable in this study. In a 
very recent systemic review of crossover trials of HH versus NH, Coppel et al (2015) noted that 
peripheral SpO2 levels were higher with NH in two out of three short studies involving a hypoxic 
duration of <30 minutes with no notable differences in studies of > 8 hours [209]. The authors 
also noted that arterial blood saturations (SaO2) were lower with HH in all three of the previously 
published short-term hypoxia-duration studies [209]. Our data is consistent with this limited 
published literature as we observed significantly lower SpO2 with HH than with NH. The 
suggested potential mechanisms to explain these observed differences, include lower minute 
ventilation, greater intravascular bubble formation and ventilation/perfusion mismatch, increased 
alveolar dead space as well as differences in alveolar fluid permeability and chemosensitivity 
with HH versus NH [209, 225].  
 
Another factor, which must be considered, is the effect of ambient temperature on SpO2 readings 
with finger pulse oximetry. It has been shown that a significant reduction in ambient temperature 
leads to peripheral vasoconstriction and can lead to a small (<1.4%) increase in SpO2 which is 
thought to be explained by temperature-dependent arteriovenous shunts in the periphery [226, 
227]. Variations in core temperature can also affect the SaO2 (and hence SpO2) by rightward shift 
of the HbO2 dissociation curve [228]. In our current study, we tried maintain a similar exercise 
intensity and ambient temperature across all four experimental conditions. However, the ambient 
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temperature was marginally, albeit significantly higher with HH (+2-3ºC) versus NH and GHA 
and unfortunately, we did not record core temperature. Nevertheless, previously published studies 
have not identified any significant differences in core temperature and thermoregulation between 
NH and HH [209]. In either case, we would not expect this small variation in ambient 
temperature across the differing experimental conditions to lead to meaningful differences in core 
temperature and SaO2. Nevertheless, the small temperature differences between experimental 
conditions are still a limitation that should be acknowledged. The fact that SpO2 was lower and 
PVR and RVSP were higher with GHA and HH than for NH strengthens our findings, given the 
well-established reciprocal relationship between SpO2 and RVSP/PVR, due to hypoxia driven 
pulmonary arterial vasoconstriction [14, 28, 64].  
The observation of a greater increase in the RV Tei index with HH versus NH is an interesting 
and novel finding. The myocardial (Tei) index is a marker of global myocardial performance, 
which includes both systolic and diastolic functional parameters in its assessment and is 
independent of heart rate and ventricular geometry [73]. It may be a more sensitive marker of 
myocardial function than many traditional indices of cardiac function with increasing and higher 
values (>0.40-0.45) indicating worsening cardiac performance [73, 221]. The RV Tei index has 
been shown to positively correlate with both mean pulmonary artery pressure and PVR in 
patients with pulmonary artery hypertension and is highly susceptible to the effects of treatment 
[103, 229]. The baseline (0.29-0.32) and post exercise increase in the RV Tei Index (up to 0.41) 
in our study is consistent with the published literature [103, 229, 230].  Huez et al previously 
noted that the RV Tei Index increased by approximately 50% (versus up to 33% in our study) 
following acute but more prolonged exposure to a higher altitude of 3750 among 15 healthy 
Caucasian adults [231]. More recently Page et al noted that the RV Tei Index increased 
significantly at genuine field HA (0.32±0.08 at 30 m to 0.43±0.15 at  3450m and 0.41±0.10 at 
4730 m; P = 0.046) and was associated with subclinical pulmonary oedema in 13 out of the 14 
subjects [104]. This increase in the Tei Index was nearly identical to that in our study that is also 
in keeping with that noted among patients with treatment responsive pulmonary hypertension 
[68, 73]. We noted an interaction between exercise and HA environment on the RV Tei (figure3). 
It has been previously demonstrated that heavy exercise under hypoxia leads to increased 
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capillary disruption and fluid leak, which may be one of the mechanisms in the development of 
high altitude pulmonary oedema [232]. We observed that the PVR positively correlated with the 
RV Tei index and interestingly the HH group had both the highest Tei index and increase in PVR 
and PASP strengthening our findings. Our data suggests that increased PVR may have a negative 
effect on RV function, perhaps by increasing RV afterload due to increased PASP. The RV Tei 
Index appears to be particularly sensitive to even short-term changes in the hypoxic environment 
supporting previous work [103, 229].  
The interaction between time and experimental conditions on the left and right ventricular S’ 
velocity appeared to relate to a more sustained increase in long axis function with GHA in 
relation to NN and NH where the changes were less marked (figure1 and 2).  We also observed 
marked differences in the right ventricular systolic (S’ and ICV), diastolic (E and A’) and global 
function (Tei) depending on the hypoxic environment.   
 
This study has a number of limitations that need acknowledgement. The sample size in the HH 
was smaller than among the other three groups, which could lead to selection bias and reduced 
power to detect a difference that was not appreciated. However, the demographics on the smaller 
HH group were similar to the other three groups and this sample size is at least as large as several 
previous comparative studies. Despite allowing for a reasonable ‘washout’ period between 
studies, it is uncertain whether the order of the studies could have influenced symptom scores and 
cardiac performance over time due to changes in physical fitness and experience of HA exposure. 
Furthermore, the effects of hyobaria was not independently assessed in this study through a 
hypobaric normoxia condition, as this was not feasible, and as such, the findings of this study 
should be reviewed in the context in which they have been presented.  
 
In conclusion, HH, NH and HH produce similar cardiac adaptations at rest. However, notable 
differences emerge following exercise in the degree of hypoxemia, RVSP, RV systolic, diastolic 
and global function.  This was most marked with HH and GH versus NH where the post exercise 
RV Tei and S’ velocity respectively were greater. The type of hypoxic environment and exercise 
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performed in this environment significantly influence the cardiac response. Observed changes in 
cardiac function with NH are not necessarily predictive of similar changes with genuine HA or 
HH and vice versa.   
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  Table 1 Baseline demographics  
Variable NN  GHA NH HH P value  
Number  11 14 12 6  
Age, years 
Range  
26.4 ± 4.0 
22-35 
25.9 ± 3.8 
21-35 
26.1 ± 4.1 
21-35 
26.3 ± 3.8 
22-33 
0.96 
Males (%) 7 (64%) 8 (57%) 8 (67%) 4 (67%) 0.99 
Height, m 175.4 ± 9.7 174.4 ± 9.6 175.5 ± 10.0 178.3 ± 9.7 0.88 
Weight, kg  72.5 ± 8.7 71.5 ± 9.9 72.9 ± 10.1 72.8 ± 11.4 0.99 
BMI, kg/m
2
 23.5 ± 1.9 23.4 ± 1.90  23.6 ± 2.0 22.8 ± 1.8  0.90 
Current smokers n,% 6 (54.5%) 7 (50%) 5 (35.7%) 2 (33.3%) 0.89 
Blood haemoglobin 
g/dL 
14.5 ± 1.6 14.5 ± 1.7 14.7 ± 1.5 15.2 ± 1.4 0.80 
Temperature, ºC 20.8±1.7 19.1±1.4 19.3±0.5 22.1±2.0 0.008a,b 
NN, normobaric hypoxia; GHA, genuine high altitude; NH, normobaric hypoxia; HH, hypobaric hypoxia 
Post-test differences: a, NH vs HH; b, GHA vs HH;  
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Table 2 Changes in acute mountain sickness (AMS) and haemodynamic variables  
Variable NN GHA NH HH P Value 
Lake Louisee Scores 
-Rest  
-15 minutes post exercise  
-2 hours post exercise 
 
0 
0 
0 
 
1 ± 1.0 
2.7 ± 3.0 
2.3 ± 2.2 
 
1.4 ± 2.3 
2.6 ± 2.5 
2.1 ± 2.1 
 
0.7 ± 1.2 
2.7 ± 3.4 
2.7 ± 3.0 
 
0.02ab 
0.004ab 
0.004ab 
Heart Rate , minute-1 
-Rest  
-15 minutes post exercise  
-2 hours post exercise 
 
60.1 ± 9.9 
79.9 ± 11.1* 
67.5 ± 9.4** 
 
72.1 ± 9.0 
89.7 ± 8.6* 
89.4 ± 10.0** 
 
65.7 ± 10.6 
86.6 ± 9.9* 
76.6 ± 15.3** 
 
65.7 ± 7.5 
88.7 ± 8.7* 
80.2 ± 11.6** 
 
0.02a 
0.09 
0.0005a,d 
Oxygen Saturations, %  
-Rest  
-15 minutes post exercise  
-2 hours post exercise 
 
98.6 ± 1.4 
98.4 ± 1.4 
98.9 ± 1.5 
 
89.3 ± 3.4 
89.3 ± 2.2 
91.6 ± 3.1** 
 
92.9 ± 1.7 
93.6 ± 2.5 
92.8 ±4.3 
 
89.0 ± 3.1 
89.8 ± 5.0 
91.8 ± 5.2 
 
<0.001abcdf 
<0.01abcdf 
<0.01abc 
NN, normobaric normoxia; GHA, genuine high altitude; NH, normobaric hypoxia; HH, hypobaric hypoxia; 
LLS, Lake Louise Scores t; AMS-C, Acute Mountain Sickness Scores  
Post-test differences: a, NN vs GHA; b, NN vs NH; c, NN vs HH; d, GHA vs NH; e, GHA vs HH; f, NH vs HH 
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Table 3 Changes in Echo derived markers of Left ventricular function  
Variable NN GHA NH  HH P Value  
Stroke volume, ml  
-Rest  
-15 minutes post exercise  
-2 hours post exercise 
 
71.5 ± 11.9 
60.6 ± 8.2 * 
66.1 ± 10.2 
 
74.1 ± 11.7 
62.7 ± 8.5* 
66.6 ± 9.3** 
 
73.6 ± 13.6 
66.5 ± 11.5 * 
70.9 ± 12.6 
 
74.7 ± 8.4 
69.8 ± 8.5 
69.7 ± 9.5 
 
0.85 
0.16 
0.58 
Cardiac output, L/minute 
-Rest  
-15 minutes post exercise  
-2 hours post exercise 
 
4.3 ± 0.8 
4.8 ± 0.8 
4.4 ± 0.5 
 
5.3 ± 1.1 
5.6 ± 1.0 
5.9 ± 1.1 
 
4.9 ± 1.3 
5.9 ± 1.1* 
5.4 ± 1.2 
 
4.9 ± 1.0 
6.2 ± 0.9* 
5.6 ± 0.9 
 
0.24 
0.01
b,c
 
0.006
a
 
-Mitral E velocity, cm/s 
-Rest 
-15 minutes post exercise  
-2 hours post exercise 
 
88.6 ± 9.6 
72.0 ± 16.2* 
76.5 ± 15.0  
 
90.1 ± 12.5 
81.8 ± 13.2 
85.4 ± 14.0 
 
92.5 ± 18.2  
77.4 ± 15.2*  
79.8 ± 13.3**  
 
95.2 ± 11.7 
84.5 ± 18.5  
76.7 ± 17.6 ** 
 
0.78 
0.19 
0.48 
Mitral A velocity, cm/s 
-Rest  
-15 minutes post exercise  
-2 hours post exercise 
 
48.5 ± 14.4 
56.7 ± 9.5 
46.6 ± 12.4 
 
51.8 ± 9.2  
63.3 ± 17.3 
59.9 ± 14.8 
 
55.2 ± 11.0 
68.5 ± 12.1* 
67.8 ± 16.7 ** 
 
58.2 ± 11.4 
64.3 ± 11.0 
62.0 ± 10.1 
 
0.39 
0.23 
0.009
b
 
Mitral E/A ratio  
-Rest  
-15 minutes post exercise  
-2 hours post exercise 
 
1.71 ± 0.27 
1.08 ± 0.25* 
1.25 ± 0.42** 
 
1.79 ± 0.42  
1.39 ± 0.45* 
1.53 ± 0.55 
 
1.71 ± 0.37 
1.15 ± 0.26* 
1.26 ± 0.42 ** 
 
1.67 ± 0.26 
1.35 ± 0.36 
1.27±0.24* 
 
0.87 
0.13 
0.32 
Septal S’ velocity, cm/s 
-Rest  
-15 minutes post exercise  
-2 hours post exercise 
 
8.9 ± 1.4 
8.3 ± 1.2 
8.9 ± 1.4 
 
10.2 ± 1.4 
10.1± 1.7 
10.9 ± 1.7 
 
9.8 ± 1.6 
9.4 ± 1.2 
9.8 ± 1.2 
 
9.0 ± 0.9 
9.8 ± 0.8 
9.7 ± 1.2 
 
0.33 
0.02
a
 
0.04
a
 
Septal E’ velocity, cm/s 
-Rest  
-15 minutes post exercise  
-2 hours post exercise 
 
13.0 ± 1.6 
10.8 ± 1.5* 
11.6 ± 1.6** 
 
12.9 ± 1.9 
12.9 ± 1.9 
12.7 ± 2.5 
 
13.3 ± 3.3 
12.7 ± 3.0 
12.0 ± 2.0 
 
13.2 ± 1.5 
12.7 ± 1.5 
11.0 ± 1.8** 
 
0.97 
0.11 
0.36 
Septal A’ velocity, cm/s 
-Rest  
-15 minutes post exercise  
-2 hours post exercise 
 
7.9 ± 2.3 
8.2 ± 1.2 
8.5 ± 1.8 
 
8.6  ± 2.2  
11.2 ± 3.4* 
10.7 ± 3.1** 
 
9.6 ± 2.2 
11.1 ± 2.2* 
10.9 ± 2.6 
 
8.3 ± 2.0 
10.8 ± 2.3* 
10.0  ± 1.1 
 
0.09 
0.003
abc
 
0.11 
Septal ICV, cm/s 
-Rest  
-15 minutes post exercise  
-2 hours post exercise 
 
6.5 ± 1.8 
7.1 ± 2.1 
7.2 ± 1.9  
 
7.1 ± 1.6 
8.4 ± 2.9 
8.8 ± 3.2 
 
7.0 ± 2.1  
7.2 ± 2.2  
7.3 ± 2.1 
 
6.8 ± 1.3  
6.8 ± 2.4  
7.7 ± 2.2  
 
0.80 
0.55 
0.46 
Lateral S’ velocity, cm/s 
-Rest  
-15 minutes post exercise  
 
11.1 ± 2.2 
10.9 ± 1.4 
 
12.1 ± 2.5 
13.8 ± 2.8 
 
12.6 ± 2.4 
12.1 ± 2.4 
 
10.7 ± 1.7 
13.5 ± 2.2* 
 
0.06 
0.03
a
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-2 hours post exercise 12.1 ± 2.3 15.1 ± 2.9** 12.9 ± 2.3 12.8 ± 1.6** 0.02
a
 
Lateral E’ velocity cm/s 
-Rest  
-15 minutes post exercise  
-2 hours post exercise 
 
18.3 ± 3.1 
16.5 ± 2.8 
17.4 ± 2.7 
 
18.6 ±2.1 
17.9 ± 3.2 
18.0 ± 3.8 
 
20.8 ± 2.8  
17.2 ± 2.5* 
18.1 ± 3.2**  
 
17.8 ± 2.8  
15.5 ± 1.6 
16.0 ± 2.3 
 
0.90 
0.52 
0.57 
Lateral A’ velocity cm/s 
-Rest  
-15 minutes post exercise  
-2 hours post exercise 
 
7.9 ± 2.5  
8.4 ± 2.3  
8.9 ± 2.2 
 
9.4 ± 2.8  
10.6 ± 2.4  
10.7 ± 3.5 
 
9.0 ± 2.6 
10.1 ± 2.5 
9.9 ± 3.2 
 
7.7 ± 2.2 
10.5 ± 2.2 
9.8 ± 2.9 
 
0.30 
0.13 
0.54 
Lateral ICV, cm/s 
-Rest  
-15 minutes post exercise  
-2 hours post exercise 
 
8.1 ± 2.0 
8.6 ± 1.8 
9.2 ± 1.8 
 
9.1 ± 2.8  
9.6 ± 3.0 
8.9 ± 3.6 
 
7.6 ± 2.0 
9.2 ±2.5 
9.5 ± 2.5** 
 
7.7 ± 1.6 
10.7 ± 3.1* 
8.8 ± 1.8 
 
0.34 
0.52 
0.94 
Left ventricular Tei Index 
-Rest  
-15 minutes post exercise  
-2 hours post exercise 
 
0.28 ± 0.04 
0.33 ± 0.04* 
0.32 ± 0.04  
 
0.30 ± 0.03 
0.32 ± 0.04 
0.33 ± 0.03 
 
0.29 ± 0.04 
0.33 ± 0.03* 
0.33 ± 0.03 
 
0.29 ± 0.03 
0.37 ± 0.06* 
0.36 ± 0.02** 
 
0.59 
0.15 
0.13 
NN, normobaric normoxia; GHA, genuine high altitude; NH, normobaric hypoxia; HH, hypobaric hypoxia ; 
ICV, isovolumic contractile velocity; Between group post-test differences: a, NN vs GHA; b, NN vs NH; c, NN 
vs HH; Within groups repeated measures post-test difference * rest vs 15 minutes post exercise; ** rest vs 2 
hours post exercise 
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Table 4 Changes in Echo derived markers of right ventricular function 
 Sea Level  GHA NH  HH P Value  
Right ventricular systolic pressure, 
mmHg 
-Rest  
-15 minutes post exercise  
-2 hours post exercise 
 
 
21.8 ± 4.0 
27.6 ± 5.2* 
28.2 ± 4.0** 
 
 
31.8 ± 3.7 
31.9 ± 6.1 
32.0 ± 6.4 
 
 
31.5 ± 5.8 
31.4 ± 5.7 
32.0 ± 5.6 
 
 
31.7 ± 4.0 
35.2 ± 5.7 
36.1 ± 8.1 
 
 
0.0002abc 
0.04c 
0.0006cf 
Pulmonary vascular resistance 
dynes/cm5 
-Rest  
-15 minutes post exercise  
-2 hours post exercise 
 
 
86.5 ± 13.8 
111.5 ± 11.3* 
106.7 ± 12.8** 
 
 
107.5 ± 12.2 
116.8 ± 20.1 
114.5 ± 22.3 
 
 
106.1 ± 15.9 
118.8 ± 19.3* 
117.2 ± 15.6 
 
 
118.7 ± 15.1 
127.3 ± 13.8 
129.1 ± 12.2 
 
 
0.0002a,b,c 
0.11 
0.04c 
TAPSE, cm 
-Rest  
-15 minutes post exercise  
-2 hours post exercise 
 
2.6 ± 0.4 
2.3 ± 0.4* 
2.3 ± 0.3** 
 
2.2 ± 0.3  
2.3 ± 0.3  
2.5 ± 0.3** 
 
2.4 ± 0.3 
2.4 ± 0.3 
2.4 ± 0.3 
 
2.6 ± 0.3 
2.5 ± 0.3 
2.6 ± 0.3 
 
0.05 
0.63 
0.27 
Tricuspid  E velocity cm/s 
-Rest  
-15 minutes post exercise  
-2 hours post exercise 
 
56.2 ± 8.3  
50.4 ± 9.1 
53.9 ± 10.2 
 
63.4 ± 18.1 
58.2 ± 12.5  
58.5 ± 14.0 
 
62.2 ±12.9 
50.8 ± 9.6*  
58.4 ± 10.5  
 
66.2 ± 11.5 
57.7 ± 9.0 
54.3 ± 10.6 ** 
 
0.43 
0.16 
0.67 
Tricuspid  A velocity cm/s  
-Rest  
-15 minutes post exercise  
-2 hours post exercise 
 
33.7 ± 5.2 
39.9 ± 9.0* 
35.4 ± 8.4 
 
37.6 ± 1.0 
45.8 ± 12.3* 
40.4 ± 7.4  
 
45.9 ± 9.6 
51.5 ± 13.1 
51.7 ± 16.0 
 
43.3 ± 10.0 
45.2 ± 13.7  
40.2 ± 7.1  
 
0.01b 
0.16 
0.006b 
Right ventricular S’ velocity, cm/s  
-Rest  
-15 minutes post exercise  
-2 hours post exercise 
 
14.7 ± 1.3  
13.2 ± 1.7 
13.9 ± 1.9  
 
15.5 ± 1.1 
15.4 ± 1.5 
16.4 ±2.0 
 
15.4 ± 1.6  
13.4 ± 1.8*  
14.3 ± 2.3  
 
14.5 ± 2.8 
15.2 ± 1.9 
14.8 ± 2.9  
 
0.45 
0.009a 
0.03a 
Right ventricular  E’ velocity, cm/s 
-Rest  
-15 minutes post exercise  
-2 hours post exercise 
 
14.2 ± 2.9 
13.3 ± 3.8 
13.7 ± 3.0  
 
16.4 ± 3.5  
16.6 ± 3.8 
16.4 ± 2.7 
 
14.8 ± 2.8 
15.3 ± 4.7 
15.4 ± 3.3 
 
15.7 ± 2.9 
15.3 ± 4.5 
15.2 ± 5.5 
 
0.30 
0.23 
0.23 
Right ventricular  A’ velocity, cm/s 
-Rest  
-15 minutes post exercise  
-2 hours post exercise 
 
11.1 ± 1.9 
10.9 ± 2.5 
12.5 ± 2.4 
 
11.5 ± 2.1 
17.5 ± 3.1* 
18.1 ± 3.7** 
 
10.2 ± 1.9 
13.2 ± 4.1* 
14.9 ± 3.3* 
 
12.2 ± 1.5 
14.8 ± 1.5 
14.8 ±1.3** 
 
0.16 
0.0001ad 
0.0007a 
Right ventricular ICV velocity, cm/s 
-Rest  
-15 minutes post exercise  
-2 hours post exercise 
 
9.5 ± 2.7 
10.8 ± 2.7 
11.3 ± 3.1 
 
10.5 ± 2.3 
12.5 ± 3.1 
12.2 ± 3.3 
 
8.9 ± 1.9 
10.2 ± 2.7 
10.6 ± 1.9 
 
9.1 ± 1.6 
11.7 ± 2.1* 
9.7 ± 1.8 
 
0.43 
0.14 
0.24 
Right ventricular Tei Index 
-Rest  
-15 minutes post exercise  
-2 hours post exercise 
 
0.29 ± 0.05  
0.33 ± 0.04 
0.32 ± 0.06 
 
0.32 ± 0.04 
0.37 ± 0.05* 
0.31 ± 0.05 
 
0.29 ± 0.03 
0.33± 0.03 
0.34 ± 0.07** 
 
0.30 ± 0.06 
0.41 ± 0.05* 
0.39 ± 0.05** 
 
0.29 
0.001cf 
0.04e 
NN, normobaric normoxia; GHA, genuine high altitude; NH, normobaric hypoxia; HH, hypobaric hypoxia; TAPSE, trans 
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annular plane systolic excursion; ICV, isovolumic contractile velocity; Between group post-test differences: a, NN vs 
GHA; b, NN vs NH; c, NN vs HH; d, GHA vs NH; e, GHA vs HH; f, NH vs HH. Within groups repeated measures post-
test difference * rest versus 15 minutes post exercise; ** rest versus 2 hours post exercise;   
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Table 5 Results of Two-Way Repeated Measures ANOVA comparing the Main Effects of 
Duration (time) and mode of hypoxia across the three hypoxia groups 
 
 Mode of hypoxia Time Interaction 
 F P value F P value F P Value 
SpO2 6.55 0.004
ac 2.4 0.10  1.2 0.34 
Heart Rate  2.32 0.12 75.47 <0.001abc 2.18 0.08 
Mitral E velocity  0.17 0.84 11.97 <0.001ac 1.2 0.32 
Mitral A velocity 1.20 0.33 5.9 0.005ac 0.35 0.85 
Mitral E/A ratio 1.93 0.16 10.79 <0.0001 0.43 0.79 
Septal S’ velocity 2.38 0.11 0.99 0.38 0.72 0.58 
Septal E’ velocity 0.20 0.82 3.37 0.04b 0.77 0.55 
Septal A’ velocity 0.29 0.75 12.32 <0.001ab 0.36 0.83 
Septal ICV  1.0 0.40 2.70 0.08 1.0 0.42 
Lateral S’ velocity 1.40 0.27 10.28 <0.001ab 3.99 0.006 
Lateral E’ velocity 2.20 0.13 7.56 0.001 ab 1.12 0.36 
Lateral A’ velocity 0.40 0.68 6.97  0.002ab 0.58 0.68 
Lateral ICV  0.12 0.89 6.99 0.002a 2.14 0.09 
LV Tei Index  2.32 0.12 6.48 0.003a 1.54 0.10 
LV stroke volume  0.39 0.68 10.37 0.004 ab 0.93 0.45 
Cardiac output  0.23 0.80 13.8 <0.001ab 2.52 0.06 
RVSP  0.70 0.51 1.47 0.24 0.88 0.48 
Pulmonary vascular resistance  2.10 0.14 5.85 0.005 ab 0.27 0.76 
Tricuspid E velocity 0.55 0.58 5.15 0.009a 0.88 0.48 
Tricuspid A velocity 3.90 0.03a 1.9 0.16 0.58 0.68 
TAPSE 1.21 0.31 1.1 0.31 2.4 0.06 
Tricuspid S’ velocity 2.60 0.09 1.3 0.30 3.12 0.02 
Tricuspid E’ velocity 0.66 0.53 0.01 0.99 0.10 0.98 
Tricuspid A’ velocity 8.20 0.002a 22.3 <0.001 ab 1.59 0.19 
Tricuspid ICV 3.40 0.048 a 6.7 0.002a 0.78 0.54 
Right ventricular Tei Index 5.0  0.01c 16.10 <0.001ab 4.10 0.006 
TAPSE, trans annular plane systolic excursion; RVSP, right ventricular systolic pressure; ICV isovolumic 
contractile velocity; Results of post hoc tests – time: a baseline versus 15 minutes post exercise, b baseline versus 2h 
post exercise, c 15 minutes versus 2 hours post exercise, mode of hypoxia: a GHA vs NH, b GHA versus HH, NH 
versus HH  
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Figure 1 Changes in the left ventricular lateral S’ velocities (marginal means) with 
differing experimental conditions and duration of hypoxia (time 1= baseline rest, time 2= 
15 minutes post exercise and time 3 =120 minutes post exercise). * demonstrates between 
group differences on post test  
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Figure 2 Changes in the right ventricular S’ velocities (marginal means) with differing 
experimental conditions and duration of hypoxia (time 1= baseline rest, time 2= 15 
minutes post exercise and time 3 =120 minutes post exercise). * demonstrates between 
group differences on post test 
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Figure 3 Changes in the right ventricular Tei Index (marginal means) with differing 
experimental conditions and duration of hypoxia (time 1= baseline rest, time 2= 15 
minutes post exercise and time 3 =120 minutes post exercise) * demonstrates between 
group differences on post test 
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Abstract 
Central arterial systolic blood pressure (SBP) and arterial stiffness are known to be better 
predictors of adverse cardiovascular outcomes than brachial SBP. The effect of progressive high 
altitude (HA) on these parameters has not been examined.  
 
Ninety healthy adults were included. Central BP and the augmentation index (AI) were measured 
at the level of the brachial artery (Uscom BP+ device) at <200m and at 3619m, 4600m and 
5140m. The average age of the subjects (70% men) were 32.2±8.7 years. Compared with central 
arterial pressures, brachial SBP (+8.1±6.4 mmHg; p<0.0001) and pulse pressure (+10.9±6.6 
mmHg; p<0.0001) were significantly higher and brachial DBP was lower (-2.8±1.6 mmHg; 
P<0.0001). Compared <200m, HA led to a significant increase in brachial and central SBP. 
Central SBP correlated with AI (r=0.50; 95% CI: 0.41 to 0.58: p<0.0001) and age (r=0.32; 21to 
0.41: p<0.001). AI positively correlated with age (r=0.39; p<0.001) and inversely with subject 
height (r=-0.22; p<0.0001) weight (r=-0.19; p=0.006) and heart rate (r=-0.49: p<0.0001). There 
was no relationship between acute mountain sickness scores (LLS) and AI or central BP. The 
independent predictors of central SBP were male sex (coefficient, t 4.7; P<0.0001), age (t=3.6; 
p=0.004) and AI (t=7.5; p<0.0001; overall r2 =0.40; p<0.0001). Subject height (t=2.4; p=0.02), 
age (7.4; p<0.0001) and heart rate (t=11.4; P<0.0001) were the only independent predictors of AI 
(overall r2=0.43; p<0.0001). Central BP and AI significantly increase at HA. This rise was 
influenced by subject-related factors and heart rate but not independently by altitude, LLS or 
SpO2.   
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Introduction  
Cardiovascular death is a leading cause of non-traumatic deaths in adults at high altitude (HA) 
[51].Despite this fact, there has been limited research into cardiovascular risk assessment at HA 
[51].
 
HA exposure leads to an increase in resting heart rate, compared with that at sea level, yet 
paradoxically, maximal heart rate is reduced [17].  The stroke volume rise noted with exercise at 
sea level is blunted at HA [17, 70]. Consequently, whilst resting cardiac output is higher at HA, 
versus sea level, at peak exercise it is comparatively lower [14, 17, 70].These factors along with 
the notable reduction in arterial oxygen content act to limit peak exercise capacity and oxygen 
consumption [14, 17]. Other reported cardiovascular responses include an increase in resting 
brachial artery systolic blood pressure (SBP) and 24hour arterial blood pressure (BP), which 
along with the increase in resting heart rate could be potential implicating factors in the increased 
cardiovascular risk [127, 128, 138, 233].    
 
The effects of HA on central arterial haemodynamics, such as central arterial BP and large artery 
stiffness, are far less well understood and have been barely reported. Central arterial BP and large 
artery stiffness are known to be more powerful predictors of adverse cardiovascular outcomes, 
including stroke and cardiovascular death than brachial artery BP as they more closely reflect the 
haemodynamic loading of vital central organs such as the heart, brain and kidneys [76, 77]. 
Brachial artery BP does not reliably reflect central BP due to the effects of peripheral 
amplification which is highly variable between individuals [76, 77].  
 
Unfortunately, the accurate non-invasive assessment of central BP and large artery stiffness has 
been traditionally very difficult. It had required the need for either arterial catheterisation or less 
portable and expensive non-invasive equipment limiting its research utility at HA, explaining the 
paucity of published research at genuine terrestrial HA [14, 233]. 
 
In the only study to investigate the influence of terrestrial HA on both large arterial stiffness and 
central BP Parati et al observed a significant increase in both central SBP and the arterial 
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augmentation index (AI, marker of arterial stiffness) in untreated subjects travelling to HA.
7 
However, the altitude gain was very rapid (4559m within 28 hours of ascent) and only a single 
altitude was studied. Nevertheless, their findings are potentially important given the huge 
numbers exposed to HA worldwide [17, 51].  
 
The Uscom BP
+
 is a novel device which is able to estimate central blood pressure using a simple 
oscillometric BP cuff on the upper arm [86]. It has shown excellent agreement with catheter 
based assessments of central BP and gold standard measures of arterial stiffness [87, 234]. It 
utilises pulse wave analysis to assess the AI which reflects the enhancement (augmentation) of 
central aortic systolic pressure by reflected arterial pulse waves. It has the advantage over several 
competing devices. It is highly portable and only requires the use of an upper arm cuff therefore 
avoiding the need to assess either the radial or digital pulse where the signal to noise ratio may be 
less favourable.   
 
In this study we sought to utilise this available technology to investigate, for the first time the 
effects of a step-wise increasing terrestrial HA on both central BP and AI during a trek to 
>5000m.  
 
Methods 
Study design and participants 
Ninety healthy British Military servicemen aged >18years were included. Inclusion was entirely 
voluntary and represented a large subset of military servicemen who had been selected to take 
part in a quadrennial military adventure training exercise to HA. Significant mountaineering 
experience was not essential but those with very limited experience were encouraged to attend a 
winter skills course (<1200m) within 3 months of departure. The subjects were assessed at near 
sea level (<200m) and during progressive ascent in the Dhaulagiri region in the Himalayas in 
March/April 2016. Health status was confirmed following a detailed baseline questionnaire. All 
subjects were assessed to be medically fit for a high altitude venture by their general practitioner. 
 
148 
To be considered fit they were all required to have passed their annual military basic fitness test 
which includes a 1.5 mile timed run.  Key exclusion criteria included a history of hypertension 
and/ or atrial fibrillation. All participants were low altitude dwellers and none had prior exposure 
to >1400m terrestrial altitude in the four weeks prior to this study. The subjects were studied 
consecutively in groups of 8-10 individuals with a two day stagger between successive groups.  
HA related symptoms were assessed using the Lake Louise Scoring System (LLS) [28, 29].  
 
High Altitude Ascent and descent profile 
The subjects flew from the UK to Kathmandu (1400m day 1-3) where they underwent a short 
period of local acclimatisation at 1400m. From there they travelled by a staged road move to 
Darbang (1030m). From there they commenced trekking on foot with loads of up to 12kg over 
the ensuing 11 days (to day 14) to an altitude of 5140m (with an overpass of 5360m) before 
commencing their decent (day 15) on foot to Marpha (2719m) and then by road back to 
Kathmandu (figure 1). Research assessments were performed at sea level and at static research 
camps at 3619m (day 9), 4600m (day 12) and 5140m (day 14) during ascent.  
 
Physiological assessments and central blood pressure measurement 
Oxygen saturations (SpO2) were measured using a Nonin Onyx (Nonin Medical Inc, Plymouth, 
Minnesota, USA) pulse oximeter.  Blood pressure and arterial stiffness assessments were 
obtained at the same time using an Uscom BP
+
 device (Uscom, Sydney, NSW, Australia) as 
previously reported [86-88, 234]. The upper arm cuff was attached to the dominant arm of seated 
subjects. All subjects were rested for at least five minutes prior to BP assessment and they were 
not permitted to drink caffeine or smoke for at least three hours and alcohol for >10 hours prior to 
BP measurements [83]. The subjects were advised not to speak during the recordings. The BP
+
 
device measures both central and peripheral BP (mmHg) using supra systolic oscillometry.  
Following an initial inflation-deflation the cuff is re-inflated to approximately >30mm Hg above 
the recorded suprasystolic pressure for 10 seconds, during which suprasystolic BP and pulse 
wave assessments are recorded via the arm cuff.  All recordings were stored on a mini SD card 
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within the device and later exported for data analysis.  Only readings with a signal-to-noise ratio 
of ≥6 was were included and tests with a ratio of <6 were repeated.  
 
The BP
+
 calculates a number of additional haemodynamic indices that were of interest to this 
study, including the AI. Its quoted AI is the arterial augmentation pressure (difference between 
the second and first systolic peaks of the central pressure waveform) expressed as a percentage of 
the pulse pressure and it is an indirect measure of large arterial stiffness. Further parameters that 
we were specifically interested in for this study were the time to systolic wave Reflection (TR) 
and the suprasystolic pulse pressure variation (ssPPV). The reflected Wave Transit Time is an 
indirect measure of pulse wave velocity and large arterial stiffness. The ssPPV is a novel measure 
of fluid responsiveness and is heavily influenced by respiratory variation and left ventricular 
stroke volume, both of which can be affected at HA [235-237].  The BP
+
 calculates the ssPPV as 
the difference between maximum and minimum pulse pressures divided by the average pulse 
pressure over the 10 second rhythm strip.  
 
Ethics 
Participation was entirely voluntary and all participants underwent detailed written informed 
consent.  The study was approved by the Ministry of Defence Research and Medical Ethics 
Committee (MODREC) and was conducted according to the standards of the declaration of 
Helsinki.  
 
Statistical analysis  
Data were analysed using GraphPad InStat version 3.05 and with all graphical figures presented 
using GraphPad Prism version 4.00 for Windows (GraphPad Software, San Diego, CA, USA). 
Sample size calculations were performed using a proprietary determined sample- size calculator 
using (GraphPad StatMate version 2.00 for Windows). The Kolmogorov-Smirnov test was 
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undertaken to assess normality of all continuous data and all continuous data are presented as 
mean ± standard deviations and median ± interquartile range for parametric and non-parametric 
data respectively. Comparison of unpaired data was performed using an unpaired T test or the 
Mann-Whitney Test for parametric and non-parametric data respectively and with a paired t test 
and Wilcoxon matched pairs test for equivalent paired data.  Continuous data from >3 groups 
were compared using a one-way Analysis of Variance (ANOVA) with either Tukey post-hoc 
tests or a Kruskal-Wallis test with Dunn post-test  for parametric and  non-parametric data 
respectively. Correlations were performed using Pearson and Spearman rank correlation (±95% 
confidence interval, CI) for parametric and non-parametric data respectively.  A two tailed P 
value <0.05 was considered statistically significant for all comparisons. All univariate predictors 
of central arterial systolic blood pressure were entered into a multiple linear regression analysis 
model in order to identify its independent predictors. A two tailed P value <0.05 was considered 
statistically significant for all comparisons.  
 
Sample size calculations  
Parati et al studied 44 subjects who travelled from sea level to 4559m within 29 hours [128]. 
From this group there were 22 subjects who were randomised not to receive prophylactic 
medication to prevent acute mountain sickness. In this group they observed a non-significant 
increase in central systolic blood pressure from 103.7±10.7 to 108.8±8.0 mmHg from sea level to 
that after 48h at HA. The AI significantly increased at HA versus sea level. Based on this data 
and the average standard deviation of their central BP readings, we calculated that a sample size 
of at least 60 subjects would have >80% power to detect a >5 mmHg change in central SBP and a 
>7% change in AI at HA at a significance level (alpha) of 0.05 (two-tailed). 
 
Results 
Ninety subjects were included. The average age of the subjects were 32.2±8.7 years with 70% 
being male. Heart rate and LLS increased and SpO2 fell at HA compared with sea level (table 1). 
The average 1.5 mile run time for included subjects was 9.9±1.2 minutes. 
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Overall brachial arterial SBP (+8.4 [5.0 to 12.0] mmHg; p<0.0001) and pulse pressure (+11 [7.0 
to 15.0] mmHg; p<0.0001) were significantly greater than that observed centrally. Conversely the 
brachial artery DBP was lower (-2.6 [-3.4 to -2.0] mmHg; P<0.0001) than the equivalent central 
readings.   
 
Compared with baseline sea level values there was a significant increase in both brachial and 
central SBP and in brachial but not central arterial pulse pressure at HA (table 2). The highest 
increase in both brachial and central SBP was between sea level and 4619m (+7.0 [-5.0 to 16.0] 
and +7.0 [-4.5 to 18.0] mmHg respectively) (table 2; figure 2).  
 
The AI and ssPPV both increased at HA whereas the reflected wave transit time and systolic 
ejection period decreased versus sea level (table 2; figure 3). Adjusting the AI to an average heart 
rate of 75 per minute (AI@75) did not alter the findings.  
 
There were significant correlations between central SBP and both AI (r=0.50; 0.41 to 0.58: 
p<0.0001) and age (r=0.32; 21to 0.41: p<0.001). Other independent, albeit weak predictors, of 
central SBP were SpO2 (r=-0.14 -0.25 to -0.05: p=0.02),  heart rate (r=-0.16; -0.27 to -0.05: 
p=.003) male sex (r =0.15; 046 to 0.26: p=0.004) ethnicity (r=0.15; 0.04 to 0.25: p=0.007) 
smoking status (r=0.18; -0.28 to -0.07; p=0.001) and altitude (r=0.10; p=0.05).  AI positively 
correlated with age (r=0.39; p<0.001) and inversely with subject height (r-0.22; p<0.0001) 
weight (r-0.19; p=0.006), and heart rate (-0.49: p<0.0001). There was no relationship between 
LLS and either AI or central BP.  
 
Multivariate analysis was performed to assess the independent predictors of central systolic BP. 
Only the univariate predictors were included in the model. The independent predictors of central 
SBP were male sex (coefficient, t 4.7; P<0.0001), age (t 3.6; p=0.004) and AI (t 7.5; p<0.0001; 
overall r
2 
=0.40; p<0.0001). If AI was removed from the model (overall r
2
=0.29; p<0.0001) then 
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the independent predictors of central systolic BP were age, heart rate and smoking history.  
Subject height (coefficient 2.4; p=0.02), age (7.4; p<0.0001) and heart rate (11.4; P<0.0001) were 
the only independent predictors of AI (overall r
2
=0.43; p<0.0001). The order of the trekking 
groups did not influence the findings when included in the multivariate analysis.  
 
Discussion 
To the author’s knowledge, this is the first study to assess the effects of stepwise increasing 
terrestrial HA on arterial stiffness and central BP over a conventional and progressive HA trek. 
We found that HA exposure led to a significant increase in central SBP and AI. Neither altitude 
nor the SpO2 were independent predictors of AI and central SBP. Heart rate was a significant 
determinant of both AI and central BP.  
 
HA exposure leads to a wide range of complex effects on both the pulmonary and systolic 
circulation which have been well described [14, 17, 70, 72]. Hypobaric hypoxia leads to 
widespread sympathetic activation leading to an increase in resting heart rate [64, 238, 239]. The 
reported effects on BP are variable and are highly dependent on the degree of hypoxia and speed 
and duration of exposure.  Furthermore, the type of hypoxic environment may be a major 
confounder [209]. Several previously published studies have used simulated hypoxia (using 
either a normobaric or hypobaric chamber) in an attempt to replicate the degree of hypoxia 
observed at genuine HA [64, 70, 72, 209]. Whilst they are very useful surrogates for HA 
exposure, simulated hypoxia does not fully reproduce the environmental and geographical effects 
genuine terrestrial HA such as the cold or the exercise burden. The reported literature has tended 
to focus on the effects of HA on brachial artery BP and largely following a relatively short 
periods (<6 hours) of simulated hypoxia [72, 209]. Available data at terrestrial HA has shown 
that HA exposure typically leads to an increase in both resting systolic and 24 hour blood 
pressure which may be more pronounced in those with background hypertension [127]. The 
effects of HA on central BP and arterial stiffness have been barely examined at HA, yet they are 
well recognised to be better predictors of cardiovascular risk than brachial BP [76, 77]. Given the 
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vast numbers of patients with known hypertension and cardiovascular disease who undergo 
recreational HA exposure annually the ability to better define cardiovascular risk in these 
individuals would be important. This has added importance given that cardiovascular death is a 
leading cause of non-traumatic death at HA [51]. An improved understanding of the effects of 
HA on central BP and other non-invasive measures of cardiovascular risk such as arterial 
stiffness might allow for tailored medical therapy at HA to reduce the cardiovascular risk to 
individuals. We observed a significant increase in brachial but not central pulse pressure 
suggesting differences in BP behaviour in the peripheral versus the central circulation. Indeed 
whilst the brachial SBP was higher than that observed centrally the increase in central SBP was 
greater and was significant across all three altitudes studied (table 2).  
 
There has only been one previous study to investigate the effects of HA on measures of both 
arterial stiffness and central BP at terrestrial altitude. Parati et al studied 44 subjects who were 
randomised to placebo or to oral acetazolamide prior to and during HA exposure [128]. 
Following sea level assessment the subjects ascended to 4559m within 28 hours by road to 
1130m, then cable car to 3647m before completing the rest of the ascent on foot. Measurements 
at HA were obtained within 4-6 hours of arrival at 4559m and again after two days at this 
altitude. They observed a non-significant increase in both central and peripheral SBP but an even 
greater and significant increase in DBP.  AI@75 significantly increased from Sea level to HA. 
However, whereas the SBP continued to increase from 4-6 hours to two days at HA there was no 
further increase in the AI@75 beyond the early increase. In our study we noted a similar sized 
increase in both brachial and central SBP to that in this previous study and the significance in our 
current study likely relate to our much larger sample size. Our data would seem to suggest that 
the increase in heart rate is a significant independent predictor of the increase in AI at HA which 
was not directly related to either the SpO2 or altitude. The observed increase in heart rate, AI, 
brachial and central SBP would strongly suggest that these increases relate to sustained 
sympathetic activation at HA as has been well described rather than a genuine increase in large 
artery stiffness [238].  
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In one of the only previously published studies to assess the effects of HA on arterial stiffness 
and brachial BP during a conventional trek Rhodes et al studied 17 subjects over an ascent from 
80m to 4770m over 11 days [138]. They found that HA led to a transient increase in large artery 
stiffness index (using finger photoplethysmography) noted at day four at 3450 m before returning 
to baseline levels. A significant rise in both systolic and diastolic BP were observed at 3450m 
and the increase was sustained throughout the HA exposure [138]. Interestingly, they observed 
that the increase in BP was not related to changes in arterial stiffness nor was there a link 
between the increase in arterial tone and the presence of AMS. We did not identify a relationship 
between LLS, SpO2 and either AI, which is an indirect measure of large artery stiffness and 
central systolic BP at HA.   
 
Consistent with previous research we found that the AI related to the subjects age and inversely 
correlated with height and heart rate [180, 240]. This is explained by the fact that the time of the 
reflected wave is related to the dimensions of the body and heart rate. In shorter individuals, a 
reduced return time for reflected waves leads to an increase in central pressure augmentation 
[240]. As a result of the noted influence of heart rate on AI it has been suggested that AI should 
be adjusted for the effects of heart rate and this has traditionally been to an average of 75 per 
minute (AI@75) [241]. Adjusting the AI@75 to account for heart rate did not alter our findings. 
It has also been more recently suggested that adjusting for heart rate on multivariate analysis of 
AI is more appropriate and this has been additionally done in our analysis [65]. Our data has 
shown that heart rate was the independent variable with the greatest impact on AI. Indeed 
augmentation of central BP is influenced by heart rate and therefore the duration of systole and 
shifting the reflected arterial wave to diastole and reducing the time to wave reflection as has 
been observed in our study [241]. Therefore it is reasonable to assume that the increase in AI at 
HA is largely related to the associated increase in heart rate leading to a rise in arterial 
augmentation and central BP rather than actual changes in large artery stiffness over only 14 days 
HA exposure.  
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In this study we were also interested in the effects of HA on the ssPPV. This is a measure of the 
variation in the pulse pressure averaged over the 10 second arterial waveform recording using the 
BP
+ 
device.  The beat to beat variation in pulse pressure is known be influenced by a number of 
factors including left ventricular preload, stroke volume and ventilation, which are all known to 
be affected at HA [72]. Clinically, probably the most widespread use of ssPPV has been to assess 
fluid responsiveness in mechanically ventilated patients intra-operatively and on intensive care 
[236, 237]. During inspiration negative intrathoracic pressure leads to an increase in venous 
return and ultimately an increase in ventricular filling. Its effect on left ventricular stroke volume 
is influenced by hydration and intravascular filling, which is dependent on the relative position 
on the Frank-Starling curve [235]. HA-related hypoxia has been shown to affect both right and 
left ventricular stroke volume with variable effects on ventricular filling [64, 70, 72]. The 
mechanisms to explain these changes are complex and include the known hypoxia mediated 
pulmonary vasoconstriction leading to an increase in pulmonary artery systolic pressure and right 
ventricular afterload [14].  HA acclimatisation is known to lead to relative dehydration and 
hypoxia-mediated hyperventilation all of which may affect biventriuclar stroke volume. Whilst 
the ssPPV cannot be used in isolation serial measurements can be used to assess filling and fluid 
responsiveness. In our study the ssPPV was very susceptible to the effects of HA exposure but 
was not related to LLS. HA led to a marked increase in the ssPPV, despite no significant increase 
in the central arterial pulse pressure.  
 
This study has a number of limitations that require acknowledgement. The subjects were studied 
in groups two days apart. This was done to accommodate the large sample size of the study and 
ensure excellent reproducibility of the measures and ensure that subject BP measurements were 
conducted robustly at each individual research station by trained researchers. The environmental 
factors, such as temperature and barometric pressure would not have been identical for the study 
groups at the time of their data collection which could have potentially influenced the findings. 
However, we did not observe any significant influence of the trekking group order of study on 
either AI or central systolic blood pressure. Unfortunately, we did not measure hormonal markers 
of sympathetic activation, such as circulating catecholamines, to better investigate the mechanism 
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for the increase in SBP and AI, however, we did note that the increases did not relate to the 
degree of hypoxia (SpO2) or LLS. 
 
In conclusion in this study we found that HA exposure led to an increase in brachial and central 
SBP and a rise in AI compared with near sea level baseline levels. The increase in central SBP 
and AI was not related to the degree of hypoxia and SpO2 at HA nor to LLS. The observed 
changes likely relate to increased sympathetic activation rather than any genuine change in large 
artery stiffness.  
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What is known about the topic?  
●  HA exposure leads to an increase in heart rate and there is evidence from a single study of 
rapid largely cable car ascent to 4559m that it leads to an increase in central SBP and arterial 
AI.  
 
What this study adds?  
●  This is the first study to examine the effects of stepwise increasing terrestrial HA on arterial 
stiffness and central BP over a conventional and progressive HA trek to >5000m. 
 We have discovered that the HA exposure led to a significant increase in central SBP and AI.  
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 Neither altitude nor the SpO2 were independent predictors of AI and central SBP. 
 The increase in AI related to the increase in heart rate at HA and did not reflect a genuine 
change in large artery stiffness.  
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Table 1: Baseline Demographics  
Demographic Result  
Age, years (range)  32.2±8.7 (18-56) 
Males n, % 63 (70%) 
Height, cm 173.5±9.1  
Weight, kg 73.4±12.3 
Body mass index kg/m
2
 24.38±2.7 
Ethnicity, % 
- Caucasian  
- Nepalese  
- South Asian 
 
78 (86.7%) 
11 (12.2%) 
1 (1.1%) 
Smoking status (N, %) 
- Current  
- Ex  
- Never 
 
9 (10%) 
11 (12.2%) 
70 (77.8%) 
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Table 2 Effect of high altitude on measured vascular parameters including central blood 
pressure and augmentation index 
Parameter Sea level 3619m 4600m 5140m P value 
Heart rate/ minute 65.2±12.8 69.6±11.8 77.3±15.3 78.2±13.6 <0.0001*†‡ 
Oxygen Saturations, % 97.7±1.4† 91.9±3.4 82.8±6.3 80.4±5.3 <0.0001*†‡ 
Lake Louise Scores 0.23 (0.64) 1.1 (1.9) 1.4 (1.6) 1.3 (1.4) <0.0001*†‡ 
Brachial artery  
systolic BP, mmHg 
132.8±14.0 136.9±13.4 138.8±13.3 138.6±13.9 0.04†‡ 
Brachial artery diastolic 
BP, mmHg 
81.8±11.7 84.7±9.4 83.7±9.8 83.9±9.7 0.28 
Mean brachial arterial 
BP, mmHg 
99.3±12.9 102.0±9.9 102.1±9.9 102.2±9.8 0.23 
Brachial artery pulse 
pressure, mmHg 
51.6±11.3 52.1±9.7 55.5±10.9 54.7±11.3 0.02† 
Central systolic BP, 
mmHg 
124.7±14.8 130.1±14.2 131.4±15.4 129.4±14.3 0.02*†‡ 
Central diastolic BP, 
mmHg 
84.0±11.6 87.5±9.6 86.8±9.6 87.3±9.5 0.09 
Central artery pulse 
pressure, mmHg 
40.7±9.5 42.6±9.6 44.6±13.4 42.1±9.9 0.26 
Augmentation  
index, % 
55.3±34.9 71.1±34.1 61.8±36.7 56.6±32.7 0.001† 
Reflected wave transit 
time, s 
0.16±0.02 0.16±0.02 0.14±0.02 0.14±0.01 <0.000*†‡ 
Systolic ejection period, s 0.30±0.03 0.31±0.02 0.29±0.03 0.28±0.02 <0.0001†‡ 
Supra Systolic pulse 
pressure variation 
0.23±0.13 
0.28±0.15 
0.37±0.20 0.34±0.19 <0.0001*†‡ 
BP, blood pressure; results of post hoc tests vs baseline sea level,  *3880m, † 4400m, ‡ 5140m 
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Figure 1 Ascent Profile the altitude and timing of data collection  
 
Figure 2 Changes in systolic blood pressure with HA exposure. Symbol* denotes significant 
difference vs baseline level   
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Figure 3 Change in Augmentation Index with high altitude 
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Abstract 
Introduction 
There is evidence to suggest that high altitude (HA) exposure leads to a fall in heart rate 
variability (HRV) that is linked to the development of acute mountain sickness (AMS).  The 
effects of sex on changes in HRV at HA and its relationship to AMS are unknown.   
Methods  
HRV (5-minute single lead ECG) was measured in 63 healthy adults (41 men and 22 women) 
aged 18-56 years at sea level (SL) and during a HA trek at 3619m, 4600m and 5140m 
respectively. The main effects of altitude (SL, 3619, 4600 and 5140m) and sex (men vs women) 
and their potential interaction were assessed using a Factorial Repeated Measures ANOVA. 
Logistic regression analyses were performed to assess the ability of HRV to predict AMS. 
Results 
Men and women were of similar age (31.2 ±9.3 vs 31.7±7.5 years), ethnicity, body and mass 
index.   There was main effect for altitude on heart rate, SDNN (standard deviation [SD] of 
normal-to-normal [NN] intervals), RMSSD (Root mean square of successive differences), NN50 
(number of pairs of successive NNs differing by >50 ms), pNN50 (NN50 / total number of NNs), 
very low frequency (VLF), low frequency (LF), high frequency (HF) and total power (TP). The 
most consistent effect on post hoc analysis was reduction in these HRV measures between 3619 
and 5140m at HA. Heart rate was significantly lower and SDNN, RMSSD, LF, HF and TP were 
higher in men compared with women at HA. There was no interaction between sex and altitude 
for any of the HRV indices measured. HRV was not predictive of AMS development.  
 
Conclusions 
Increasing HA leads to a reduction in HRV. Significant differences between men and women 
emerge at HA. HRV was not predictive of AMS.   
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Introduction  
The assessment of heart rate variability (HRV) has rapidly evolved from what was predominantly 
a research tool to an increasingly appreciated clinical modality [58]. Its most widespread 
translational use at present is in the assessment of psychological stress, physical fitness and the 
prevention of overtraining [58, 167]. The improved portability and reduced cost of HRV-
measurement equipment have also played a significant role in this regard.  HRV assessment 
relies on the detailed assessment of the variations in the time-intervals between consecutive heart 
beats which are subject to continuous autonomic control [60, 167]. From these data, the changes 
in the beat-beat intervals over time (time-domain analyses) can be more robustly quantified from 
as little as 1-5 minutes of recording [58, 164, 170]. The beat-to-beat data can be further examined 
by frequency domain analysis whereby the generated sinusoidal waveforms of these intervals 
over time, are placed into various frequency components, allowing for a more in depth analysis 
of autonomic balance [60, 167]. 
 
An area of recent interest has been in the effects of high altitude (HA) on HRV [91, 150, 151, 
216]. HA exposure challenges several physiological systems that are heavily reliant on 
continuous autonomic control and are likely to influence [151, 152, 187, 216, 242]. Acute 
hypoxia and HA leads to marked sympathetic activation yet paradoxically there is also evidence 
of increased competing parasympathetic activity which contributes to the reduction in maximal 
heart rate in proportion to the altitude gained [137, 151, 152, 216]. Hypobaric hypoxia, cold, 
exercise, stress and fatigue, which are synonymous with HA exposure, are all known individually 
to influence HRV [151, 187, 243].  
 
There are data to suggest that acute hypoxia and HA exposure leads to a decline in HRV [150, 
151] with conflicting data on its potential link to HA-related symptoms and acute mountain 
sickness (AMS) [162-164]. Published studies on HRV at HA have been derived from relatively 
small cohorts, with very little data on the effects of genuine terrestrial, rather than simulated HA 
[91, 162, 163]. Moreover, there has been an under-representation of women, in current datasets, 
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despite their obvious physical and potentially important physiological differences compared to 
men. Resting heart rate tends to be higher in women than men, yet their stroke volumes and 
cardiac outputs are lower and these differences are sustained and even enhanced with hypoxia 
[168, 244]. Resting minute ventilation, which affects HRV, is relatively greater in women under 
both normoxia and hypoxia (23). Time-domain measures of HRV are typically higher in healthy 
men (<50 years) compared with age-matched women (Boos, Mellor et al. 2016, Koenig and 
Thayer [153]. However, the power spectral density (PSD) of HRV in females is usually 
characterized by less total power (TP), greater or similar high-frequency (HF) and lower low-
frequency (LF) power and LF/HF ratios [60, 168, 170].  
 
There are some data to suggest that women may be also more vulnerable to both AMS 
development and worsening symptom severity compared with men [172-174].  Given the 
possible sexual dimorphism in HRV and AMS incidence/severity coupled with the reported links 
between HRV and AMS an investigation of comparative HRV in men and women and its 
relationship to AMS development is warranted.  
 
In this study, we aimed to investigate, for the first time, the influence of sex on time and 
frequency-domain measures of HRV with increasing terrestrial HA and its potential link to AMS 
development. 
 
Methods 
Study design and participants 
Sixty-three healthy British Military servicemen aged >18years were included. They were all 
assessed at near SL (<200m) and again at three further altitudes during progressive HA ascent in 
the Dhaulagiri region of the Himalayas in March/April 2016. Health status was confirmed 
following a detailed baseline questionnaire. For inclusion, all subjects needed to be low altitude 
dwellers and were required to be deemed medically fit for HA exposure by their medical 
practitioners. All participants were required to have successfully completed their mandatory 
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military Personal Fitness Assessment 1.5 mile run in accordance with published standards 
(adjusted to age and sex) prior to inclusion. This run was undertaken in sports clothing on a flat 
surface. Subjects with a history of cardiac arrhythmias were excluded. The subjects were studied 
consecutively in groups of 8-14 at sea level and at HA with a two-day stagger between successive 
groups.  All trekking groups followed an identical ascent and exercise recovery profile with 
similar morning wake times. Sea level (SL) baseline assessments were performed in the UK 
approximately six weeks prior to each departure.  
 
High Altitude Ascent and descent profile 
The subjects flew from the UK to Kathmandu (1400m) where they underwent two days of local 
acclimatisation (Days 1-3). Thereafter, they travelled by road over two days to 1030m (Darbang). 
From there they commenced trekking on foot over the ensuing 11 days to an altitude of 5140m 
(with an overpass of 5360m) before commencing their decent on foot to Marpha (2719m) and 
then by road back to Kathmandu. Research assessments were performed at SL and at static 
research camps at 3619m, 4600m and 5140m during HA ascent.  
 
Physiological Assessments and Heart Rate Variability 
Oxygen saturations (SpO2) were measured using a Nonin Onyx (Nonin Medical Inc, Plymouth, 
Minnesota) pulse oximeter with sampling over approximately 15 seconds. HA-related symptoms 
were recorded using the Lake Louise Scoring (LLS) system. AMS was defined as a LLS of >3 in 
the presence of headache [28, 30].  HRV assessments were undertaken using dedicated battery-
operated portable HRV devices which records a single lead ECG at a sampling rate of 
250/second (CheckMyHeart Plus™ Daily Care Biomedical, Taiwan) as previously described. 
The first of the two surface ECG electrodes were placed at the right sternal edge at one finger 
breathe below the suprasternal notch and the second over the left 5
th
 intercostal space at the mid 
clavicular line (i.e. cardiac apex).  Measurements were taken on fully rested subjects over a five-
minute period in the early morning post-micturition and prior to breakfast or caffeine [91]. All 
subjects were studied seated in a warm building at sea level and wearing warm clothing and in a 
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tent at HA and were advised not to talk during HRV assessment. All stored recordings were 
exported via USB hook up for offline data analysis (CheckMyHeart Plus™ R30 V4, Daily Care 
Biomedical, Taiwan). 
 
The R waves of the stored ECG were used as the fucidal point to determine the beat to beat 
interval with full ECG disclosure. Non-normal-to-normal-(NN) intervals and ectopic beats were 
identified using customised software non-linear algorithms and were highlighted by colour 
coding within the HRV software to ease their identification. All ECG data was inspected in six 
second windows for further identification and manual editing of potential non NN intervals if 
necessary. All confirmed non NN intervals due to ectopy were excluded.   The average five-
minute heart rate, and the SDNN, RMSSD, NN50 and pNN50 time domain measures, as 
previously described, were recorded [60, 167]. The SDNN refers to the standard deviation of the 
NN intervals from the acquired ECG. The RMSSD (Root mean square of successive differences) 
is the square root of the mean of the squares of the successive differences between adjacent NN 
intervals. The NN50 describes the number of pairs of successive NNs that differ by >50 ms and 
the pNN50 refers to the proportion of NN50 divided by total number of NN intervals. Frequency-
domain analysis was performed using the non-detrend method of fast Fourier transformation 
(FFT) with full graphical display of the power spectral data. Key frequency band data collected 
were the HF power (0.15-0.40 Hz), LF power (LF; 0.04-0.15 Hz), very low frequency power 
(VLF; 0.01-0.04 Hz), TP and the LF: HF ratio as previously defined [152, 245]. Normalized 
HRV values of LF (LFnu) and HF (HFnu) were calculated as a percentage of the total spectral 
power minus the VLF respectively [60].  
 
Ethics 
All participation was voluntary and all subjects underwent detailed written informed consent.  
This study was approved by the Ministry of Defence Research and Medical Ethics Committee 
(MODREC) and was conducted according to the standards of the Declaration of Helsinki.  
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Statistical analysis  
Data were analysed using GraphPad InStat version 3.05 and SPSS
®
 statistics version 22 with all 
graphical figures presented using GraphPad Prism version 4.00 for Windows (GraphPad 
Software, San Diego, CA, USA). Sample size calculations were performed using a proprietary 
determined sample size calculator using (GraphPad StatMate version 2.00 for Windows). Data 
inspection and the Kolmogorov-Smirnov test was undertaken to assess normality of all 
continuous data, which were presented as mean ± standard deviations and as the standard error of 
the mean (SEM) for figures. Categorical variables were compared using a Chi-Squared test. 
Comparison of unpaired data was performed using an independent t test and a Mann-Whitney test 
for parametric and non-parametric data respectively.  Correlations were performed using Pearson 
and Spearman rank correlation (±95% confidence interval, CI) for parametric and non-parametric 
data respectively.  A Factorial Repeated Measures ANOVA with Bonferroni correction (to 
minimise type I error) was performed to assess the main effect of sex (men vs women) over the 
four altitude time points (SL, 3619m, 4600m and 5140) and any interaction of altitude x sex on 
HRV scores. Binary logistic regression analyses (enter) were undertaken to assess potential 
continuous HRV and other univariate predictors of AMS development (yes or no) and its 
coefficient (B). We also undertook an additional exploratory analysis of the categorical HRV 
measures of RMSSD <30ms, LF:HF >1.3 and LFnu <20% that have been previously reported to 
be associated with AMS  [162, 163].  Non-parametric data was log (Ln) transformed and 
normality confirmed for the ANOVA and logistic regression analyses. A two tailed P value <0.05 
was considered statistically significant for all comparisons.  
 
Sample size calculations  
In a recent pilot study in Dhaulagiri, which included 12 subjects, we observed a non-significant 
but 11% (-7.9 ms) fall in the RMSSD time domain measure of HRV from baseline to 3600m, 
using identical HRV (CheckMyHeart Plus™) devices [91]. Hence, by studying an even greater 
altitude of >5000m we calculated that a sample size of >18 subjects in each group (men vs 
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women) would have >80% power to detect a significant change in the RMSSD at HA at a 
significance level (alpha) of 0.05 (two-tailed). In another recent study Saleem et al documented 
that the SDNN was significantly higher in 27 healthy men versus 18 healthy women (24). We 
estimated that a sample size of at least 18 women and >30 men studied across four differing 
altitudes would have sufficient power to detect a significant sex difference in HRV including 
SDNN.  
 
Results 
HRV data were available on 62 subjects at SL and at 3619 m and on 58 subjects at 4600m and 
5140m respectively. The men (31.2±9.3 years) and women (31.7±7.5 years) were well matched 
for age, ethnicity, smoking history and body mass index (table 1). As expected, the men were on 
average taller and heavier with higher systolic blood pressures at baseline, with faster completion 
times for their mandatory annual 1.5 mile running fitness test (P<0.0001) (table 1).  
HA exposure led to a significant fall in SpO2 and an increase LLS among both men and women, 
compared to baseline with no effect for subject sex (table 2). Heart rate (five-minute average) 
increased at HA in both sexes, with women having consistently higher rates than men both at SL 
and at HA (table 2 and 4). 
 
There was a significant main effect for altitude on all time-domain measures of HRV. On post-
hoc analysis this represented a significant reduction in time-domain measures of HRV most 
consistently between 3619m to 5140m (table 2 and 4; figure 1). There was a significant main 
effect for altitude on LF, HF and TP. This difference was again most marked on post-hoc 
analyses between 3619m and 5140m where significant reductions in LF, HF and TP were 
observed (table 3 and 4; Figures 2).  
 
Time domain measures of HRV were non-significantly higher in men at SL and significant 
differences emerged at HA, where all measures were notably higher in men (table 2 and 4; figure 
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1).  There was also a main effect for sex among the frequency domain measures of TP, LF and 
HF power which were all significantly higher in men at HA (table 3 and 4, figure 2). There were 
no interactions between sex (men vs women) x altitude (SL, 3619m, 4600m and 5140m) on any 
measures of HRV (table 4) or heart rate.  
 
SpO2 inversely correlated with LLS (r=-0.38; 95% CI -0.50 to -0.24; p<0.0001) and positively 
with RMSSD (r=0.16; p=0.02), SDNN (r=0.18; 0.05 to 0.30: p=0.007), VLF (r=0.17; 0.04 to 
0.30; p=0.01), LF (r=0.16; 0.03 to 0.29; p=0.2) and TP (r=0.17; 0.03 to 0.29; P=0.02).  
 
The prevalence of AMS increased at HA from 15.2% at 3619m to 27.3%  at 4600m and 32.5% at 
5140m (p=0.004). Reducing SpO2 (B -0.13; P<0.0001) and increasing altitude (B 0.80; P 
<0.0001) and mean heart rate (B 0.03; P=0.04) were the only univariate predictors of AMS. None 
of the continuous measured HRV parameters or the categorical variable of subject sex (men vs 
women) were predictive of AMS. RMSSD <30ms, LF:HF >1.3 and LFnu <20% were not 
predictive of or associated with AMS.  
 
Discussion 
This is the largest study to assess the effects of HA on HRV, and to the author’s knowledge the 
first study to investigate the influence of sex on HRV at terrestrial HA. In this study HRV was 
influenced by HA. Minor sex-related differences in HRV that were observed at SL were 
sustained at genuine terrestrial HA. A link between HRV and symptoms of AMS were not found.    
 
We observed a significant fall in resting SpO2 and an increase in LLS with increasing HA. There 
was also a significant main effect for altitude on heart rate (which increased) and all the evaluated 
time-domain measured of HRV. The most consistent change was between 3619 and 5140m, and 
hence at higher altitude, where there was a significant fall in SDNN, RMSSD, NN50, PNN50, LF 
and HF power.  These findings are in keeping with published data that has shown a fall in time-
domain measures of HRV at HA [162-164]. These changes are in part explained by a number of 
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factors linked to the HA environment. These include reducing sleep quality, extremes of cold and 
heat, physical exhaustion and increasing anxiety which are all known to adversely affect and 
reduce time domain measures of HRV [137, 163, 171].  
 
We also observed a significant main effect for sex on heart rate and time domain measures of 
HRV at HA, with men having consistently higher scores and greater variability. This is a novel 
finding. Published data have shown a consistent trend to higher time domain measures of HRV in 
young adult men versus women at SL [153, 168, 246]. This is the first comparative study at HA. 
The trend to higher time domain HRV measures at SL became significant at HA. There was no 
interaction of altitude on sex on the time domain HRV parameters. This finding can be partly 
explained by the sex differences in heart rate which was consistently lower in the men. Heart rate 
is well known inversely correlate with all main time domain measures of HRV [60].  
 
We also observed a significant effect of altitude (SL, 3619m, 4600m and 5140m) on TP, VLF, 
LF and HF power. The most consistent finding, on post-hoc analyses was a reduction in these 
parameters at the highest altitude of 5140m vs sea level and 3619m. HA exposure was also 
associated with a significant main effect of sex with greater TP, LF and HF power among the 
men. Results from a very recently published meta-analysis of comparative HRV measures among 
men and women at SL, that included more than 60,000 participants, demonstrated that when 
compared to that seen in women, PSD in men is generally characterised by lower HF power and 
greater LF, TP and LF/HF ratios [168]. This is thought to reflect their higher resting sympatho-
vagal tone (hence greater LF and LF/HF ratios) compared with women. Our LF data supports this 
previous data. However, contrary to the published data we found that HF power was actually 
higher with variable effects on LF/HF power among the men.  There are several potential factors 
that might explain these results. It is known that LF, HF power and their relative ratios (LF/HF) 
can be markedly influenced by a number of factors which include age, respiratory rate, recording 
length and heart rate [60, 167, 168, 187, 245, 246].  Whilst the ages were similar between the 
men and the women the greater heart rates in women would have led to the analysis of a higher 
number of beat-to-beat intervals, despite an identical recording period,  which could be an 
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important  confounder. Secondly, whilst increasing heart rate and minute ventilation are HA are 
thought to relate to enhanced sympathetic activation there is also evidence of elevated 
parasympathetic neural activity [72, 152, 187, 216, 242]. This increase in competing vagal 
activation at HA is thought to contribute to the reduction in maximal heart rate at HA [216]. LF 
power and the LF/HF ratio have been traditionally thought to represent sympathetic activation 
and net sympatho-vagal balance respectively with RMSSD and HF power reflecting 
parasympathetic nerve activity [60]. However, there is evolving evidence to show that these 
arbitrary assumptions about the discrete autonomic effects these HRV measures, may be overly 
simplistic [247].   
 
Our identified sex-related dissimilarities in the time and frequency domain HRV measures at HA 
could also relate to differences in fitness levels. Indeed, the men in our study had higher time 
domain measures of HRV and lower 1.5 mile run times. Our findings could also relate 
dissimilarities in acclimatisation in men vs women. Acclimatisation encompasses the cumulative 
effects of multiple factors such as hydration, ventilation and enuresis that are known to influence 
autonomic balance and HRV [248]. HRV, and in particular frequency domain analysis can be 
significantly affected by breathing pattern and ventilation, which are markedly affected HA 
where hypoxia driven hyperventilation predominates [168, 173, 249]. In our study paced 
breathing during HRV assessments were not performed, but the participants were encouraged to 
relax and breathe normally.  The majority of published studies on HRV at HA have utilised 
spontaneous non-paced breathing, hence were keen to utilise a comparative methodology [153, 
172, 216, 248].  Our participants were assessed at far higher altitudes and under greater hypoxia 
than most of the previous HA HRV studies to date, hence the potential challenge to paced 
breathing was likely to have been greater. We anticipated that at 4600 and 5140m controlled 
breathing under significant hypoxia and a high ventilatory drive might paradoxically increase 
subject anxiety and perceived breathlessness.  By enforcing a similar paced breathing protocol in 
both men and women we risked neutralising genuine sex-related differences in HRV related to 
well-reported dissimilarities in ventilation between men and women at HA [137, 247]. 
Unfortunately, we did not measure comparative respiratory rate and ventilation among the men 
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vs women. This is an obvious limitation as sex-related differences in their spontaneous breathing 
it could have provided further insight into the observed differences in HRV identified.  
 
We did not observe a link between AMS and HRV in this current study. There is limited 
evidence linking changes in HRV to AMS, raising the prospect of using HRV as a non-invasive 
predictor of AMS development [162, 163]. In a previous study Karinen et al investigated 36 
different healthy climbers ascending from 2400 m to 6300 m altitudes during five differing 
expeditions and noted that a lower RMSSD and HF at 2400m was a marker of AMS at 3000 to 
4300m [163]. However, contrary to our study, the speed of ascent varied between their five 
studied groups. Furthermore, they measured HRV over two rather than five minutes. In another 
study, of similar size (n=32), Hang et al noted that a HF% <20% (nu) or LF/HF ratio >1.3 at 
lower altitudes was predictive of AMS at 3400m [162](9). These HRV parameters failed to be 
either associated or predict AMS in our study. Willie et al in a prolonged normobaric hypoxia 
study and our group in another recent study (ithlete RMSSD-derived HRV score), failed to 
identify a clear link between AMS and HRV supporting our data [91, 164].   
 
The potential reasons for the contradictory findings in HRV to predict AMS may relate to 
differences in study design, HA environment, ascent/hypoxic profile, HRV recording time as 
well as the actual HRV parameters measures.  Even the definitions of AMS that were used 
differed between these studies. For example, Karinen et al defined AMS as a LLS of >3 in their 
study whereas in the study by Willie they a LLS ≥4 was used to define AMS [163, 164]. In our 
study we used the Lake Louisee Consensus definition (1992) for AMS, which is refers to LLS 
score of >3 in the presence of headache [28, 72]. It is well known that AMS is a highly complex 
and heterogeneous condition. Its causative mechanisms include changes in cerebral arterial blood 
flow and increased vascular permeability within the blood brain barrier, both of which may be 
influenced by local autonomic control [15]. Whilst HRV reflects overall cardiac autonomic 
control it is relatively non-specific and is not indicative of local autonomic balance [247].  
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This study has several additional imitations that should be mentioned. The subjects were studied 
in consecutive groups of 8-14 two days apart and not all together in one batch. This was because 
of the large sample size for this type of remote field study and the need to undertake at HRV in 
the early morning pre-breakfast and caffeine.  We measured five minute HRV which may be 
more vulnerable to short-term sex and situational bias than that obtained from longer recordings 
[60]. However, five minute HRV measurement is well-validated and endorsed by the current 
HRV Task Force Guidelines and is more potentially applicable to clinical practice than that of 
longer recordings [60]. We included a larger proportion of men than women and cannot exclude 
the possibility of sample bias, despite their similarities in age, ethnicity, smoking history and 
body mass index.   
 
In conclusion our findings indicate that increasing HA was associated with a reduction in HRV 
which was most notable at 4600m and above.  There were significant sex related differences in 
HRV between men and women which were sustained at HA. There was no interaction between 
sex and altitude on any of the HRV parameters measured. These sex-related differences may 
reflect dissimilarities in their autonomic balance and acclimatisation to HA. HRV was not 
predictive of AMS.    
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Table 1: Baseline Demographics  
   Demographic Overall Men Women P value* 
Number (%) 63, 100% 41 (65%) 22 (35%)  
Age, years (range) 31.41 ± 8.7 (18-56) 31.2 ± 9.3 31.7 ± 7.5 0.83 
Height, cm 173.4 ± 9.7 177.1±9.3 166.5±5.8 <0.0001 
weight 72.5 ± 13.0 77.4±12.1 63.2 ± 9.3 <0.0001 
Body mass index, kg/m
2
 24.0 ± 2.8 24.2 ± 3.0 23.5± 2.6 0.36 
Systolic blood pressure  132.1 ± 15.6 136.9 ± 15.1 123.7 ± 12.7 <0.0001 
Diastolic blood pressure  80.5 ± 14.6 80.8 ± 12.4 78.7 ± 10.7 0.53 
Basic fitness time 
(minutes) (1.5 mile run) 
9.9  ± 1.3 9.5 ± 1.1 10.8 ± 1.2 <0.0001 
Ethnicity, % 
- Caucasian  
- Non Caucasian  
 
56 (88.9%) 
7 (11.1%) 
 
35 (85.4%) 
6 (14.6%) 
 
21 (95.5%) 
1 (5.5%) 
 
 
0.40 
Smoking status (%) 
- Never  
- Current 
- Ex 
 
51 (81.0%) 
4 (6.3%) 
8 (12.7%) 
 
33 (80.4%) 
4 (9.8%) 
4 (9.8%) 
 
18 (81.8%) 
0 (0%) 
4 (18.2%) 
 
 
 
0.23 
*P value refers to results of comparison of men vs women only  
 
  
 
178 
Table 2 Changes in SpO2 and time domain measures of Heart rate Variability at sea 
level to increasing high altitude 
  
 
Sea level 3619m 4600m 5140m Post-test Paired 
differences for 
effects of altitude 
SpO2 (%) 
-Men   
-Women   
 
97.7 ±1.3 
97.9 ± 1.3 
 
93.1 ± 3.2 
90.9 ± 4.5 
 
83.5 ± 6.0 
80.4 ± 8.5 
 
81.3 ± 5.3 
78.6 ± 5.4 
 
abcef 
 
Lake Louise Scores 
-Men   
-Women   
 
0.4 ± 0.6 
0.5 ±  0.9 
 
1.0 ± 2.1 
1.5 ± 2.4 
 
1.9 ±2.2  
2.3 ± 1.2 
 
1.5 ± 1.5 
1.3 ±1.4 
 
abc 
Mean heart rate/minute 
-Men   
-Women   
 
57.6 ± 9.0 
60.8 ± 9.7 
 
63.6 ± 12.0 
69.5 ± 9.4 
 
72.7 ± 15.2 
79.5 ± 12.8 
 
74.5 ± 15.7 
81.1 ± 11.8 
 
abcde 
SDNN (ms) 
-Men   
-Women   
 
78.1 ± 25.2 
76.0 ± 28.3 
 
94.8 ± 55.9 
74.6 ± 29.1 
 
85.0 ± 451.7 
52.5 ± 20.8 
 
72.1 ± 49.2 
51.4 ± 28.0 
 
abcde 
RMSDD (ms) 
-Men   
-Women 
 
67.0 ± 31.6 
59.6 ± 32.2 
 
93.2 ± 72.9 
60.8 ± 30.2 
 
76.2 ± 56.4 
37.3 ± 19.5 
 
62.2 ± 54.6 
41.5 ± 32.6 
 
cde 
NN50 
-Men   
-Women   
 
104.8 ± 38.6 
96.3 ± 54.6 
 
113.0 ± 76.0 
104.8 ±59.1 
 
105.5 ± 75.2 
54.4 ± 51.4 
 
81.9 ± 64.0 
60.0 ± 65.3 
 
ce 
pNN50 (%) 
-Men   
-Women   
 
37.8 ± 19.8 
32.8 ± 19.8 
 
39.6 ± 27.8 
32.2 ± 18.8 
 
34.1 ± 25.6 
14.7 ± 14.3 
 
26.5 ±22.2 
16.4 ± 18.8 
 
cde 
Results of post hoc paired differences with time (altitude) for both men and women: a, sea level vs 3619m; b sea level 
vs  4600m; c sea level vs 5140m; d, 3619m vs 4600m; e, 3619 vs 5140m; f 4600m vs 5140m 
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Table 3 Changes Frequency domain measures of Heart rate Variability at sea level to 
increasing high altitude 
 
Sea level 3619m 4600m 5140m Post-test Paired 
differences for 
effects of altitude 
Total power (ms2) 
-Men   
-Women   
 
7.87 ± 0.7 
7.75 ± 0.7 
 
7.95 ± 1.4 
7.73 ± 0.8 
 
7.86 ± 1.6 
7.05 ± 0.7 
 
7.34 ± 1.5 
7.0 ± 1.0 
 
cef 
VLF (ms2) 
-Men   
-Women   
 
6.06 ± 0.7 
6.16 ± 0.8 
 
6.11 ± 1.2 
5.92 ± 0.9 
 
6.00 ± 1.3 
5.44 ± 0.7 
 
5.62 ± 1.3 
5.28 ± 1.1 
 
ce 
LnLF (ms2) 
-Men   
-Women   
 
6.80 ± 0.8 
6.44 ± 0.7 
 
6.61 ± 1.4 
6.67 ± 1.0 
 
6.62 ± 1.7 
5.89 ± 0.9 
 
6.19 ± 1.4 
5.76 ± 1.0 
 
ce 
LnHF (ms2) 
-Men   
-Women   
 
6.55 ± 0.8 
6.23 ± 1.0 
 
6.87 ± 1.7 
6.36 ± 0.9 
 
6.50 ± 2.1 
5.47 ± 1.0 
 
6.09 ± 1.8 
5.43 ± 1.3 
 
e 
LF%, nu 
-Men   
-Women   
 
55.4 ± 15.9 
44.5 ± 18.8 
 
44.7 ± 18.0 
56.8 ± 15.6 
 
52.7 ± 17.9 
58.8 ± 16.4 
 
52.0 ± 18.8 
56.8 ± 20.6 
 
NS 
HF%, nu 
-Men   
-Women   
 
44.6 ± 15.9 
45.7 ± 18.4 
 
55.4 ± 18.0 
43.2 ± 15.6 
 
47.3 ± 17.6 
41.2 ± 16.4 
 
48.0 ± 18.8 
43.2 ± 20.6 
 
NS 
LF / HF 
-Men   
-Women   
 
1.7 ± 1.3 
1.4 ± 1.1 
 
1.0  ± 0.80 
1.6  ± 1.0 
 
1.6 ± 1.5 
2.1 ± 1.8 
 
1.6 ± 1.5 
2.2 ± 2.2 
 
NS 
NS, Non-significant; Results of post hoc paired differences with time for men and women 
combined: a, sea level vs 3619m; b sea level vs  4600m; c sea level vs 5140m; d, 3619m vs 
4600m; e, 3619 vs 5140m; f 4600m vs 5140m  
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Table 4 Results of Two-way Repeated Measures ANOVA comparing the main effects of 
altitude (SL, 3619m, 4600m and 5140m) and sex (men vs women) on measures of heart 
rate variability  
 Time (altitude) Sex  Interaction 
 F P value F P value F P Value 
SpO2 165.20 <0.001
abcef
 0.49 0.48 0.21 0.89 
Lake Louise Scores 4.30 0.008
abc 
0.37 0.55 0.63 0.60 
Mean heart rate 47.3 <0.001
abcde
 4.10 0.04 0.43 0.73 
SDNN   40.6 <0.001
abcde
 4.00 0.04
 
 1.14 0.26 
RMSDD  8.10 <0.001
cde
 4.40 0.04 0.94 0.43 
NN50  8.20 <0.001
ce
 3.20 0.08 0.82 0.47 
PNN50 10.7 <0.001
cde
 3.50 0.06 0.94 0.41 
SD1 / SD2  1.89 0.13 4.90 0.03 0.34 0.80 
Total power 8.40 <0.001
cef
 4.20 0.04 1.87 0.14 
VLF 7.10 <0.001
ce
 2.00 0.17 1.76 0.16 
LF 7.10 <0.001
ce
 3.80 0.048 1.70 0.17 
HF 5.80 0.001
e
 5.80 0.02 1.26 0.29 
LFnu 0.39 0.76 3.10 0.09 1.70 0.17 
HFnu 0.39 0.76 3.10 0.09 1.70 0.17 
LF / HF  0.50 0.70 1.60 0.20 3.50 0.07 
SpO2, oxygen saturations;  Results of post hoc paired differences with time (altitude) a, sea level vs 
3619m; b sea level vs  4600m; c sea level vs 5140m; d, 3619m vs 4600m; e, 3619 vs 5140m; f 4600m 
vs 5140m 
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Figure 1 Comparative Changes in the RMSSD (mean ± SEM) among men and women at 
sea level and increasing high altitude. Post-test differences on repeated measures 
ANOVA: * versus sea level, ‡ 3619 vs 5140m, †3619 vs 4600m. 
 
 
Figure 2 Comparative Changes in Low frequency (LnLF) Power (mean ± SEM) among 
men and women at sea level and increasing high altitude. Post-test differences on 
repeated measures ANOVA: * versus sea level, ‡ 3619 vs 5140m. 
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Abstract 
Introduction 
There is conflicting data at sea-level to suggest that paced (PB) versus spontaneous breathing 
(SB) during short-term heart rate variability (HRV) measurement improve data reliability.  
Aims 
This study sought to examine the effects of SB versus sus PB on HRV, at high altitude (HA).  
Material and Methods  
This was a prospective observational study on thirty healthy adult men who were investigated 
over nine days at altitudes of 800-4107m.Cardiac inter-beat interval data were measured over 
55 seconds, twice daily, using an ithlete finger sensor linked to a mobile phone to generate an 
HRV score. Agreements in the paired (SB vs PB) HRV scores were examined using paired t 
tests, correlation coefficients and F-Testing. A factorial Repeated Measures ANOVA was 
used to examine the main effect of altitude and breathing method on the paired differences in 
HRV Scores 
Results  
HA led to a significant reduction in SpO2 and increase in acute mountain sickness (AMS) 
Scores. HRV scores (511 paired scores) were consistently higher with PB versus SB (mean 
difference +6.0; 96.1% within 95% agreement limit), though the variance was lower (F = 1.2; 
P=0.04) and the scores strongly correlated (r=0.78; p<0.0001). HRV scores were lower with 
AMS (versus without AMS), but this difference was only significant with SB (68.1±12.1 vs 
74.3±11.4 vs; p=0.03) but not PB (76.3±11.8 vs 80.3±10.4 vs; p=0.13). There was a 
significant main-effect for altitude (F=5.3; p<0.0001) and breathing (F=262.1; p<0.0001) on 
HRV scores but no altitude-x-breathing interaction (F=1.2; p=0.30).  
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Conclusion 
Ithlete HRV scores obtained with PB and SB strongly correlate at moderate HA but are 
consistently higher and the variance lower with PB. Whilst the actual per se does not affect 
this difference, the presence of AMS may be an important confounder.  
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Introduction 
Heart rate variability (HRV) refers to the temporal changes in the beat-to-beat intervals in the 
heart, which is subject to continuous autonomic nervous system (ANS) and competing 
sympathetic versus parasympathetic control. HRV assessment has rapidly progressed in 
recent years from being predominantly a research-based tool to its translational use across 
several mainstream clinical and sporting applications [59, 61, 250]. These include the 
prevention of overtraining in relation to physical performance and in the management of 
mental stress [58, 59, 61, 251, 252]. The miniaturisation and increased portability of HRV 
equipment with the availability smartphone-based platforms has significantly helped in this 
regard.   
 
There is now a plethora of available HRV measures of varying complexity, however it is 
some of the short-term (<5 minutes) measures that have provided the greatest use in day-to-
day practice [58, 250-252]. One of the most utilized HRV parameters is the RMSSD (root 
mean square of successive differences), which can be obtained from ultrashort beat-to-beat 
recordings of less than two minutes [59, 60, 93, 253]. It is thought to be a non-invasive 
surrogate for parasympathetic activity and vagal tone [60, 250].  
 
One of the areas of novel clinical interest in HRV assessment has been in the field of high 
altitude (HA) medicine. HA related hypoxia leads to a compensatory rise in respiratory rate 
and tidal volume, known as the hypoxic ventilatory response, which acts to preserve tissue 
oxygenation [10, 254]. This physiological response may be of considerable practical 
importance in relation to HRV measurement at HA, given the recognized influence of 
respiratory rate and tidal volume (ie minute ventilation) on HRV and its measurement [255].  
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An area of ongoing debate is the issue of whether controlled/paced breathing during HRV 
measurement generates more reliable HRV data than with relaxed and regular spontaneous 
breathing [166, 256, 257][14-18]. The comparative effects of spontaneous versus paced 
breathing on HRV have never been examined at HA. Establishing their potential influence on 
HRV at HA is a crucial methodological consideration. It plausible to hypothesize that by 
enforcing a paced breathing pattern genuine changes in HRV appreciated with the 
physiological hyperventilation of HA, could be obscured [258].  Furthermore, the ventilatory 
influence of HA-related illnesses such as HA pulmonary oedema (HAPE), and acute 
mountain sickness (AMS) on HRV could also be potentially mitigated by the use of paced 
breathing during HRV measurement. This issue assumes even greater importance given 
several recent publications suggesting a potential link between changes in HRV and AMS 
development [162, 165, 187, 252]. The published HRV at HA studies to date have mainly 
utilized spontaneous breathing during HRV measurement and the comparative effects of 
spontaneous versus paced breathing has not been examined [90, 91, 150, 162, 163, 165]. 
 
In this study we aimed to assess, for the first time, the effect of spontaneous versus paced 
breathing on HRV at HA as well as the influence of AMS on their level of agreement.  
 
Materials and Methods  
This was a prospective observational study conducted over nine days on 30 healthy British 
military servicemen trekking in the Bernese Alps in Switzerland in June 2017. Baseline data 
was collected at 800m (basecamp; days 0-1).  On day 2 the participants moved by road to 
1200m then on foot to  Blumlisalphutte (2840m) over 4 hours carrying a weight of 15kg. 
There they spent three days (days 2-5) with training serials on a nearby glacier before 
returning to basecamp (day 5). At basecamp the subjects were split into three groups. Team 1 
(n=9) remained at Basecamp (800m) until day 9 (pm). Team 2 (n=12) went to Mönchsjoch 
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Hut (3658m) by train and then light trek over the last one hour. From there they climbed to 
the 4107m over days 5-8 before returning to basecamp (day 8) where they stayed till the end 
of the data collection (day 9). Team 3 (n=9) travelled by road followed by a 4 hour trek to 
2543m. From there they climbed to 3583m on days 5-8, before returning to basecamp (days 
8-9). Measurement of HA-symptoms, HRV and heart rate were measured twice daily.  Saboul 
et al observed significant differences in short term daily measures of HRV including RMSSD 
and heart rate between spontaneous and controlled breathing in 10 healthy subjects [255]. 
Based on this data and an expected correlation between pairs of >0.70 we calculated that at 
sample size of >20 subjects measured twice daily over at least 7 days (>280 paired samples) 
would have >90% power to detect a mean difference in HRV score of >1.5. 
 
 
Physiological and Physical assessments  
HA-related symptoms were recorded using the Lake Louise Scoring (LLS) system. AMS was 
defined as LLS of >3 in the presence of headache and a recent altitude gain [28, 38]. The 
Borg Rating of Perceived exertion was recorded (Borg) at the end of each day. This is a 15 
point numerical scale numbered from 6 – 20, with values of 6 representing the resting state 
and 20, exhaustive exercise (Borg 1970) that has been used at HA previously [28]. The 
highest Rating of perceived exertion (RPE) during the day was recorded to reflect the overall 
effort [259].      
 
Assessment of Heart Rate Variability  
This was performed twice daily post micturition and prior to breakfast/dinner or caffeine. 
Conditions were kept consistent with previous studies of HRV at HA with all subjects being 
seated in a covered environment, wearing warm clothing for at least five minutes before the 
HRV recordings were obtained [90, 91].   HRV variability was obtained using a finger sensor 
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attached to mobile phone (Apple
TM 
iPhone 6s) installed with the ithlete HRV app (HRV Fit 
Ltd. Southampton, UK) as previously described and validated [91, 94, 150, 187, 260]. Two 
consecutive 55 second HRV recordings were obtained separated by a one minute wash out 
rest period. This validated time period is set by the device and cannot be altered. The first 
HRV reading was undertaken with the subjects breathing spontaneously, after 5 minutes of 
relaxation. The second HRV measurement was recorded during paced breathing at frequency 
of7.5 breaths per minute. This guided breathing protocol within the ithlete mobile phone app 
is delivered via visual onscreen prompts to guide the speed and duration of both inspiration 
and expiration [91, 94, 150, 260]. 
 
The ithlete™ HRV score modifies the acquired RMSSD (root mean squared of successive 
differences) by taking the natural log transformation and multiplying by twenty (lnRMSSD × 
20). This provides a more interpretable figure for the user on a ∼100 point scale [94, 260].  In 
a previous study of 12 healthy subjects studied over seven altitudes from the 1400-3600m the 
coefficient of variation for paired HRV readings using paced breathing was 5.5% [91].  
 
Statistical Analysis  
Sample size calculations were performed using a proprietary determined sample- size 
calculator (GraphPad StatMate version 2.00 for Windows). Data was analysed using 
GraphPad InStat version 3.05 and with all graphical figures presented using GraphPad Prism 
version 4.00 for Windows (GraphPad Software, San Diego, CA, USA; www.graphpad.com). 
Data inspection and the Kolmogorov-Smirnov test was undertaken to assess normality of all 
continuous data. Results are presented as mean ± standard deviation (SD). Paired 
comparisons of parametric and non-parametric continuous data were assessed using a paired t 
test and a Wilcoxon matched pairs test and their correlation using Pearson and Spearman 
correlation coefficients ± 95% confidence interval (CI) respectively. Only correlations with 
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an R>0.20 were reported. An F-Test was performed to assess whether any potential 
differences in standard deviations in HRV scores between spontaneous versus paced 
breathing were significant.  
 
The accuracy of agreements in HRV Scores between that obtained from spontaneous versus 
paced breathing were assessed using Bland-Altman plots [91, 261] in which the difference 
between the two values were compared with the average values from the comparative two 
readings. The bias was defined as the mean ± standard deviation [SD] of the difference 
between the readings. Reasonable agreement was defined as <5% of readings being within 
1.96SD (95% CI) from the mean. 
 
A factorial Repeated Measures ANOVA was undertaken to assess the main effects of altitude 
and breathing (spontaneous vs paced) on HRV scores and any potential interactions of 
altitude and breathing method on the paired differences in HRV Scores. A p value of <0.05 
was considered significant for all comparisons. 
  
Results  
The average age of the 30 included participants was 33.3 ±7.7 years with an age range of 22-
54 years. They were all Caucasian and non-smokers with a mean body mass index of 26.0 ± 
2.3 kg/m
2
. There was a significant reduction in SpO2 and an increased in LLS and heart rate at 
higher altitudes of >2543m (Table 1). There was an inverse correlation between SpO2 and 
LLS (r=-0.25; -0.33 to -0.16: p<0.0001). The prevalence of AMS was 13.3% at 2840m, 
22.2% at 2543-3658m and 41.7% at 3583-4107m. The cases AMS were generally mild 
(>90% LLS 3-5).  
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There were a total of 511 paired HRV scores obtained. Overall, HRV scores obtained from 
spontaneous versus paced breathing strongly correlated (511 pairs; r=0.79: 0.75-0.82; 
P<0.0001) (Figure1). This significant correlation was consistent at both lower (<2543m) 
altitudes and higher altitudes (>2543m). There was significant inverse correlation between 
heart rate and the HRV score (r=-0.68; -0.73 to -0.63; P<0.0001). Borg RPE scores positively 
correlated with resting heart rate (r=0.26; 0.13 to 0.38; P<0.0001) and inversely with HRV 
Score (r=-0.30; -0.42 to -0.17; P<0.0001) measured at the same time.  
 
The HRV scores were consistently higher with paced versus spontaneous breathing 
(73.3±11.4 vs 80.1±10.4; mean difference +6.1: P<0.0001) (Table 1, figure 2.). The standard 
deviation around HRV scores was marginally, yet significantly higher, for spontaneous versus 
paced breathing (F = 1.2; P=0.04). HRV scores were lower in those with vs without AMS for 
both breathing methods. However, this difference was only significant for spontaneous 
(74.3±11.4 vs 68.1±12.1; p=0.03) but not paced breathing (80.3±10.4 vs 76.3±11.8; p=0.13). 
 
On Bland Altman analysis identified a strong level of agreement between HRV scores (511 
pairs: 96.1% within the 95% limit of agreement) obtained with spontaneous versus paced 
breathing but with a consistent bias to higher scores with paced breathing (mean difference 
[bias] +6.00; 95% CI -8.0 to 20.1) (figure 3). This bias further increased when only those 
(n=15) with AMS were examined (93.8% within 95% limit of agreement; bias + 8.0: 95% CI 
-5.5 to +22.0).  
 
There was a significant main effect for altitude (F=5.3; p<0.0001) and breathing (F=262.1; 
p<0.0001) on the paired HRV scores. However there was no altitude-x-breathing interaction 
(F=1.2; P=0.30). For the dependent variable of heart rate there was a main effect for altitude 
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(F=7.0; p<0.0001) and breathing (F=10.7; P=0.001) but again no altitude-x-breathing 
interaction (F=0.60; P=0.70). 
 
Discussion 
This is the first study to assess the comparative effects of paced versus spontaneous breathing 
on short term measures of HRV at sea level and HA. We found that there was a strong 
agreement between the two methods. HRV scores were consistently higher, though less 
variable with PB. These differences increased with AMS. Whilst there was a significant main 
effect for altitude and method of breathing on HRV scores there was no overall interaction 
between altitude and breathing method on HRV scores. The RPE inversely correlated with 
HRV, with higher perceived exertion being linked to lower HRV.  
 
The influence of ventilation on heart rate and HRV has been well investigated at sea level 
[52, 166, 169, 255-257]. The concept behind using paced breathing during HRV assessment 
is that by standardizing the breathing pattern (respiratory rate, tidal volumes, inspiratory and 
expiratory time) the inter-sampling variability between HRV measurements should be 
reduced and validity improved.  Published comparative data on differences in HRV 
measurements between spontaneous versus paced breathing have yielded inconsistent results. 
This variability may, in part relate to relative differences in environmental conditions, the 
duration and frequency of paced breathing used and the HRV parameters examined [255, 256, 
262]. These disparities probably explain why a consensus guideline on paced breathing 
during HRV measurement has not yet been established.  
 
The effects of breathing method during HRV measurement at HA had not previously 
investigated, despite an increasing number of published studies in this environment, which 
was the impetus for this study. Increasing minute ventilation is one of the most consistent 
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physiological effects of HA exposure and acclimatization [10, 254]. Hypoxic stimulation of 
arterial chemoreceptors leads to compensatory hyperventilation in order to limit the fall in 
alveolar PO2 and the degree of arterial hypoxaemia [10].  Despite these factors we still 
observed a strong correlation in the ithlete HRV scores (r=0.79) between spontaneous and 
paced breathing over several days at variable altitudes. This degree of correlation is 
remarkably similar to the comparative published sea level data (correlation coefficients of 
>0.70) [255].  
 
The paced breathing rate generated by the ithlete app was fixed throughout our study, 
whereas it was not controlled during spontaneous breathing. Respiratory rate and minute 
ventilation (respiratory rate x tidal volume) are known rise in response to the worsening 
hypoxia at increasing HA [10, 254]. We anticipated that this would lead to greater relative 
differences in the minute ventilation between spontaneous and paced breathing at higher 
altitudes during  HRV measurement: as whilst the spontaneous respiratory rate would 
expectedly increase the paced rate, would obviously remain unchanged at 7.5 breaths per 
minute. Given the recognized influence of respiratory rates on HRV, this should have 
translated into greater discordance in HRV scores between the two breathing modes at higher 
altitudes, yet this phenomenon was not observed. Although we noted a significant main effect 
for altitude and breathing modality (higher HRV score with paced breathing), there was no 
altitude-x-breathing interaction on HRV scores at HA. This would suggest that paced 
breathing does not appear to negate the HA related changes in the ithlete HRV score and 
RMSSD. However, given that the higher HRV scores with paced breathing, the two methods 
cannot be used interchangeably.  
 
HRV scores tended to be lower with AMS (versus without) and inversely correlated with 
increasing RPE, which is an expected finding and consistent with previous research [52, 91, 
95, 162, 163]. Nevertheless, it is interesting that whilst this difference was observed for both 
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spontaneous and paced breathing this difference was only statistically significant for 
spontaneous breathing. This might be a chance effect or related to bias due to the smaller 
sample size for the AMS group. A further exploration of comparative HRV measurements at 
higher altitudes and with a greater AMS burden and severity is clearly warranted. This is 
needed to better determine whether paced breathing could act to mitigate some genuine 
changes in HRV with very HA and significant AMS, by the implementation a short period of 
forced and unnatural breathing at HA.   
 
We only assessed one measure of HRV obtained over an ultrashort recording time using the 
ithlete validated HRV protocol [91, 167].  This device was specifically selected as it is battery 
operated (via the mobile phone charge), portable, user friendly and affordable which is ideal 
for HA research and maximizes its translational potential  [94, 263]. Its HRV score is derived 
from the RMSSD which is strongly correlated with other time domain measures of HRV 
[7,23]. The ithlete HRV score is thought to reflect parasympathetic control and  is thus highly 
responsive to acute changes in vagal tone and may be useful as a marker of HA 
acclimatization [10, 94, 150]. It has been shown that HA acclimatization is associated with 
changes in parasympathetic output and the withdrawal of cardiac vagal modulation has been 
implicated in AMS development [90, 264].  
 
The order of the breathing in the protocol was fixed throughout this study with spontaneous 
breathing always preceding paced breathing. This sequence was chosen for two important 
reasons. Firstly this order is consistent with several other published comparative studies [166, 
169, 257, 258]. Secondly, this sequence is logistically easier and makes physiological sense 
as the first 55 second HRV measurement during spontaneous breathing was conducted 
immediately after five minutes of spontaneous breathing. We felt that reversing this order 
could lead to negative bias. A parallel study of age matched groups randomized to 
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spontaneous then fixed breathing and vice versa would have been ideal but would have 
required a larger sample size.   
 
Limitations 
This study has a number of limitations that should be acknowledged. The altitudes studied 
were modest, the incidence of AMS was relatively low and the majority of AMS were very 
mild (predominantly LLS 3-4), which may have limited the impact of our finding. We only 
measured one measure of short term HRV using the RMSSD derived ithlete HRV score 
obtained over only 55 seconds. Hence we cannot be certain of applicability of these findings 
to other HRV measures obtained over a longer recording period (>1 minute).  We did not 
measure the comparative respiratory rates and tidal volumes of the two breathing strategies, 
hence we do not know for certain what their true differences were.   
 
In conclusion we found that the ithlete HRV score measured using spontaneous breathing was 
strongly correlated with that for paced breathing at moderate HA. However the score was 
consistently and significantly higher and the variance lower with paced breathing. Whilst the 
relative differences in HRV with spontaneous and paced breathing were not affected by 
altitude, the presence of AMS may be an important confounder. Further data at higher altitude 
and with a greater of AMS would be useful to further explore this finding.  
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Table 1 The effects of High altitude on HRV, Physiological and Mountain sickness scores.  1 
Altitude 800m 2840m 800m 2543 -
3658m 
3583-
4107m 
800m P Value 
HRV Score  
-Spontaneous breathing 
-Paced breathing  
 
75.2±10.8 
80.9±10.1* 
 
74.1±12.2 
81.1±10.6* 
 
71.3±10.6† 
76.5±10.2†* 
 
75.5±11.4 
81.0±10.3* 
 
72.2±10.9 
78.8±10.3* 
 
78.8±9.9† 
84.1±8.9†* 
 
0.0006 
<0.0001 
Heart rate  
-Spontaneous breathing 
-Paced breathing 
 
65.4±8.5 
65.3±8.8 
 
70.1±11.3† 
69.3±10.7† 
 
72.9±10.6† 
71.8±10.2† 
 
69.3±8.6† 
68.6±8.7† 
 
70.6±8.4† 
69.1±8.2† 
 
65.1±10.1 
64.7±8.8 
 
<0.0001 
<0.0001 
SpO2,  95.9±2.6 91.9±3.0↑ 96.0±1.8 89.8±3..3† 89.9±4.3† 96.6±2.2 <0.0001 
Lake Louisee Score  0.21±0.6 1.0±4.3† 0.22±0.7 1.2±1.5† 1.3±1.4† 0.30±0.60 <0.0001 
†Significance vs baseline on Post-test;  *Significant paired differences between spontaneous vs paced breathing 
 2 
  3 
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Figure 1 Linear regression (95% CI) of comparative HRV scores obtained with 4 
spontaneous versus  paced breathing. 5 
 6 
Figure 2 Comparison of relative HRV scores (mean± standard deviation) with each 7 
altitude for spontaneous versus paced breathing 8 
 9 
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Figure 3 Comparison of HRV scores obtained by spontaneous versus paced breathing over 10 
all time points: differences (Y axis) are compared with the average HRV score 11 
 12 
 13 
 14 
  15 
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Abstract 57 
Background 58 
High altitude (HA) exposure can lead to changes in resting heart rate variability (HRV), which 59 
may be linked to acute mountain sickness (AMS) development. Compared with traditional HRV 60 
measures, non-linear HRV appears to offer incremental and prognostic data, yet its utility and 61 
relationship to AMS have been barely examined at HA. This study sought to examine this 62 
relationship at terrestrial HA. 63 
 64 
Methods 65 
Sixteen healthy British military servicemen were studied at baseline (800m, first night) and over 66 
eight consecutive nights, at a sleeping altitude of up to 3600m. A disposable cardiac patch 67 
monitor was used, to record the nocturnal cardiac inter-beat interval data, over one hour (0200-68 
0300 hours), for offline HRV assessment. Non-linear HRV measures included Sample entropy 69 
(SampEn), the short (α1, 4-12 beats) and long-term (α2, 13-64 beats) detrend fluctuation 70 
analysis slope and the correlation dimension (D2). The maximal rating of perceived exertion 71 
(RPE), during daily exercise, was assessed using the Borg 6-20 RPE scale.  72 
Results  73 
All subjects completed the HA exposure. The average age of included subjects was 31.4±8.1 74 
years. HA led to a significant fall in SpO2 and increase in heart rate, LLS and RPE. There were 75 
no significant changes in the ECG-derived respiratory rate or in any of the time domain 76 
measures of HRV during sleep.  The only notable changes in frequency domain measures of 77 
HRV were an increase in LF and fall in HFnu power at the highest altitude.  Conversely, 78 
SampEn, SD1/SD2 and D2 all fell, whereas α1 and α2 increased (p<0.05). RPE inversely 79 
correlated with SD1/SD2 (r=-0.31; p=0.002), SampEn (r=-0.22; p=0.03), HFnu (r=-0.27; 80 
p=0.007) and positively correlated with LF (r=0.24; p=0.02), LF/HF (r=0.24; p=0.02), α1 81 
 
203 
(r=0.32; 0.11 to 0.49: p=0.002) and α2 (r=0.21; p=0.04). AMS occurred in 7/16 subjects (43.8%) 82 
and was very mild in 85.7% of cases. HRV failed to predict AMS. 83 
 84 
Conclusions 85 
Non-linear HRV is more sensitive to the effects of HA than time and frequency domain indices. 86 
HA leads to a compensatory decrease in nocturnal heart rate variability and complexity, which is 87 
influenced by the RPE measured at the end of the previous day. HRV failed to predict AMS 88 
development.  89 
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Introduction  90 
High altitude (HA) exposure leads to a number of well recognized physiological responses under 91 
hypobaric hypoxia [10]. These include increases in resting minute ventilation and pulmonary 92 
artery systolic pressure [10]. Resting cardiac output increases which is principally driven by a 93 
rise in resting heart with little change in stroke volume [72].  94 
 95 
The influence of HA on the changes in cardiac inter-beat intervals (IBI), known as heart rate 96 
variability (HRV), has been an area of significant recent research interest [90, 91, 150, 162, 97 
163]. This attention relates, in part, to the fact many of the factors that are known to affect HRV 98 
(eg fatigue, stress, insomnia, hypoxia and cold) are predominant at HA [10, 251, 252]. The 99 
improved portability and reduced cost of HRV recording equipment has helped to create new 100 
research opportunities at HA, that were previously untenable. Cardiac patch monitoring 101 
represents a significant advance in this regard. Patch monitors can non-invasively and accurately 102 
measure the cardiac IBIs, whilst negating the need for intrusive chest straps or electrocardiogram 103 
cables that are prone to interference and detachment. Despite these advantages, their utility to 104 
assess HRV at HA has not been examined.  105 
 106 
There is evidence to suggest that HA exposure is associated with significant changes in HRV 107 
compared with sea-level/low altitude [90, 91, 150, 162, 163]. However, the majority of the 108 
published data relate to short-term HRV recordings (1-5 minutes) obtained conducted in hypoxic 109 
chambers during ‘simulated’ rather than genuine terrestrial HA [265-268]. The hypoxic period 110 
examined has been generally brief (minutes to <8 hours) with a tendency to assess at a single 111 
HA [165, 269] leading to an under appreciation of the influence of acclimatization on HRV.  112 
Furthermore, despite the known influence of sleep on autonomic function, there has been a 113 
distinct lack of research into nocturnal HRV at HA [270, 271].   114 
 115 
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Despite these research limitations there is some, albeit limited data, supporting a potential link 116 
between changes in HRV at HA and acute mountain sickness (AMS) development [90, 162, 163, 117 
165]. However, there are marked inconsistencies in the published results. This may relate to the 118 
heterogeneity, in the methods used to assess HRV, the HA environment (terrestrial versus 119 
simulated; severity and duration of hypoxia), exercise intensity and in the populations studied  120 
[38, 91]. 121 
 122 
There is an increasing appreciation that traditional time and frequency domain measures of HRV 123 
that have dominated the literature, provide an incomplete representation of the complexity of IBI 124 
variability and autonomic balance [167]. Consequently, a number of non-linear measures of 125 
HRV have emerged that provide incremental and prognostic data [167]. To date these 126 
parameters have barely been examined at terrestrial HA [272].  127 
 128 
In this study we aimed to assess, for the first time, the use of a cardiac patch monitor to assess 129 
both linear and non-linear measures of HRV at terrestrial HA.  130 
 131 
  132 
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Materials and Methods  133 
Subjects  134 
Sixteen healthy British military servicemen, undergoing military training in the Bernese Alps, 135 
were studied (the ascent profile is shown in figure 1). All participants arrived by road to their 136 
800m basecamp, where they spent their first night. Thereafter, their 2
nd
 and 3
rd
 nights were at 137 
2840m (accessed by road to 1200m then on foot over 4 hours carrying a weight of 15kg). During 138 
their days at 2840m they underwent training serials on a nearby glacier. Their 4
th
 night was spent 139 
back at the 800m basecamp. Following this they were split into two equal groups of eight 140 
participants with one group of eight spending their 5
th
 and 6
th
 nights in huts at 3658m and the 141 
other at 2543m. Those based at 3658m underwent a daytime HA acclimatization climb to 142 
4100m, whereas those at 2543m climbed to 3583m. Both groups descended to their huts to 143 
sleep.  All subjects spent their 7
th
 and 8
th
 nights back at basecamp (800m) where they stayed till 144 
the end of the data collection (day 9). The subjects slept in sleeping bags in tents at 800m and in 145 
beds with sleeping bags in huts at the higher altitudes.  146 
 147 
Physiological and Physical assessments  148 
Assessment of SpO2 and HA related symptoms were measured, during seated rest, in the early 149 
morning at each altitude. HA-related symptoms were recorded using the Lake Louise Scoring 150 
(LLS) system [29]. This allocates a symptom score ranging from 0 (none) to 3 (severe) to the 151 
following five symptoms: difficulty sleeping, gastrointestinal symptoms, fatigue/weakness, 152 
dizziness/lightheadedness and headache. A LLS of >3 in the presence of headache and a recent 153 
altitude gain was used to define AMS as previously described [29, 91].  Mild AMS was defined 154 
as the presence of AMS and a LLS of 3-4 and severe when the LLS was >5 [29, 91]. The rating 155 
of perceived exertion during the day (sessional RPE) was assessed at the end of each day, using 156 
a 6-20 scale as previously described [38, 259, 273].     157 
 158 
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Assessment of Heart Rate Variability  159 
Continuous cardiac IBIs for each subject were recorded using a lightweight (6 grams) disposable 160 
120 x 42 x5 mm adhesive patch monitor (Healthstrip, LumiraDx; [274] that was provided for 161 
this study free of charge. It was made available for investigational use in this study and is 162 
currently awaiting a CE mark.  The Healthstrip contains two internal hydrogel electrodes (Figure 163 
2). The patches were placed following simple skin preparation (shaving and an alcohol wipe). 164 
The subjects wore their patches continuously throughout the study period and the patches were 165 
replaced as necessary. The patches were placed over the 2
nd
 to the 4
th
 intercostal space at angle 166 
of 45 degrees (towards the cardiac apex). The data was stored on the patch monitor prior to daily 167 
data Bluetooth transfer to an iPhone 6s smartphone. This coded cardiac data were then securely 168 
transferred using Wi-Fi for later HRV analysis.  169 
 170 
HRV was assessed over a one hour nocturnal cardiac recording period from 0200 to 0300 hours 171 
during sleep each of the eight consecutive nights. The Healthstrip also records physical activity 172 
and body position (upright, supine on back, lying on side) by a movement sensor, which 173 
supports the confirmation of genuine sleep, which was documented as an activity 174 
percentage/minute.  A 36 second full disclosure single lead ECG (Sampling frequency 250Hz) 175 
was additionally recorded over the middle 36 seconds (0230 hours) of each one hour.   176 
 177 
HRV analysis of the exported nocturnal one hour IBI data from the Healthstrip were performed 178 
on desktop computer using dedicated HRV software (Kubios® Premium ver. 3.0.2; 179 
http://www.kubios.com/) as previously described [275]. Prior to HRV computation all IBI data 180 
were visually inspected for correctness and then underwent automatic artefact correction. The 181 
default sample length was set to 3600s (one hour) and over the number of IBIs generated in this 182 
time frame.  183 
 184 
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Time and frequency domain measures of HRV were calculated according to the HRV Task 185 
Force Guidelines [60]. The following established time domain measures of HRV were assed: 186 
SDNN (standard deviation of the NN intervals), RMSSD (root mean square of successive 187 
differences), pNN50% (the number of NN intervals that differ by >50ms divided by the total 188 
number of NN intervals). Prior to calculation of the spectral HRV parameters, the Kubios default 189 
smoothness priors detrending was employed (Lambda, λ value=500) as previously described 190 
[275, 276]. The IBIs were transformed to evenly sampled time series with 4-Hz interpolation 191 
resampling rate. The detrended and interpolated IBIs were used for the frequency-domain HRV 192 
analysis. HRV spectra were calculated by using the fast-Fourier-transform (FFT) with Welch's 193 
periodogram method (50% overlap window and 300 s window width) as previously described 194 
(Gasior et al., 2016). We reported the LF (low-frequency) (0.04-0.15 Hz) and HF (high-195 
frequency) power (0.15-0.40 Hz) and the LF/HF ratio as previously described  [60]. Due to 196 
skewed distributions, LF and HF power were transformed by natural logarithms (ln). In order 197 
obtain greater insight into the relative HF power it was also reported in normalized units HF 198 
(HFnu) which was calculated as HF/(LF + HF) (Task Force., 1996). Non-linear HRV assessment 199 
were examined as previously described [167] using Poincaré plots and the derived ratio of the 200 
standard deviation (SD) of long term (SD2) to short term (SD1) variability known as SD1/SD2 201 
ratio, Sample entropy (SampEn), the short (α1, 4-12 beats) and long term detrend fluctuation 202 
analysis (DFA) slopes (α2, 13-64 beats) and the correlation dimension (D2) [167]. The Poincaré 203 
plot is a scatterplot in which current IBIs are plotted as a function of previous interval. SD1 204 
represents the standard deviation of short-term HRV and SD2 (or major axis) the continuous 205 
longer term IBIs [60]. The SD1/SD2 ratio measures the unpredictability of the RR time series 206 
[277]. SampEn is a measure of the regularity and fluctuation of a time series with lower values 207 
representing less complexity and greater self-similarity in a time series [278].  DFA detects the 208 
simple correlations between successive RRIs over differing time scales with α1 reflecting the 209 
slope over shorter fluctuations and α2 over longer time periods [277].  D2 is an estimation of the 210 
number of independent variables necessary to describe a systems behavior with a higher value 211 
representing greater complexity [167].    212 
 
209 
Calculation of the respiratory rate was obtained by ECG-derived respiration (EDR) software 213 
within the HRV analysis package as previously described, using the 36 second  Healthstrip ECG  214 
recording [279].  215 
 216 
Statistical Analysis and sample size calculation  217 
Data were analyzed using GraphPad InStat version 3.05 and with all graphical figures presented 218 
using GraphPad Version 3.10 (GraphPad Software, San Diego, CA, USA; www.graphpad.com). 219 
Data inspection and the Kolmogorov-Smirnov test was undertaken to assess normality of all 220 
continuous data. Results are presented as mean ± standard deviation (SD) for all data. 221 
Comparison of continuous data between altitudes was performed using a one-way ANOVA with 222 
Tukey posttest and with Kruskal-Wallis test with Dunn-Post test for parametric and non-223 
parametric data respectively.  Correlations of continuous data were assessed using the Pearson 224 
and Spearman rank correlation coefficients (r) and 95% confidence interval, for parametric and 225 
non-parametric data respectively. A two-sided p value of <0.05 was considered as significant for 226 
all analyses. 227 
 228 
In a previous, yet recent study, we had observed a significant 11% (7.9ms) change in the 229 
RMSSD-derived HRV score between baseline sea level and 3619m in a cohort of 12 persons 230 
[91]. Zhang et al recently observed a significant fall in SampEn in eight healthy male subjects, 231 
following short term exposure to simulated HA from sea level to 3600 m [280]. Based on this 232 
later data, we calculated that a sample size of at least 14 subjects would have sufficient power to 233 
examine for differences in RMSSD and a > 80% to detect a difference in mean SampEn of >0.18 234 
at a significance level (alpha) of 0.05 (two-tailed) (GraphPad Statmate). 235 
 236 
  237 
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Ethics 238 
All participation was entirely voluntary and all subjects underwent detailed written informed 239 
consent >24hours after being sent a participant information sheet for the study. This study was 240 
approved by the Ministry of Defence Research and Medical Ethics Committee (MODREC) and 241 
was conducted according to the standards of the Declaration of Helsinki. 242 
 243 
Results 244 
The average age of included subjects was 31.4±8.1 years. They had mean height of 179.8±5.0 245 
cm, weight of 84.6±11.0 kg and body mass index of 26.1±2.7 kg/m
2
. All of the participants were 246 
non-smokers and were not on any regular medication.  247 
 248 
Compared with baseline, ascent to HA >2543m was associated with a significant fall in SpO2, 249 
higher RPE scores,  and an increase in average heart rate, LLS and in the average sleep score 250 
component of the LLS (table 1).  251 
 252 
The mean number of patches used per subject over the study was 1.94±.25 (range 1-2), with all, 253 
but one subject, requiring two patches. The recorded cardiac IBI data were good quality with an 254 
artefact rate of <3% at all altitudes studied, but was significantly higher at higher altitude at 255 
>2543m versus baseline 800m (table 1).  There were no significant overall changes in any of the 256 
time domain measures of HRV (table 2).  The only notable change in frequency domain 257 
measures of HRV was an increase in LF power and fall in HFnu at the highest altitude (table 2). 258 
There were significant changes in all of the non-linear measures of HRV at HA:  SampEn, 259 
SD1/SD2 and D2 fell, whereas α1 and α2 increased (P<0.05) (table 3).   260 
 261 
 
211 
RPE inversely correlated with HFnu, SD1/SD2 and SampEn and positively correlated with LF, 262 
LF/HF, α1 and α2, but not the other HRV indices (table 4). Among the non-linear indices only 263 
SD1/SD2 inversely correlated with α1 (r=-0.87; -0.91 to -0.81: p<0.0001), α2 (r=0.28; - 0.44 to -264 
0.10: p=0.003).  SampEn inversely correlated with α2 (r=-0.27; -0.44 to 0.01: p=0.003) and D2 265 
inversely with α2 (r=-0.35; - 0.51 to -0.17: p=0.0001).   266 
 267 
Seven out of the sixteen subjects (43.8%) suffered with AMS. These were all self-limiting and in 268 
all but one were mild episodes (LLS score 3-4). HRV scores failed to predict AMS.  269 
 270 
Discussion 271 
This is the first study to assess the utility of a cardiac patch monitor to assess non-linear 272 
measures of HRV at HA. We found that non-linear HRV was more sensitive to the effects of HA 273 
than traditional time and frequency domain HRV measurements.  HA led to a significant fall in 274 
SD1/SD2, D2 and SampEn and an increase in α1 and α2.  We observed a significant relationship 275 
between nocturnal HRV and RPE measured at the end of the previous day. HRV measures failed 276 
to predict the development of AMS.   277 
 278 
We chose to examine the effects of HA on several non-linear HRV parameters, given the paucity 279 
of data at HA and their potential advantages over established time and frequency domain HRV 280 
parameters. Their advantages include its lower sensitivity to the presence of cardiac ectopy, 281 
artifacts and to the recording period, which is of greater relevance at HA [281]. The non-linear 282 
HRV parameters examined in this study were the SD1/SD2 ratio obtained from Poincaré plots, 283 
SampEn, α1 and α2 and D2.  We found that SampEn was significantly lower at HA at both 2840 284 
and 2543-3658m compared with baseline. Conversely the α1 and α2 increased from baseline to 285 
2480 and 2543-3658m, with a return to near baseline levels at 800m.  D2 and SD1/SD2 values 286 
were also significantly lower at HA versus 800m. These findings suggest that HA to >2543m 287 
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leads to a compensatory change in autonomic balance with increased regularity (lower HRV) 288 
and lower complexity and chaos in the cardiac IBI signal [277].   289 
 290 
Our data is largely consisted with that obtained from several recent acute hypoxia studies. In 291 
their study of eight healthy men exposed to acute normobaric hypoxia (equivalent to 3600m) for 292 
10 minutes, Zhang et al also reported a fall in SampEn, measured over a one minute recording 293 
period [280]. Their observed values of α1, which was also studied, were similar to our current 294 
study and very close to 1.0, but did not change significantly.   In another study of ten healthy 295 
men, supine HRV was measured during intermittent periods of acute normobaric hypoxia 296 
(simulated HA; FIO2 down to 9.8%) [282]. Again, a significant fall in SampEn was observed, 297 
but on this occasion it was associated with a significant increase in α1, which is consistent with 298 
our data. Due to the brevity of the HRV recording period in their study, α2 and other non-linear 299 
HRV measures were not examined.    300 
 301 
In this study we assessed HRV during sleep at HA. Our interest in specifically examining this 302 
period was stimulated by a number of factors. Firstly, it has been well shown that sleep and its 303 
stages are associated with marked variability in autonomic modulation of cardiac activity that is 304 
typified higher parasympathetic tone during normal non-Rapid Eye Movement Sleep (REMS) 305 
and a shift toward sympathetic predominance during normal REMS [52, 270, 283]. Secondly, 306 
ventilation, which can have a significant influence on HRV, is affected by HA [60]. Alterations 307 
in breathing patterns and even periodic breathing (PB) are a well-established phenomenon at 308 
high altitude [24]. PB represents an abnormal ventilatory pattern in which apneas and hypopneas 309 
alternate with periods of hyperventilation [24]. 2016). The worsening hypobaric hypoxia at HA 310 
leads to compensatory hyperventilation until a point when the arterial PCO2 (PaCO2) falls below 311 
the threshold required to stimulate breathing leading to either hypopnea or even apnea, followed 312 
by the restoration of hyperventilation as the hypoxia worsens and the paCO2 resets  [24]. This 313 
phenomenon is subject to marked individual variability, but is generally observed at >2000m  314 
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[24].  Unfortunately, we were not able to measure ventilation throughout the one hour recording 315 
period, but did quantify the ECG derived respiratory rate during part of the HRV recording 316 
period.  It is highly likely that there were cases of PB and the observed swings in the IBI raise 317 
this suspicion. Nevertheless, wary of the confounding effect of sleep stage and potentially PB on 318 
HRV we selected a one-hour HRV recording period in preference to a traditional five-minute 319 
recording to minimize this potential bias [60].  320 
 321 
By using an adhesive cardiac patch monitor (and avoiding ECG cables and minimizing 322 
movement artifact) we were able to overcome the obvious challenges of accurately, yet non-323 
intrusively measuring HRV during sleep at HA.  However, poor sleep was still a significant 324 
contributor to the total LLS at each altitude in our study. The sleep score component of the LLS 325 
was significantly higher at 2840m compared with 800m, indicating perceptually worse sleep at 326 
higher altitude (table 1). Whilst reduced HRV with insomnia is a widely accepted concept, it has 327 
not been well supported by empirical evidence [284]. Reduced sleep quality and insomnia are 328 
common at HA, but its effect on HRV has not been examined. Unfortunately, we were unable to 329 
assess the sleep stages during the HRV recording or the total sleep time prior to HRV recording.  330 
However, the subjects generally went to sleep before 2300 hours each night and the activity 331 
sensor on the Healthstrip confirmed that subjects were supine and largely inactive during the 332 
HRV defined nocturnal HRV recording period.  333 
The significant, yet modest, relationship between end of day RPE and nocturnal HRV is a novel 334 
finding at HA. Our data support the temporal effects of heavy exercise and exhaustion on HRV 335 
[271]. Higher RPE appeared to be associated with lower nocturnal HRV and greater LF/HF 336 
dominance.  337 
 338 
This study has a number of additional strengths and limitations that should be acknowledged. The 339 
fact that we were we studied three separate terrestrial altitudes, yet included a far larger sample 340 
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size than the majority of published acute hypoxic chamber studies are obvious strengths. The 341 
wide breadth of HRV parameters and physiological measurement examined, allowed for a 342 
comprehensive assessment of HRV at HA.  Baseline HRV studies were performed at 800m rather 343 
than sea level due to practical issues, which could have reduced the effect size. It was not 344 
possible to control the subjects sleeping position (eg prone or on side) and their sleeping 345 
conditions varied with altitude which may be potential confounders [285].  The altitude studied 346 
was modest and the majority of AMS cases were mild, hence we cannot be certain whether our 347 
findings would be reproducible at higher altitudes and with worsening AMS severity. The 348 
duration and intensity of exercise varied with altitude, which whilst being a relevant confounder, 349 
reflects the reality of a real world terrestrial HA venture. We were only able to absolutely 350 
confirm the presence of normal sinus rhythm at the time of the 36 second ECG capture. Whilst 351 
this does not fully exclude the possibility of arrhythmias at other time points visualization of the 352 
IBI data coupled with the altitude and healthy population studied would strongly suggest against 353 
the presence of an undetected significant cardiac arrhythmia [96].  354 
 355 
In conclusion this study demonstrated that moderate terrestrial HA exposure leads to significant 356 
changes in resting nocturnal non-linear HRV that is typified by increased regularity and lower 357 
complexity and chaos of the cardiac inter-beat signal. These changes are influenced by the 358 
intensity of exercise over the previous day. Nocturnal HRV was not predictive of AMS.  359 
 360 
Acknowledgements 361 
The authors would like to thank the Surgeon General and the Defence Medical Services for the 362 
support and for the subjects who undertook what was a very challenging clinical study to 363 
perform.  364 
 365 
  366 
 
215 
Author Contributions 367 
CB, LS, CB and KB performed all the experiments. CB, AM, DW, TQ and MS initiated the 368 
project. CB, TQ and LS performed the data analysis. All the authors contributed to data paper 369 
writing. 370 
 371 
Funding 372 
This work was supported by the Surgeon Generals Department and the cost of the patches was 373 
funded by LumiraDx.  374 
 
216 
Table 1 Changes in physiological measurements, Lake Louise Scores and rating of perceived exertion (RPE)  
Altitude 800m(1)  2840m 800m(2)  2543-
3658m 
800m(3)  P Value 
SpO2, % 96.8±1.2 92.2±2.4 96.1±2.0 90.0±3.3 95.9±3.0 <0.0001
acef 
Mean Heart rate, minute-1  53.2±7.3 68.8±14.9 68.9±17.9 65.0±13.4 60.8±9.3 0.001abc 
ECG-derived  
Respiratory rate  
16.7±3.9 17.3±2.0 16.8±3.6 16.9±3.4 16.9±4.6 0.90 
Lake Louisee total Scores 0.2±0.6 1.0±1.1 0.5±1.2 1.4±1.5 0.4±0.70 <0.0001acf 
Lake Louise Sleep Scores  0.0±0.2 0.6±0.8 0.0 0.3±0.7 0.1±0.5 <0.0001ae 
RPE Score 10.8±2.8 11.40±2.6 10.2±3.5 12.4±2.5 10.4±1.9 0.02cef 
SpO2, capillary oxygen saturation; RPE rating of perceived exertion (Borg 14-20 score); 
Significant post-test differences vs baseline 800m (1): a 2840m; b 800(2) m; c 2543-3658m; d 800(3) m;  
e 800(2)m vs 2840m; f  800(2)m vs 2543-3658m 
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Table 2 Comparative Time and Frequency Domain heart rate variability parameters at high altitude 
Altitude 800m (1) 2840m 800(2)m 2543-3658m 800(3) m P Value 
Artefact % 1.1±1.1 2.4±1.8 1.6±1.0 2.6±1.7 1.1±0.7 0.001acg 
LnSDNN 4.2±0.4 4.3±0.6 4.2±0.7 4.5±0.40 4.0±0.8 0.09 
LnRMSSD 4.4±0.5 4.2±0.8 4.2±0.8 4.40±0.60 4.0±0.9 0.45 
pNNI% 39.4±18.9 28.9±23.3 21.8±25.1 37.7±18.4 25.4±22.7 0.35 
Triangular Index 15.1±3.70 15.1±8.70 16.6±13.3 19.6±11.2 14.2±9.1 0.09 
LnLF 7.6±0.6 7.6±1.0 7.5±1.3 8.4±0.8 7.0±1.5 0.004eg 
LnHF 7.3±1.0 7.1±1.6 7.2±1.6 7.5±1.2 6.8±1.6 0.59 
HFnu,% 40.5±15.1 36.4±17.4 43.3±16.3 31.9±16.0 43.3±15.7 0.04fg 
LF/HF ratio 1.7±1.0 2.8±2.6 1.7±1.2 2.9±2.0 1.6±01.1 0.09 
SDNN, standard deviation of normal-to-normal; RMSSD, root mean square of successive differences; pNNI%, 
Percentage of successive RRs >50ms; LF. Low frequency; HF high frequency; Significant post-test differences: vs 
baseline 800m (1), a 2840m, b 800(2) m, c 2543-3658m, d 800(3) m; e 800(2)m vs 2840m; f 800(2)m vs 2543-3658m; g 
800(3)m vs 2543-3658m 
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Table 3 Effect of high altitude on Non-linear measures of Heart rate Variability  
Altitude 800m (1) 2840m 800(2) m 2543-
3658m 
800(3) m P Value 
SD1/SD2 0.6±0.1 0.5±0.2 0.6±0.2 0.5±0.2 0.6±0.2 0.02
cf 
Sample Entropy 1.6±0.2 1.4±0.3 1.6±0.3 1.4±0.2 1.7±0.2 0.0004
ace
 
DFA α1 1.0±0.2 1.2±0.3 1.0±0.3 1.1±0.2 0.9±0.2 0.006acef 
DFA α2 0.4±0.10 0.5±0.10 0.4±0.1 0.4±0.1 0.4±0.2 0.03ac 
D2 3.4±1.4 2.1±1.3 2.3±1.5 2.9±1.3 2.1±1.6 0.03
ad 
SD, standard deviation; DFA detrend fluctuation analysis; D2, Correlation Dimension;  
Significant post-test differences vs baseline 800m (1): a 2840m; b 800(2) m; c 2543-3658m; d 800(3) 
m; e 800(2)m vs 2840m; f 800(2)m vs 2543-3658m 
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Table 4 Correlation between Rating of Perceived Exertion (RPE) and HRV Measures 
HRV parameter Correlation 
coefficient  
95% Confidence 
interval  
P value 
HFnu -0.27 -0.45 to -0.07 0.007 
LF  0.24 0.04 to 0.44 0.02 
LF/HF  0.24 0.04 to 0.42 0.02 
SD1/SD2 -0.31 -0.49to -0.10 0.002 
Sample Entropy -0.22 -0.40 to 0.02 0.03 
α1 0.32 0.11 to 0.49 0.002 
α2 0.21 01 to 0.40 0.04 
LF. Low frequency; HF high frequency; SD, standard deviation  
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Legend for Figures  
Figure 1 Ascent Profile of the subjects. HRV recordings were taken at 0200-0300 each 
night 
 
Figure 2 Illustration of the Healthstrip Cardiac Patch Monitor 
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It has been suggested, though still unproven, that high altitude (HA) exposure is proarrhythmic and 
could potentially contribute to an increased risk of sudden cardiac death (SCD).
1,2
  However, there are 
very limited data, particularly above 5000m to substantiate this claim. We hypothesised that extreme 
HA leads to an increased risk of pathological cardiac tachyarrhythmias, detected using an implantable 
cardiac monitor (ICM).  
 
Sixteen healthy adult Caucasian male British Military servicemen underwent continuous ECG 
monitoring, using a Reveal LINQ ICM ( Medtronic Ltd), for >7 weeks before, during and >8 weeks 
after an attempted summit of Mount Dhaulagiri (8,167 m). They were required to have a normal 12-
lead ECG and transthoracic echocardiogram at recruitment and were excluded if they had a history of 
cardiac arrhythmia.  They underwent written informed consent and the study was approved by the 
Ministry of Defence Research and Medical Ethics Committee. The participants flew from the UK to 
Kathmandu, Nepal (1400m, days 1-2), then by road (day 3-4) to 2679m. Thereafter, they trekked 
carrying moderate loads to 3720m (day 5), 4150m (day 7) and 5140m where they remained (days 11-
24) for attempts on 6035m and 6800m peaks. One subject aborted at 4100m, due to severe 
gastrointestinal symptoms. On day 25, five subjects descended and 10 climbers remained at 4800m 
for an attempted summit of Mount Dhaulagiri over days 26-51(days 26-51). The subjects were 
monitored wirelessly pre and post-departure (Medtronic MyCareLink
TM 
Monitor) and during trekking 
using a portable Medtronic Programmer every 2-5 days, depending on environmental conditions.    
 
The subjects were 35.1±6.6 (24-48) years. Fifteen (93.8%) achieved an altitude of >6035m, six to 
6800m, one to 7100m and three to 7500m. Unfortunately, an attempted summit of Mount Dhaulagiri 
became impossible, due to adverse weather conditions.  SpO2 significantly fell at increasing HA from 
96.4±1.6% at 1400m to 93.2±2.8% at 2650m, 88.8±3.5% at 4100m, 80.6±5.0% at 5140m and 
78.1±4.5% at 5340 (Ordinary ANOVA P<0.0001).  The ICM rhythm-detection settings are shown in 
table 1 (footnote). Significant rhythm abnormalities were observed in 9 out of 16 subjects (56.3%) at 
HA and only at >4100m. Symptom-related device activation was triggered on 18 occasions in 8/16 
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subjects at HA and related to extreme breathlessness and palpitations. Subject five developed an 
episode of nocturnal symptomatic rapid atrial fibrillation (AF) at 4100m, during the initial ascent 
phase, which occurred immediately after drinking cold water. It lasted for 282 minutes at a mean 
ventricular rate 133/minute.  Subject four, developed an episode of supraventricular tachycardia 
(SVT) lasting for 30.8 seconds (mean rate 207/ minute). It occurred immediately on attempting to lift 
a 30kg load, at 5200m and was associated with sudden and transient light-headedness and 
breathlessness.  
 
Significant pauses (>3 seconds) were identified at HA in 8 out of 15 (53.3%) subjects at HA at 
>4800m only, with none detected in any subjects below this altitude (Fisher’s Exact Test p=0.0008). 
There were 82 pauses (3.0-7.0s) in total, which were sinus in 80 with evidence of high grade heart 
block in two cases (mean number10.3±14.1; range 1-41) (table 1).  The number of pauses increased 
with altitude gain from 0 at <4800m to 4.2 at 4800m and 14.3 at >6000m (Kruskal-Wallis Test 
P<0.0001) with 19.3±20.6 pauses at 7550m (n=3) versus 1.9±4.2 among the rest of the subjects 
(n=13; Chi-squared Test p=0.007).  The number of pauses increased with duration of HA exposure: 6 
during first 17 days (tercile, 15-16 subjects), 29 during days 18-34 (10-15 subjects) and 47 (10 
subjects) during days 35-51. The pauses typically occurred following cyclical periods of heart rate 
acceleration then deceleration preceding it.   
 
This is the first study to convincingly demonstrate the pro-arrhythmic risks of significant HA and to 
the author’s knowledge the first to continuously monitor healthy subjects above 6325m at terrestrial 
HA. In the only previous ICM study at HA nine subjects were studied using first generation Reveal 
ICM, which lacked auto-detection capabilities and only two subjects were assessed at 6325m.
1
 They 
observed one short-lived episode of atrial flutter at 150/minute (8.5 minutes) immediately after a 
severe exertion at 4500 m. The episode of nocturnal AF detected in our study would suggest vagally-
mediated AF. We would also postulate that the pauses observed in our study were likely physiological 
and also related to the effects of increased nocturnal vagal tone and sleep-disordered breathing which 
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are well recognised at HA.
3,4
  We believe the episode of SVT relates to the combination of 
sympathetic activation, hypoxia and sudden explosive exercise at HA. In addition to the factors 
outlined above the proarrhythmic effects of HA may be partly explained by other factors including 
acclimatization, changes in heart rate variability, sleep deprivation, dehydration and anxiety.
5 
 
In conclusion HA exposure to >4100m is associated with significant brady and tachy-arrhythmias in 
healthy adult men supporting a potential proarrhythmic risk. There was no link between HA and 
sustained ventricular arrhythmias linked to an increased risk of SCD.  
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Table 1.  ICM detection settings, key cardiac rhythm findings and altitudes achieved  
Subject 
number  
Age  Maximal 
altitude 
achieved 
Significant 
Findings  
Key Abnormalities No of pause 
Episodes 
Longest pause 
duration in 
seconds 
1 30 6035m No None - - 
2 40 6200m No None - - 
3 41 7550m Yes Pauses 41 6.0 
4 30 6800m Yes SVT and pauses 5 5.0 
5 32 7550m Yes Atrial fibrillation - - 
6 24 4100m No None*  - - 
7 38 6200m Yes Pauses 15 4.0 
8 25 6800m No None - - 
9 48 6800m Yes Pause 1 3.3 
10 30 7550m Yes Pauses 17 7.0 
11 33 6035m Yes Pause 1 4.4 
12 41 7100m No None - - 
13 38 6800m No None - - 
14 38 6035m No None - - 
15 32 6800m Yes Pause 1 3.4 
16 41 6200m Yes Pause 1 5.0 
SVT, supraventricular tachycardia; *descended due to gastrointestinal illness; Tachycardias were 
defined as a heart rate/minute >230-age in years for >16 beats; bradycardia as a heart rate <30/minute 
for >12 beats, pause R-R interval >3 seconds and atrial tachycardia/fibrillation/flutter as episodes 
fitting morphology detection criteria lasting >10minutes. 
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Chapter 11 
Conclusions 
This thesis presents the conduct and findings of a series of studies using both simulated and terrestrial 
HA, with a specific focus on elucidating the cardiovascular effects of hypoxia using novel portable 
equipment. The key findings of this research are as follows. 
 Biventricular cardiac systolic function remains preserved with acute hypoxia and HA exposure. 
 Whilst minor changes in biventricular diastolic function were observed this likely reflects 
augmented atrial contraction as the estimated biventricular filling pressures remains unchanged 
and were not increased.  
 Minor elevations in cardiac troponin and natriuretic peptides can occur at HA and are more likely 
to reflect the influence of exercise at HA and the increase in PASP rather than related to adverse 
changes in biventricular function.  
 Genuine HA, NH and HH produce similar short term cardiac adaptations, at rest. Following 
exercise the fall in SpO2 and increase in right ventricular systolic pressure appears to be greater 
with HH and natural HA compared with NH.  
 High Altitude exposure is associated with an increase in brachial and central blood pressure and 
the peripheral augmentation index. These increases are likely explained by increased wave 
reflections and peripheral vasoconstriction of the more peripheral muscular arteries in response 
to hypobaric hypoxia rather than persistent changes in the arterial wall.  
 Increasing HA affects HRV and leads to a reduction in time domain measures of HRV, increased 
low frequency power initially and high frequency power during acclimatization. Changes in non-
linear HRV indices are characterized by greater self-similarity and reduced signal chaos and 
entropy. Changes in HRV at HA were not predictive of AMS development or its severity.  
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 There are consistent differences in HRV scores between men and women at sea level which. 
These differences were maintained at HA. There is no evidence for a sex-x-altitude/hypoxia 
interaction on the changes in HRV at HA. 
 Increasing HA leads to an increasing risk of nocturnal bradycardia and significant pauses and HA 
is pro-arrhythmic.  
 My data from this thesis would largely suggest that in healthy adults moderate HA exposure does 
not pose any over effects on cardiovascular function.  
 However HA exposure does lead to an increase in both peripheral and central blood pressure and 
more extreme HA above 4100m is associated with a pro-arrhythmic risk. This has important 
implications for persons with poorly controlled hypertension or at risk of cardiac arrhythmias 
where there the potential risk of exacerbation at HA may be increased. 
 Further carefully conducted research amongst ‘at-risk populations’ including those with known 
hypertension are needed.  
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